0001757064-23-000009 | 20-F | XBRL Viewer

Print Document View Excel Document

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2022 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-38844
Entity Registrant Name	GENFIT S.A.
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	885, avenue Eugène Avinée
Entity Address, Postal Zip Code	59120
Entity Address, City or Town	Loos
Entity Address, Country	FR
Title of 12(b) Security	American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share
Trading Symbol	GNFT
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	49,834,983
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001757064
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	885, avenue Eugène Avinée
Entity Address, Postal Zip Code	59120
Entity Address, City or Town	Loos
Entity Address, Country	FR
Contact Personnel Name	Parc Eurasanté
Country Region	+33
City Area Code	(0)3
Local Phone Number	2016 4000
Contact Personnel Fax Number	+33 (0)3 2016 4001

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Ernst & Young et Autres
Auditor Location	Paris, France
Auditor Firm ID	1704

Consolidated Statements of Financial Position - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	€ 136,001	€ 258,756
Current trade and others receivables	15,906	7,236
Other current financial assets	4,550	0
Other current assets	1,998	2,101
Inventories	4	4
Total - Current assets	158,459	268,097
Non-current assets
Intangible assets	43,957	174
Property, plant and equipment	8,210	9,015
Non-current trade and other receivables	0	3
Other non-current financial assets	4,914	4,431
Deferred tax assets	0	0
Total - Non-current assets	57,081	13,623
Total - Assets	215,540	281,720
Current liabilities
Current convertible loans	415	415
Other current loans and borrowings	4,665	1,773
Current trade and other payables	14,845	40,988
Current deferred income and revenue	14,479	14,298
Current provisions	61	313
Other current tax liabilities	4,906	5,051
Total - Current liabilities	39,370	62,837
Non-current liabilities
Non-current convertible loans	49,861	47,682
Other non-current loans and borrowings	20,334	24,365
Non-current trade and other payables	448	450
Non-current deferred income and revenue	9,706	25,821
Non-current employee benefits	782	864
Deferred tax liabilities	510	602
Total - Non-current liabilities	81,641	99,786
Shareholders' equity
Share capital	12,459	12,454
Share premium	444,683	444,438
Retained earnings (accumulated deficit)	(337,550)	(405,076)
Currency translation adjustment	(1,344)	22
Net profit (loss)	(23,719)	67,259
Total - Shareholders' equity	94,528	119,097
Total - Shareholders' equity & liabilities	215,540	281,720
Interest income	137	274
Net foreign exchange gain	7,470	8,876
Finance income from renegotiation of debt	0	35,578
Other finance income	605	52
Financial income	8,212	44,780
Interest expense	(4,341)	(4,846)
Interest Expenses For Leases	(69)	(109)
Net foreign exchange loss	(340)	(2,163)
Other finance cost	(8)	(5)
Finance costs	(4,758)	(7,122)
Finance income (cost)	€ 3,453	€ 37,658

Consolidated Statements of Operations - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues and other income
Revenue	€ 20,195	€ 80,069	€ 765
Other income	6,371	5,510	6,993
Revenues and other income	26,566	85,579	7,758
Operating expenses and other operating income (expenses)
Research and development expenses	(35,818)	(35,166)	(59,097)
General and administrative expenses	(16,405)	(16,153)	(14,270)
Marketing and market access expenses	(992)	(1,539)	(11,216)
Reorganization and restructuring income (expenses)	11	(142)	(5,308)
Other operating income (expense)	(652)	(763)	(764)
Operating income (loss)	(27,289)	31,816	(82,897)
Financial income	8,212	44,780	6,544
Financial expenses	(4,758)	(7,122)	(25,296)
Financial profit (loss)	3,453	37,658	(18,752)
Net profit (loss) before tax	(23,836)	69,474	(101,649)
Income tax benefit (expense)	116	(2,215)	428
Net profit (loss)	(23,719)	67,259	(101,221)
Attributable to owners of the Company	€ (23,719)	€ 67,259	€ (101,221)
Basic and diluted earnings (loss) per share
Basic earnings (loss) per share (€/share)	€ (0.48)	€ 1.51	€ (2.60)
Diluted earnings (loss) per share (€/share)	€ (0.48)	€ 1.23	€ (2.60)

Consolidated Statements of Other Comprehensive Loss - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of comprehensive income [abstract]
+ Net profit (loss)	€ (23,719)	€ 67,259	€ (101,221)
Actuarial gains and losses net of tax	258	216	196
that will never be reclassified to profit or loss	258	216	196
Exchange differences on translation of foreign operations	(1,366)	113	(106)
that are or may be reclassified to profit or loss	(1,366)	113	(106)
Total comprehensive income (loss)	(24,827)	67,589	(101,131)
Attributable to owners of the Company	€ (24,827)	€ 67,589	€ (101,131)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

Consolidated Statements of Cash Flows - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
+ Net profit (loss)	€ (23,719)	€ 67,259	€ (101,221)
Adjustments to reconcile profit (loss) [abstract]
+ Depreciation and amortization on tangible and intangible assets	1,832	2,742	3,559
+ Impairment and provision for litigation	(179)	(1,996)	3,015
+ Expenses related to share-based compensation	245	470	1,236
- Gain on disposal of property, plant and equipment	(16)	420	80
+ Net finance expenses (revenue)	2,042	4,663	10,335
+ Income tax expense (benefit)	(116)	2,215	(428)
+ Other non-cash items	2,210	(35,538)	(1,818)
Operating cash flows before change in working capital	(17,702)	40,235	(85,242)
Changes In Working Capital [Abstract]
Decrease (increase) in trade receivables and other assets	(8,565)	4,344	318
(Decrease) increase in trade payables and other liabilities	(46,226)	55,335	(11,447)
Change in working capital	(54,791)	59,680	(11,129)
Income tax paid	(145)	0	0
Net cash flows provided by (used in) in operating activities	(72,638)	99,915	(96,371)
Purchase of interests in associates	41,525	0
Cash flows from investment activities
- Acquisition of property, plant and equipment	251	(537)	(900)
+ Proceeds from disposal of / reimbursement of property, plant and equipment	20	309	0
- Acquisition of financial instruments	(5,012)	(3,148)	(66)
Net cash flows provided by (used in ) investment activities	(46,266)	(3,377)	(966)
Cash flows from financing activities
+ Proceeds from issue of share capital (net)	5	27,972	7
+ Proceeds from subscription / exercise of share warrants	0	0	0
+ Proceeds from new loans and borrowings net of issue costs	0	15,270	0
- Repayments of loans and borrowings	(628)	(48,436)	207
- Payments on lease debts	(1,120)	(1,887)	(2,150)
- Financial interests paid (including finance lease)	(2,180)	(2,109)	(7,762)
+ Financial interests received	137	274	1,442
Net cash flows provided by (used in ) financing activities	(3,786)	(8,916)	(8,256)
Increase (decrease) in cash and cash equivalents	(122,690)	87,622	(105,593)
Cash and cash equivalents at the beginning of the period	258,756	171,029	276,748
Effects of exchange rate changes on cash	(66)	105	(126)
Cash and cash equivalents at the end of the period	€ 136,001	€ 258,756	€ 171,029

Consolidated Statements of Changes in Equity - EUR (€) € in Thousands	Total	Share capital	Share premium	Treasury shares	Retained earnings (accumulated deficit)	Currency translation adjustment	Net profit (loss)	Retained earnings, excluding profit (loss) for reporting period [member]
Balance at beginning of period (in shares) at Dec. 31, 2019		38,858,617,000
Balance at beginning of period at Dec. 31, 2019	€ 84,065	€ 9,715	€ 377,821	€ (478)	€ (237,862)	€ 14	€ (65,144)
+ Net profit (loss)	(101,221)						(101,221)
Other comprehensive income (loss)	90				196	(106)
Total comprehensive income (loss)	(101,131)				196	(106)	(101,221)
Allocation of prior period profit (loss)	0				(65,144)		65,144
Capital increase (shares)		29,762,000
Capital increase	0	€ 7	0		(7)
Share-based compensation	1,236		1,236
Treasury shares	(333)			(333)
Other movements	(268)		0					€ (268)
Balance at end of period (in shares) at Dec. 31, 2020		38,888,379,000
Balance at end of period at Dec. 31, 2020	(16,430)	€ 9,722	379,057	(811)	(303,086)	(92)	(101,221)
+ Net profit (loss)	67,259						67,259
Other comprehensive income (loss)	330				216	113
Total comprehensive income (loss)	67,589				216	113	67,259
Allocation of prior period profit (loss)	0				(101,221)		101,221
Capital increase (shares)		10,927,110,000
Capital increase	65,332	€ 2,732	62,600		0
Share-based compensation	470		470
Treasury shares	€ (174)			(174)
Balance at end of period (in shares) at Dec. 31, 2021	49,815,489	49,815,489,000
Balance at end of period at Dec. 31, 2021	€ 119,097	€ 12,454	444,438	(986)	(404,090)	22	67,259
Equity component Bond issue OCEANE	2,311		2,311
+ Net profit (loss)	(23,719)						(23,719)
Other comprehensive income (loss)	(1,108)				258	(1,366)
Total comprehensive income (loss)	(24,827)				258	(1,366)	(23,719)
Allocation of prior period profit (loss)	0				67,259		(67,259)
Capital increase (shares)		19,494,000
Capital increase	0	€ 5	0		(5)
Share-based compensation	245		245
Treasury shares	8			8
Other movements	€ 5							€ 5
Balance at end of period (in shares) at Dec. 31, 2022	49,834,983	49,834,983,000
Balance at end of period at Dec. 31, 2022	€ 94,528	€ 12,459	€ 444,683	€ (978)	€ (336,573)	€ (1,344)	€ (23,719)

Statement of financial position, current/non-current

12 Months Ended

Dec. 31, 2022

Statement of financial position [abstract]

Financial Income and Expenses

FINANCIAL INCOME AND EXPENSES


Financial income and expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31


Interest income	1,442	274	137
Foreign exchange gain	4,983	8,876	7,470
Financial income from renegotiating the convertible bond debt OCEANE	0	35,578	0
Other financial income	119	52	605
TOTAL - Financial income	6,544	44,780	8,212
Financial expenses
Interest expenses	(11,643)	(4,846)	(4,341)
Interest expenses for leases	(134)	(109)	(69)
Foreign exchange losses	(13,508)	(2,163)	(340)
Other financial expenses	(11)	(5)	(8)
TOTAL - Financial expenses	(25,296)	(7,122)	(4,758)
FINANCIAL GAIN (LOSS)	(18,752)	37,658	3,453

Interest income recognized is almost exclusively related to current financial assets. Other financial income similarly is almost exclusively related to accrued interest income for ongoing current financial assets at the end of the year.

The financial expenses are related to the interest of the OCEANEs and they mainly relate to the payment of coupons at the rate of 3.5% and the amortization of the discount of the bond debt at the effective interest rate of 8.8% to accrete the bond debt up to the amount that will be repaid (or converted) at maturity, recognizing a theoretical annual interest accrual as a result of the accretion on the period of an amount equivalent to the equity component at an effective interest rate.

The portion of financial gain related to currency exchange is a net gain of €7,130 in 2022 notably due to the difference in currency exchange recognized on the cash equivalents and other current financial assets in US dollars, as GENFIT has decided to keep some of its cash in US dollars. See Note 13 “Cash and cash equivalents”. These cash investments in US dollars are to be used to pay directly expenses in US dollars (natural currency hedge).

As a reminder, financial income in 2021 included notably the one-time buyback bonus of €35.6 million issued from the renegotiation of the OCEANEs completed in said year.

Summary of Financial Income and Expenses


Financial income and expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31


Interest income	1,442	274	137
Foreign exchange gain	4,983	8,876	7,470
Financial income from renegotiating the convertible bond debt OCEANE	0	35,578	0
Other financial income	119	52	605
TOTAL - Financial income	6,544	44,780	8,212
Financial expenses
Interest expenses	(11,643)	(4,846)	(4,341)
Interest expenses for leases	(134)	(109)	(69)
Foreign exchange losses	(13,508)	(2,163)	(340)
Other financial expenses	(11)	(5)	(8)
TOTAL - Financial expenses	(25,296)	(7,122)	(4,758)
FINANCIAL GAIN (LOSS)	(18,752)	37,658	3,453

Commitments

COMMITMENTS

Obligations under the terms of subcontracting agreements

The Group enters into contracts for its business needs with clinical research organizations (CROs) for clinical trials, as well as with Contract Manufacturing Organizations (CMOs) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Group’s agreements generally provide for termination with specified periods of advance notice.

Such agreements are generally cancellable contracts and not included in the description of the Group’s contractual obligations and commitments.

Obligations under the terms of license and collaboration agreements

The Company has entered into a licensing agreement with Genoscience Pharma whereby we are obligated to pay royalties and milestone payments based on future events that are uncertain and therefore they constitute contingent liabilities not recognized in the Company's consolidated financial statements for the period ending December 31, 2022. Refer to N ote 24 "Provisions ".

Obligations related to the Versantis acquisition

The company entered into an agreement with the former shareholders of Versantis whereby we are obligated to pay milestone payments based on future events that are uncertain and there therefore they constitute contingent liabilities not recognized in the Company's consolidated financial statements for the period ending December 31, 2022. Refer to Note 2.1.

Obligations under the terms of lease agreements

The Company has guaranteed its rental payment obligation under the lease agreement for the headquarters in Loos, France in the amount of €600 at December 31, 2022, €600 at December 31, 2021.

Contingent assets

The Company has entered into a licensing agreement with Terns Pharma whereby we could receive milestone payments based on future events that are uncertain and therefore they constitute contingent assets not recognized in the Company's consolidated financial statements for the period ending December 31, 2022.

Milestones include Development Milestone Payments upon the achievement of the development milestones for the licensed product and Commercial Milestone Payments upon the achievement of commercial milestones depending on reaching certain aggregate thresholds. There are also potential mid-teen royalties based on sales by Terns Pharmaceuticals in Greater China. The potential Development and Commercial Milestone payments may represent up to $193 million .

Related Parties

RELATED PARTIES

Compensation of key management personnel

The aggregate compensation of the members of the Company’s Board of Directors (including the Chairman of the Board) and to the Chief Executive Officer includes the following:


	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Fixed compensation owed	518	518	585
Variable compensation owed	71	163	169
Attendance fees - board of Directors	456	488	421
Contributions in-kind	26	23	21
Share-based payments	41	58	74
Employer contributions	405	443	410
Consulting fees	0	0	0
TOTAL	1,517	1,693	1,680

Biotech Avenir

Biotech Avenir SAS is a holding company incorporated in 2001 by the Company's founders. Most of its share capital is currently held by individuals, i.e. the four co-founders of the Company and twelve Company employees.

Jean-François Mouney, the Chairman of the Company, is also the Chairman of Biotech Avenir SAS.

At December 31, 2022, Biotech Avenir SAS held 3.79% of the share capital of the Company.

The Company did not carry out any transactions with Biotech Avenir in 2022, 2021, or 2020, with the exception of the domiciliation without charge.

Ipsen Pharma SAS

The licensing agreement signed with Ipsen Pharma SAS in December 2021 provides for a certain number of service agreements that were signed with the Company in 2022, notably the Inventory Purchase Agreement and the Transition Services Agreement.

These agreements cover support for Ipsen in future proceedings and processes (other than knowledge transfer) and the provision of drug tablets which Ipsen may require to execute its clinical trial. As per the agreement signed with Ipsen in December 2021, the prices under these agreements cover all costs borne by the Company to provide the relevant goods and services, without economic benefit for Ipsen.

See note 7.1 "Revenue s and oth er income ".

The Company	12 Months Ended
The Company	Dec. 31, 2022
Company Information [Abstract]
The Company	THE COMPANY Founded in 1999 under the laws of France, GENFIT S.A. (the "Company") is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative drugs and diagnostic tools in therapeutic areas of high unmet need due in particular to the lack of effective treatments or diagnostic solutions and/or the increase in patients worldwide. The Company focuses its research and development (R&D) efforts on the potential marketing of therapeutic and diagnostic solutions to combat certain metabolic, inflammatory, autoimmune and fibrotic diseases affecting in particular the liver (such as Primary Biliary Cholangitis or PBC) and more generally gastroenterological diseases. The head office address is : 885 Avenue Eugène Avinée – 59120 Loos, France. The consolidated financial statements of the Company include the financial statements of GENFIT S.A. and those of its wholly-owned subsidiaries: GENFIT CORP. (U.S. subsidiary), Versantis AG (Swiss subsidiary), Versantis, Inc. (U.S. Subsidiary), and GENFIT PHARMACEUTICALS SAS (French subsidiary, liquidated prior to December 31, 2022) (together referred to in these notes to the consolidated financial statements as "GENFIT" or the "Group" or “we “ or “us”). There are no non-controlling interests for any period presented herein.

Major Events in the Period and Events After the Period - EUR (€)
€ in Millions

9 Months Ended

12 Months Ended

Sep. 29, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Disclosure Of Major Events In The Period And Events After The Period [Abstract]

Impact On Subcontracting Costs

€ 1.1

ReorganizationAndReductionInForce

171

523

Disclosure of detailed information about business combination [text block]

The consolidated value of net assets acquired of Versantis AG and Versantis, Inc. on September 29, 2022 is as follows :


Total acquired assets and liabilities, in thousands of euros			29/9/2022
Cash and cash equivalents			5,076
Current trade and others receivables			209
Other current assets			78
Intangible assets			45,323
Property, plant and equipment			326
Other non-current financial assets			14
Total acquired assets			51,026

Current trade and other payables			3,202
Current provisions			858
Other current tax liabilities			63
Lease liabilities			302
Total acquired liabilities			4,425

Total purchase price			46,601

Major Events in the Period and Events After the Period

MAJOR EVENTS IN THE PERIOD AND EVENTS AFTER THE PERIODAcquisition of the Clinical-stage Biopharmaceutical Company Versantis

On September 19, 2022, the Company announced it had signed an exclusive agreement with Versantis AG ("Versantis") to acquire all the shares and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. This acquisition aims at:

1.Consolidating GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)

2.Significantly expanding GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-HAC, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE), and

3.Combining Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development

The deal closed effective September 29, 2022.

Total purchase price and contingent milestone payments

This transaction includes:

•an initial payment of 40 million CHF (€41.9 million) due and paid at the date of closing,

•a net cash adjustment payment of 2.8 million CHF (€2.9 million) at the end of the year in accordance with the terms of the acquisition agreement

•additional milestone payments of up to 65 million CHF contingent on the following outcomes:

◦positive Phase 2 results related to VS-01-ACLF,

◦regulatory approval of VS-01-ACLF, and

◦positive Phase 2 results related to VS-02.

Furthermore, the former shareholders of Versantis are eligible to receive 1/3 of the net proceeds resulting from the potential sale of the Priority Review Voucher of VS-01’s pediatric application by GENFIT to a third party, or 1/3 of the fair market value of this Voucher if GENFIT opts to apply it to one of its own programs.

Acquisition costs totaled €1.8 million.

The impact of this acquisition as reflected within the line item "Acquisitions of consolidated undertakings, net of cash acquired" in the consolidated statement of cash flows is a net cash outflow of €41.5 million.

Accounting treatment - IFRS 3

Paragraph B7B sets out an optional test (the concentration test) to permit a simplified assessment of whether an acquired set of activities and assets is not a business. An entity may elect to apply, or not apply, the test. The concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

GENFIT chose to use the available option stated as per IFRS 3 and perform a concentration test to determine if the transaction qualifies as a business combination or asset acquisition. In accordance with the concentration test methodology as defined in paragraph B7B of IFRS 3, the acquisition of Versantis by GENFIT was determined to be an asset acquisition based on the VS-01-ACLF program because its fair value represents more than 90% of the value of all assets acquired. Therefore, the acquisition costs of €1.8 million were included and capitalized in the total cost of the operation to determine the net book value of the VS-01-ACLF program on the date of the acquisition. Conditional milestone payments were not included in this analysis.

Accounting treatment - IAS 21

Consistent with paragraph 8 of IAS 21, Versantis AG is considered as a foreign operation as its activities are conducted primarily in Swiss Francs. The Swiss Franc is thus also considered to be Versantis AG's functional currency. Versantis AG's subsidiary, Versantis Inc., is considered as a foreign operation as its activities are conducted primarily in US Dollars. The US Dollar is thus considered to be Versantis Inc.'s functional currency. For further information on converting and presenting Versantis' activity in euros, refer to note 4.3.2 - Translation of foreign subsidiary financial statements.

Note that on the Consolidated Statements of Other Comprehensive Income and Loss, for the period ending December 31, 2022, on line item "Other comprehensive income (loss) that are or may be reclassified to profit or loss," substantially all of the loss amount of €1.4 million is due to the application of IAS 21 for Versantis.

Supplementary information

The consolidated value of net assets acquired of Versantis AG and Versantis, Inc. on September 29, 2022 is as follows :


Total acquired assets and liabilities, in thousands of euros			29/9/2022
Cash and cash equivalents			5,076
Current trade and others receivables			209
Other current assets			78
Intangible assets			45,323
Property, plant and equipment			326
Other non-current financial assets			14
Total acquired assets			51,026

Current trade and other payables			3,202
Current provisions			858
Other current tax liabilities			63
Lease liabilities			302
Total acquired liabilities			4,425

Total purchase price			46,601

The exchange rate used above to convert the assets and liabilities of Versantis AG into euros was 1.04843 (1 CHF = 1.04843) on September 29, 2022. The exchange rate used above to convert the assets and liabilities of Versantis, Inc. into euros was 0.9706 (1 USD = 0.9706) on September 29, 2022.

The net book value of assets and liabilities as of December 31, 2022 is as follows, per the application of IAS 21:


Net assets, in thousands of euros			31/12/2022
Cash and cash equivalents			2,168
Current trade and others receivables			17
Other current assets			197
Intangible assets			43,850
Property, plant and equipment			295
Other non-current financial assets			13
Total assets			46,540

Current trade and other payables			1,614
Current provisions			672
Other current tax liabilities			33
Lease liabilities			282
Total liabilities			2,601

Net assets			43,939

The exchange rate used above to convert the assets and liabilities of Versantis AG into euros was 1.01554 (1 CHF = 1.01554) on December 31, 2022. The exchange rate used above to convert the assets and liabilities of Versantis, Inc. into euros was 0.93756 (1 USD = 0.93756) on December 31, 2022.

Research and development expenses for the period between September 29, 2022 and December 31, 2022 attributable to Versantis total €1,187 thousand. If the acquisition had taken place on January 1, 2022, research and development expenses would have been €5,833 thousand.

General and administrative expenses for the period between September 29, 2022 and December 31, 2022 attributable to Versantis total €228 thousand.

For further information, refer to N ote 14 - "Goodwill and Intangible Assets"

Agreements and partnership with Ipsen

2021 Collaboration and License Agreement

In December 2021, GENFIT and Ipsen Pharma SAS ("Ipsen") entered into an exclusive licensing agreement for elafibranor, a Phase 3 asset evaluated in Primary Biliary Cholangitis (PBC), as part of a long-term global partnership ("Collaboration and License Agreement"). The agreement gives Ipsen exclusive worldwide license (with the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals, Inc. ("Terns Pharmaceuticals") holds the exclusive license to develop and commercialize elafibranor) to develop and commercialize elafibranor, GENFIT's first-in-class drug candidate, a PPAR alpha and PPAR delta agonist, for people living with PBC, a rare chronic inflammatory liver disease.

The Collaboration and License Agreement qualifies as a contract under IFRS 15, and meets the criteria under IFRS 15.9.

Under this agreement:

•GENFIT remains responsible for the Phase 3 ELATIVE trial until the completion of the double-blind period. Ipsen will assume responsibility for all additional clinical development, including completion of the long-term extension period of the ELATIVE trial, and commercialization.

•GENFIT received from Ipsen an upfront cash payment of €120 million in December 2021 (with an additional €24 million in collected VAT), of which €80 million was recognized as revenue in 2021. The remainder of this upfront payment (€40 million) has been recognized in 2021 as deferred revenue and will be recognized as revenue throughout the execution of the double-blind period of the ELATIVE study, in accordance with IFRS 15. In 2022, of the initial €40 million of deferred revenue, €15.9 million was recognized as revenue for services provided in accordance with IFRS 15.

•GENFIT is also eligible for milestone payments up to €360 million. These milestone payments constitute future variable income, dependent on the completion of key steps related to the development and sales of the licensed products. As such, in accordance with IFRS 15, this income will be recognized as revenue depending on the completion of these milestones. No such milestone payments were made in 2021 or 2022.

•GENFIT is eligible for tiered double-digit royalties of up to 20%, applied to the annual sales of licensed products realized by Ipsen. As such, in accordance with IFRS 15, this income will be recognized as revenue depending on the realization of these sales. No such royalties were earned in 2021 or 2022.

Beyond the collaboration between GENFIT and Ipsen in PBC, this agreement also constitutes a strategic partnership, allowing Ipsen to access the research skills of GENFIT and other clinical programs, including some rights to first negotiation (while not being constitutive of a service obligation under IFRS 15).

Ipsen Ownership Stake in GENFIT

Additionally, in 2021, Ipsen also became a shareholder of GENFIT through the purchase of 3,985,239 newly issued shares representing 8% of GENFIT S.A after issuance, via a €28 million investment. The new shares were issued pursuant to the twentieth resolution of GENFIT’s June 30, 2021 shareholders’ meeting. As of December 31, 2022, they are still subject to a lock-up period, ending in the event of positive ELATIVE results, on the earlier of i) the date on which the EMA makes a formal recommendation to the European Commission for the marketing authorization of elafibranor in PBC or ii) the date on which the U.S. FDA grants approval of elafibranor in PBC. In addition, during the shareholder's meeting on May 25, 2022, GENFIT proposed and approved Ipsen as a board member. Ipsen is represented by Dr. Steven Hildemann, MD., PhD. He serves as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance at Ipsen.

2022 Follow-on Agreements: Transition Services Agreement and Inventory Purchase Agreement

In 2022, GENFIT and Ipsen entered into a Transition Services Agreement, which outlines the scope of services to facilitate the transition of some activities related to the Phase 3 clinical trial evaluating elafibranor in Primary Biliary Cholangitis. This agreement is a supplementary follow-on to the Collaboration and License Agreement mentioned above. We evaluated the agreement under IFRS 15 and we concluded that the services constitute a single performance obligation for which revenue is recognized as services are performed. In 2022, €1.0 million in revenue was generated from the services rendered by GENFIT to Ipsen in accordance said agreement and consistent IFRS 15.

In 2022, GENFIT and Ipsen entered into an Inventory Purchase Agreement, pursuant to which Ipsen purchased inventory from GENFIT, namely the elafibranor active pharmaceutical ingredient and related drug product, during the second half of 2022 with the prospect of transferring the conduct of the ELATIVE study to Ipsen. We evaluated the agreement under IFRS 15 and we concluded that the services constitute a single performance obligation for which revenue is recognized when inventory is provided to Ipsen. In 2022, €3.3 million was recognized as revenue from the sale of said inventory in accordance with said agreement and consistent IFRS 15.

Regarding the application of IFRS15, see Note 7 "Revenue s and other income.".

Termination of RESOLVE-IT and the development program of elafibranor in NASH

Following the decision by the Company in July 2020 to terminate its Phase 3 RESOLVE-IT trial (see 2020 Form 20-F), the impacts of the RESOLVE-IT termination process, and more broadly the discontinuation of the elafibranor development program in NASH continued to have a significant impact in 2021.

Impact on subcontracting costs

In 2022, the residual impact of the RESOLVE-IT study are based on two main topics:

•Firstly, the Company did not received any charge in 2022 from the main subcontractor (CRO) for this study, because of the investigation sites closure and invoicing of final residual costs in 2021 .

•Secondly, the Company reversed 2021 accruals, amounting of €1.1 million, based on communication with the CRO (in particular as it relates to investigator costs).

Finally, the Company benefited in 2022 from an "end of study" credit note, ending the study in July, and bringing the provision recognized in the balance sheet for RESOLVE-IT to zero.

Impact on scientific equipment leased and owned

The Group has analyzed the impact of the closing of RESOLVE-IT and its decision to reorganize its activities on its scientific equipment. An inventory of the equipment that could be sold, kept as a spare, or disposed of, was completed in the second half of 2020.

Leased equipment

Following the sale and/or disposal of part of this equipment in 2021 and 2022, the loss in value of the remaining equipment (determined in order to take into account the potential loss compared to the net book value of the right of use to assets) amounted to €28 at December 31, 2022 (compared to €62 at the end of 2021 and €503 at the end of 2020).

Owned equipment

Following the disposal of part of this equipment in 2021 and an updated impairment analysis in 2022 related to certain unused equipment, the loss in value of the remaining equipment amounts to €27 at December 31, 2022 (compared to €25 at the end of 2021 and €363 thousand euros at the end of 2020).

Premises

The loss in value of the right to use the premises leased by the Company in Lille and Paris amounts to €479 (including the layout of the premises) as of December 31, 2022 (compared to €596 at the end of 2021 and €1,275 at the end of 2020), taking into account in particular the relocation of the Company's Paris offices in 2021 and the indexation of rent at the Loos site.

See Note 8 - “Property, Plant and Equipment”.

Reorganization and reduction in force

Following the reorganization and reduction in force plan (plan de sauvegarde de l’emploi or “PSE”) implemented by the company during the second half of 2020, the residual provision relating to the support measures granted under this PSE (premiums for quick return to employment, training, business creation aid) amounted to €21 at December 31, 2022 (compared to €171 at the end of 2021 and €523 at the end of 2020), taking into account reversals of €77 recorded in 2022.

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2022
Disclosure Of Basis Of Presentation [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The Consolidated Financial Statements of GENFIT have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), and in accordance with IFRS as adopted by the European Union at December 31, 2022. The Comparative information is presented as of and for the years ended December 31, 2021 and December 31, 2020. The consolidated financial statements have been prepared using the historical cost measurement basis except for certain assets and liabilities that are measured at fair value in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality and aggregation These consolidated financial statements for the year ended December 31, 2022 were prepared under the responsibility of the Board of Directors that approved such statements on April 13, 2023. The term IFRS includes International Financial Reporting Standards ("IFRS"), International Accounting Standards (the "IAS"), as well as the Interpretations issued by the Standards Interpretation Committee (the "SIC"), and the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting methods used to prepare the Consolidated Financial Statements are described below. All financial information (unless indicated otherwise) is presented in thousands of euros (€). hanges in accounting policies and new standards or amendments The accounting policies applicable for these consolidated annual financial statements are the same as those applied to the previous consolidated annual financial statements. The following new standards are applicable from January 1, 2022, but do not have any material effect on the Group’s financial statements as of and for the year ended December 31, 2022. •Amendment to IAS 37 - Onerous Contracts — Cost of Fulfilling a Contract, •Amendment to IFRS 3 - Reference to the Conceptual Framework, •Amendment to IAS 16 - Proceeds before intended use, and •Annual IFRS improvements - 2018-2020 Cycle. Standards, interpretations and amendments issued but not yet effective The GENFIT Group has not identified any standards or amendments issued and in force and anticipated as of January 1, 2021 or applicable to the periods starting as of January 1, 2022 that may have a significant impact on the Group's consolidated financial statements, notably: –IFRS 17 Insurance Contracts, effective in 2023, –Amendments to IFRS 17 - First application of IFRS 17 and IFRS 9 - Comparative Information, effective in 2023, –Amendments to IAS 1 and Practice Statement 2 - Disclosure of Accounting Policies, effective in 2023, –Amendments to IAS 8 Definition of Accounting Estimates, effective in 2023, –Amendments to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction, effective in 2023, and –Amendments to IAS 1 Classification of Liabilities as Current or Non-current, effective in 2024.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Disclosure of voluntary change in accounting policy [abstract]

Disclosure of significant accounting policies [text block]

SUMMARY OF MATERIAL ACCOUNTING INFORMATIONUse of estimates and judgments

In preparing these consolidated financial statements, management makes judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, incomes and expenses. Actual amounts may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

The estimates and underlying assumptions mainly relate to research tax credits (see Note 7.2 "O ther income ", employee benefits (see Note 25 "Employee benefits"), leases (see Note 15 “Property, plant and equipment including Leases”), share-based payments (see Note 9 "Share-based compensation"), accruals related to clinical trials (see Note 8 "Operating expenses"), convertible loans (see Note 20.1 "Breakdown of convertible loan"), accounting judgments related to the Versantis acquisition (see Note 2.1 "Acquisition of the Clinical-stage Biopharmaceutical Company Versantis "), the valuation of our investment in Genoscience (See Note 18 "Other fi nancial assets "), and the allocation of income to the performance obligations provided for in the agreement entered into with Ipsen (see Note 7 "Revenues and Other Income").

When assessing going concern, the Group’s Board of Directors considers mainly the following factors:

The liquidity available at the statement of financial position date, the cash spend projections for next 12-month period as from the date of the financial statements are issued and the availability of other funding.

Consolidation

Going concern

The consolidated financial statements were prepared on a going concern basis. The Group believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication.

Consolidated entities

The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity.

The Group controls all the entities included in the scope of consolidation.

GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.

Foreign currency

4.3.1.Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of the entities of the Group at the exchange rates applicable at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the reporting date.

The resulting exchange gains or losses are recognized in the statements of operations.

4.3.2.Translation of foreign subsidiary financial statements

The assets and liabilities of foreign operations having a functional currency different from the euro are translated into euros at the closing exchange rate. The income and expenses of foreign operations are translated into euros at the exchange rates effective at the transaction dates or using the average exchange rate for the reporting period unless this method cannot be applied due to significant exchange rate fluctuations.

Gains and losses arising from foreign operations are recognized in the statement of other comprehensive loss. When a foreign operation is partly or fully divested, the associated share of gains and losses recognized in the currency translation reserve is transferred to the statements of operations.

The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.

The functional currency of GENFIT CORP and Versantis, Inc. is the U.S. dollar. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

SEGMENT INFORMATION

The Board of Directors and Chief Executive Officer are the chief operating decision makers.

The Board of Directors and the Chief Executive Officer oversee the operations and manage the business as one segment with a single activity; namely, the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Revenues from contracts with customers

Accounting policy overview

Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, i.e., when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service.

Under this standard, each contract must be analyzed, on a case-by-case basis, in order to verify whether it contains performance obligations towards third parties, and, if applicable, to identify their nature in order to determine the appropriate accounting of amounts that the Company has received or is entitled to receive from third parties, for example:

•The transfer of control over the intellectual property, via a license granted by the Company, as it exists at the time of the sale, the date of which will determine that of the revenue recognition;

•If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime;

•The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and

•Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.

Research tax credit

The Research Tax Credit ("Crédit d'Impôt Recherche," or "CIR") is granted to entities by the French tax authorities in order to encourage them to conduct technical and scientific research. Entities that demonstrate that their research expenditures meet the required CIR criteria receive a tax credit that may be used for the payment of their income tax due for the fiscal year in which the expenditures were incurred, as well as in the next three years. If taxes due are not sufficient to cover the full amount of tax credit at the end of the three-year period, the difference is paid in cash to the entity by the tax authorities. If a company meets certain criteria in terms of sales, headcount or assets to be considered a small/mid-size company, immediate payment of the Research Tax Credit can be requested. The Group meets such criteria.

The Group applies for CIR for research expenditures incurred in each fiscal year and recognizes the amount claimed in the line item "Other income" in the statements of operations in the same fiscal year. In the notes to the financial statements, the amount claimed is recognized under the heading "Research tax credit" (see Note 16, "Trade and other receivables" and the table below).

7.2.2.Government grants

Government grants

The Group received until 2016 various forms of government grants. This government aid is provided for and managed by French state-owned entities, and specifically "BPI France" ("Banque Publique d'Investissement"), formerly named "OSEO Innovation".

Subsidies received are non-refundable.

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

Contracted research and development activities conducted by third parties include services subcontracted to research partners for technical and/or regulatory reasons. In particular, this includes the production of active ingredients and therapeutic units, all or a part of clinical trials and preclinical trials that are necessary to the development of GENFIT's drug candidates and biomarker candidates.

General and administrative expenses include:

•employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions;

•facility-related costs;

•marketing, legal, audit and accounting fees;

•press relations and communications firm fees;

•the cost of external employees seconded to the Company (such as security, reception, and accounting...);

•other service costs (recruitment, etc.); and

•intellectual property fees corresponding to the maintenance of the Group's patents.

Marketing and market access expenses include:

•employee-related costs for marketing and business development functions; and

•marketing, and market access firm fees.

Reorganization and restructuring expenses include:

•the accruals and provisions recognized within the scope of the reduction in force plan;

•the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT;

•the impairment of the right of use of the leased equipment and premises;

•the portion of the OCEANEs renegotiation expenses;

•the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.

Accounting policies

The fair value of equity-settled share-based compensation granted to employees, officers, board members and consultants as determined on the grant date is recognized as a compensation expense with a corresponding increase in equity, over the vesting period. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market performance conditions are expected to be met.

Evaluation models

The fair value of equity-settled share-based compensation granted to employees are measured using i) the Black-Scholes model for share warrants ("Bons de Souscriptions d'Actions" or "BSA") and stock options ("SO") and ii) the Monte Carlo model for free shares ("actions gratuites" or "AGA").

Data and key assumptions used in evaluations

For evaluating BSAs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: issue price, exercise price, expected volatility, exercise period, expected dividends, risk free interest rate (based on government bonds), and conversion ratio.

For evaluating AGAs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: grant date, share price at grant date, expected volatility, vesting period, expected dividends, risk free interest rate (based on government bonds), conversion ratio, and expected employee turnover.

For evaluating SOs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: grant date, share price at grant date, exercise price, expected volatility, vesting period, exercise period, expected dividends, risk free interest rate (based on government bonds), conversion ratio, and expected employee turnover.

Regarding SOs and AGAs, market conditions are taken into account in the determination of the fair value of the plans award. For share-based compensation awards with non-vesting conditions, the grant date fair value of the share-based compensation is measured to reflect such conditions and there is no adjustment for differences between expected and actual outcomes.

Volatility assumptions in the above tables are determined by reference to the Company's historical share price observed on the grant date over a two- and three-year period prior to the grant date, adjusted for extreme variations, if any.

Consultants

GENFIT may also grant equity-settled share-based compensation in exchange for services to consultants who are not considered employees. In such cases, the value of the services is measured when they are rendered by the consultants and the share-based compensation exchanged for the services is measured at an equal amount. If the value of the services cannot be measured reliably, then such value is measured with reference to the fair value of the equity instruments granted.

Accounting policies

Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable.

Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities.

Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that:

•it is probable that future taxable profit will be available against which they can be used; or

•if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.

Earnings (loss) per share

Basic earnings (loss) per share are calculated by dividing profit or loss attributable to the Company's ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings (loss) per share are calculated by adjusting profit attributable to ordinary shareholders and the average number of ordinary shares outstanding weighted for the effects of all potentially dilutive instruments (share warrants, redeemable share warrants, free shares, stock options and bonds convertible into new and/or existing shares).

CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise cash on hand, bank accounts and term deposits, together with short-term deposits and highly liquid investments. They are readily convertible to a known amount of cash and thus present a negligible risk of a change in value. They also include Undertakings for Collective Investments in Transferable Securities (UCITs) whose characteristics allow them to be classified as cash and cash equivalents.

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Goodwill

The company does not have any goodwill.

Intangible assets

Intangible assets mainly consist of software and operating licenses acquired by the Group. They are recognized at cost less accumulated amortization and impairment. Amortization expense is recorded on a straight-line basis over the estimated useful lives of the intangible assets. The estimated useful lives of both software and license agreements are between 1 and 8 years.

Leases

IFRS 16 introduces for the lessee a single model of accounting on the balance sheet for leases. The lessee recognizes a "right of use" asset which represents its right to use the underlying asset, and a lease liability for its obligation to pay the rent.

The Group recognizes a "right of use" asset and a lease liability at the start of the lease term. The "right of use" asset is initially measured at cost and then at cost less any amortization and accumulated impairment losses. The amount can be adjusted based on certain revaluations of the lease liability.

The lease liability is initially measured at the discounted value of the rents owed and not yet paid at the start date of the contract. The discount rate used is the implicit interest rate of the contract or, if it cannot be easily determined, the Company’s incremental borrowing rate of the lessee. The Group generally uses the latter as the discount rate.

The lease liability is then adjusted by the interest expense minus the amounts of rent paid. It is revalued in the event of a change in future rents following a change in the index or rate, a new estimate of the amount to be paid under a residual value guarantee or, where applicable, a revaluation of the exercise of an option to purchase or to extend, or the non-exercise of an option to terminate (which then becomes reasonably certain).

The Group has exercised its judgment in determining the term of the lease agreements that provide for extension options. The fact that the Group has determined that it is reasonably certain to exercise such options has an impact on the lease term used and has a significant impact on the amount of lease debt and the "right of use" asset in the accounts. The amount of short term or low value leases which are not included in the IFRS 16 model is not material.

TRADE AND OTHER RECEIVABLES

Accounting policies

Trade and other receivables are recognized at fair value, which is the nominal value of invoices unless payment terms require a material adjustment for the time value discounting effect at market interest rates. Trade receivables are subsequently measured at amortized cost. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables .

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

INVENTORIES

The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements.

These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is initially recognized as measured at amortized cost, at fair value through other comprehensive income - debt instrument, at fair value through other comprehensive income - equity instrument, or at fair value through profit or loss.

Financial assets will not be reclassified after initial recognition, unless we change our economic model of financial asset management. If so, all affected financial assets would be reclassified as of the first day of the first reporting period following the change in economic model.

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

At the time of initial recognition of an equity instrument that is not held for trading, we may irrevocably choose to present future changes in fair value in other comprehensive income. This choice is made for each investment.

All financial assets that are not categorized as measured at amortized cost or at fair value through other comprehensive income as previously described are measured at fair value through profit or loss.

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

The bonds convertible or exchangeable into new or existing shares (OCEANEs—see Note 20 .1 "Breakdown of convertible loan ") are recognized as follows: in accordance with IAS 32, Financial Instruments—Presentation, if a financial instrument has different components and the characteristics indicate that some should be classified as liabilities and others as equity, the issuer must recognize the different components separately.

The liability component is measured, at the date of issuance, at its fair value on the basis of future contractual cash flows discounted at market rates (taking into consideration the issuer's credit risk) of a debt having similar characteristics but without the conversion option.

The value of the conversion option is measured by the difference between the bond's issue price and the fair value of the liability component. After deduction of the pro rata portion of expenses related to the transaction, this amount is recognized in the line item "Share premium" under shareholders' equity and is subject to a calculation of deferred tax according to IAS 12.28.

The liability component (after deduction of the pro rata portion of the transaction expenses attributed to the liability and the conversion option) is measured at amortized cost. A non-monetary interest expense, recorded in net loss is calculated using an effective interest rate to progressively bring the debt component up to the amount which will be repaid (or converted) at maturity. A deferred tax liability is calculated on the basis of this amount. The shareholders' equity component is not remeasured.

TRADE AND OTHER PAYABLES

Accounting policies

Trade and other payables are initially recognized at the fair value of the amount due. This value is usually the nominal value, due to the relatively short period of time between the recognition of the instrument and its repayment.

ProvisionsAccounting policies

In accordance with IAS 37, Provisions Contingent Liabilities and Contingent Assets, provisions are recognized when the Group has a present obligation (legal, regulatory, contractual or constructive) as a result of a past event, for which it is probable that an outflow of resources will be required to settle the obligation, and of which the amount can be estimated reliably.

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

A provision for reorganization is recognized when the Group has approved a formal and detailed plan for its reorganization and has either started to implement it or publicly disclosed it. A provision for onerous contract is estimated at the actual value of the lowest expected cost of either the cancellation or the execution of the contract, the latter being established on the basis of the additional costs required to fulfill the obligations stipulated by the contract. Before a provision is established, the Group recognizes any impairment loss that occurred on the assets dedicated to this contract.

Future milestone and revenue based royalty payments may be recorded pursuant to Contingent liability under IAS 37 or intangible asset under IAS 38. Under IAS 38, we record a provision when we have a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources. Under IAS 38, we record intangible asset when it is probable that the expected future economic benefits that are attributes to the assets will flow to us and the cost of asset can be measured reliably.

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Defined benefit plans relate to French retirement benefit plans under which the Group is committed to guaranteeing a specific amount or level of contractually defined benefits. The obligation arising from these plans is measured on an actuarial basis using the projected unit credit method. The method consists of measuring the obligation based on a projected end-of-career salary and vested rights at the measurement date, according to the provisions of the collective bargaining agreement, corporate agreements and applicable law.

Actuarial assumptions are used to determine the benefit obligations. The amount of future payments is determined on the basis of demographic and financial assumptions such as mortality, staff turnover, pay increases and age at retirement, and then discounted to their present value. The discount rate used is the yield at the reporting date on AA credit-rated bonds with maturity dates that approximate the expected payments for the Group's obligations.

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

The Group determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments.

25.2.Defined contribution plans

Under defined contribution plans, the management of plans is performed by an external organization, to which the Group pays regular contributions. Payments made by the Group in respect of these plans are recognized as an expense for the period in the statements of operations.

25.3.Short-term employee benefits

A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

EQUITY

Accounting policies

Share capital comprises ordinary shares and ordinary shares with double voting rights classified in equity. Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium.

The liquidity agreement consists of a share buyback program contracted to an investment service provider. Purchases and sales of the Company's shares carried out under the contract are recognized directly in shareholders’ equity under treasury shares. See N ote 18 “Other financial assets”

Operating segments

12 Months Ended

Dec. 31, 2022

Segment information [Abstract]

Disclosure of entity's operating segments [text block]

The assets, liabilities and operating income (loss) are mainly located in France and in Switzerland (the latter as a result of the acquisition of Versantis in September 2022).

Revenue breakdown by geographical area


Revenue by destination	Year ended
(in € thousands)	12/31/2020		12/31/2021		12/31/2022
Revenue from France	100	%	100	%	100	%
Revenue from other countries	—	%	—	%	—	%
TOTAL	100	%	100	%	100	%

In 2022, revenue was generated entirely in France. Substantially all revenue was generated from Ipsen in 2022.

In 2021, revenue was generated entirely in France. Substantially all revenue was generated from Ipsen in 2021.

In 2020, revenue was generated entirely in France. Revenue originated from license agreements with Labcorp and one-off revenue resulting from the sale of goods and services notably within the scope of the license and collaboration agreement with Terns Pharmaceuticals.

Non-current assets by geographical area

Non-current assets break down by geographical area as follows:

NON-CURRENT ASSETS

As of December 31, 2021

As of December 31, 2022

(thousands of euros)

France

Switzerland

Total

France

Switzerland

Total

TOTAL

13,623

12,923

44,158

57,081

Financial Risks Management

12 Months Ended

Dec. 31, 2022

Foreign exchange rates [abstract]

Financial Risks Management

FINANCIAL RISKS MANAGEMENTThe Group may be exposed to the following risks arising from financial instruments: foreign exchange risk, interest rate risk, liquidity risk and credit risk.Foreign exchange risk

The Group's overall exposure to the foreign exchange risk depends, in particular, on:

•the currencies in which it receives its revenues;

•the currencies chosen when agreements are entered into, such as licensing agreements, or co-marketing or co-development agreements;

•the location of clinical trials on drug or biomarker candidates;

•the ability, for its co-contracting parties to indirectly transfer foreign exchange risk to the Company;

•the Group’s foreign exchange risk policy; and

•the fluctuation of foreign currencies against the euro.

Given the significant portion of its operations denominated in US dollars, the Group decided to limit the conversions into euros of its US dollar denominated cash, issued notably from its March 2019 Nasdaq IPO in US dollars, and not to use any specific hedging arrangements, in order to cover expenses denominated in US dollars over the coming years.

The following table shows the sensitivity of the Group's cash and cash equivalent and expenses in U.S. dollars to a variation of 10% of the U.S. dollar against the euro in 2020, 2021 and 2022.


Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10%	As of
of the US dollar against the euro
(in € thousands or in US dollar thousands, as applicable)	2021/12/31	2022/12/31
Cash and cash equivalents denominated in US dollars	81,713	34,192
Equivalent in euros, on the basis of the exchange rate described below	72,146	32,057
Equivalent in euros, in the event of an increase of 10% of US dollar vs euro	80,163	35,619
Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro	65,588	29,143


Sensitivity of the Group's expenses to a variation of +/- 10%	Year ended
of the US dollar against the euro
(in € thousands or in US dollar thousands, as applicable)	2020/12/31	2021/12/31	2022/12/31
Expenses denominated in US dollars	47,277	12,566	14,884
Equivalent in euros, on the basis of the exchange rate described below	38,528	11,095	13,955
Equivalent in euros, in the event of an increase of 10% of US dollar vs euro	42,808	12,328	15,506
Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro	35,025	10,086	12,686

2022/12/31: Equivalent in euros, on the basis of 1 euro = 1.0666 dollars US.

2021/12/31: Equivalent in euros, on the basis of 1 euro = 1.1326 dollars US.

2020/12/31: Equivalent in euros, on the basis of 1 euro = 1.2271 dollars US.

The following table shows the sensitivity of the Group's cash and cash equivalent and expenses in Swiss Francs to a variation of 10% of the Swiss Franc against the euro in 2022.

Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10%

As of

of the CH franc against the euro

(in € thousands or in CH franc thousands, as applicable)

2020/12/31

2021/12/31

2022/12/31

Cash and cash equivalents denominated in CH franc

N/A

2,321

Equivalent in euros, on the basis of the exchange rate described below

N/A

2,357

Equivalent in euros, in the event of an increase of 10% of CH franc vs euro

N/A

2,618

Equivalent in euros, in the event of a decrease of 10% of CH franc vs euro

N/A

2,142

Sensitivity of the Group's expenses to a variation of +/- 10%

Year ended

of the CH franc against the euro

(in € thousands or in CH franc thousands, as applicable)

2020/12/31

2021/12/31

2022/12/31

Expenses denominated in CH franc

N/A

2,016

Equivalent in euros, on the basis of the exchange rate described below

N/A

2,048

Equivalent in euros, in the event of an increase of 10% of CH franc vs euro

N/A

2,275

Equivalent in euros, in the event of a decrease of 10% of CH franc vs euro

N/A

1,862

2022/12/31: Equivalent in euros, on the basis of a 1 euro = 0.9847 CHF.


Cash, cash equivalents and financial assets	As of
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
At origin, denominated in EUR
Cash and cash equivalents	80,391	186,609	101,536
Current and non current financial assets	1,391	4,355	9,456
Total	81,782	190,964	110,993
At origin, denominated in USD
Cash and cash equivalents	90,637	72,147	32,057
Current and non current financial assets	67	76	7
Total	90,704	72,223	32,064
At origin, denominated in CHF
Cash and cash equivalents	—	—	2,358
Current and non current financial assets	—	—	—
Total	—	—	2,358
Total, in EUR
Cash and cash equivalents	171,029	258,756	136,001
Current and non current financial assets	1,458	4,431	9,464
Total	172,486	263,187	145,464

Interest rate risk

As of December 31, 2022, the Group was only liable for governmental advances or conditional advances and bank loans with no interest or interest at a fixed rate, generally below market rate.

As of December 31, 2021 and 2022, the Group's financial liabilities totaled €74.2 million and €75.3 million respectively (net of the equity component of the convertible loan and debt issue costs). Current borrowings are at a fixed rate. The Group's exposure to interest rate risk through its financial assets is also insignificant since these assets are mainly euro-denominated Undertakings for the Collective Investment of Transferable Securities (UCITs), medium-term negotiable notes or term deposits with progressive rates denominated in euros or US dollars.

Liquidity risk

The Group's loans and borrowings mainly consist of bonds convertible or exchangeable into new or existing shares (OCEANE), repayable for an nominal amount of €57 million on October 16, 2025 (see Note 20.1 "Breakdown of convertib le l oan "), government advances for research projects and bank loans. For conditional advances, reimbursement of the principal is subject to the commercial success of the related research project (see Note 20.2.1 "Refundable and conditional advances ").

The Company has conducted a specific review of its liquidity risk and considers that it is able to meet its future maturities. On December 31, 2021 and 2022, the Group had €263,187 and €145,464 respectively in cash and cash equivalents and other financial assets. The Company does not believe it is exposed to short-term liquidity risk. The Company believes that the Group's cash and cash equivalents and current financial instruments are sufficient to ensure its financing for the next 12 months, in light of its current projects and obligations.

If the Group's funds are insufficient to cover any additional financing needs, the Group would require additional financing. The conditions and arrangements for any such new financing would depend, among other factors, on economic and market conditions that are beyond the Group's control.Credit riskCredit risk is the risk of financial loss if a customer or counterparty to a financial asset defaults on their contractual commitments. The Group is exposed to credit risk due to trade receivables and other financial assets.The Group's policy is to manage this risk by transacting with third parties with good credit standards.

Cash and Cash Equivalents

12 Months Ended

Dec. 31, 2022

Cash and cash equivalents [abstract]

Cash and Cash Equivalents

CASH AND CASH EQUIVALENTS

The main components of cash equivalents were:

•UCITS and interest-bearing current accounts, available immediately;

•Term accounts, available within the contractual maturities or by the way of early exit with no penalty; and

•Negotiable medium-term notes, available with a quarterly maturity or by the way of early exit with no penalty.

These investments, summarized in the tables below, are short-term, highly liquid and subject to insignificant risk of changes in value.


Cash and cash equivalents	As of
(in € thousands)	2021/12/31	2022/12/31
Short-term deposits	69,045	119,090
Cash on hand and bank accounts	189,711	16,910
TOTAL	258,756	136,001

Short-term deposits

As of

(in € thousands)

2021/12/31

2022/12/31

TERM ACCOUNTS

69,045

119,090

TOTAL

69,045

119,090

Cash and cash equivalents

CASH AND CASH EQUIVALENTS

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Intangible Assets

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about intangible assets [abstract]

Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The company does not have any goodwill.

Intangible assets

In the event of an acquisition not qualifying as a business combination under IFRS 3, GENFIT initially records the acquired asset at cost of the consideration transferred, excluding variable payments that are dependent on future events. No liability is recognized initially for these contingent payments. A liability will be recorded when the condition that triggers the obligation occurs.

The variable payments that would be due if the asset acquired complies with agreed-upon specifications at specific dates in the future are recognized as an adjustment to the cost of the related asset.

Acquisition of Versantis

As previously noted in note 2.1 Acquisition of the Clinical-stage Biopharmaceutical Company Versantis, on September 29, 2022, GENFIT acquired Versantis AG, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases.

The Phase 2 ready program, VS-01-ACLF, a program in scavenging liposomes technology, was deemed to be the asset with substantially all attributable value in accordance with the optional concentration test of fair value under paragraph B7A of IFRS 3. Of the total acquisition price paid of €46.6 million, €43.9 million was allocated to Intangible assets in accordance with IAS 38 - Intangible Assets. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction. Further, given the nature of the intangible asset, it was determined to have a definite useful life of 20 years, consistent with patents lifetimes in the United States and the European Union. Amortization will start upon EMA/FDA regulatory approval and until then will be subject to an annual impairment test in accordance with IAS 38 - Intangible Assets.

The following tables show the variations in intangible assets for the years ended December 31, 2021 and 2022:


	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	12/31/2020			adjustments		12/31/2021
Gross


Software	1,440	126	(255)	—	(17)	1,294
Patents	91	—	(21)	—	—	70

Other intangibles	—	—	(17)	—	17	—
TOTAL—Gross	1,531	127	(294)	—	—	1,364
Accumulated depreciation and impairment


Software	(1,213)	(152)	176	—	—	(1,190)
Patents	(21)	—	21	—	—	—

Other intangibles	—	—	—	—	—	—
TOTAL - Accumulated depreciation and impairment	(1,234)	(152)	197	—	—	(1,190)
TOTAL - Net	297	(26)	(97)	—	—	174


	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	12/31/2021			adjustments		2022/12/31
Gross


Software	1,294	81	(398)	—	—	977
Patents	70	281	—	—	—	351

Other intangibles	—	43,569	—	—	—	43,569
TOTAL—Gross	1,364	43,931	(398)	—	—	44,897
Accumulated depreciation and impairment


Software	(1,190)	(79)	329	—	—	(940)
Patents	—	—	—	—	—	—

Other intangibles	—	—	—	—	—	—
TOTAL - Accumulated depreciation and impairment	(1,190)	(79)	329	—	—	(940)
TOTAL - Net	174	43,852	(69)	—	—	43,957

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about property, plant and equipment [abstract]

Property, Plant and Equipment

PROPERTY, PLANT AND EQUIPMENT

Property, Plant and Equipment

Property, plant and equipment are initially recognized at cost. Cost includes expenditures that are directly attributable to the acquisition of the asset. Routine maintenance costs are expensed as incurred.

Subsequently, depreciation expense is recognized on a straight-line basis over the estimated useful lives of the assets. If components of property, plant and equipment have different useful lives, they are accounted for separately. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted, if appropriate.

Estimated useful lives are as follows:


Building on non-freehold land			10 years
Fittings and fixtures			Between 9 and 25 years
Scientific equipment			Between 2 and 12 years
Computer equipment			Between 2 and 5 years
Furniture			Between 4 and 10 years
Vehicles			Between 4 and 6 years

Any gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the item. The net amount is recognized in the consolidated statements of operations under the line item "Other operating income (expenses)."

Leases

The following tables show the variations in tangible assets for the years ended December 31, 2021 and 2022:


Property, plant and equipment - Variations	As of As of	Increase	Decrease	Translation	Reclassification	As of As of
(in € thousands)	As of 2020/12/31			adjustments		As of 2021/12/31
Gross


Buildings on non-freehold land	12,167	—	(1,912)	—	56	10,311
Scientific equipment	9,080	71	(2,831)	—	—	6,320
Fittings	1,703	(4)	(234)	—	9	1,474
Vehicles	99	60	(67)	—	—	91
Computer equipment	1,534	30	(18)	—	(4)	1,542
Furniture	329	—	(50)	—	—	279
In progress	—	330	(342)	—	12	—
TOTAL - Gross	24,911	487	(5,454)	—	74	20,017











Accumulated depreciation


Buildings on non-freehold land	(2,603)	(1,417)	1,120	—	—	(2,900)
Scientific equipment	(5,952)	(1,061)	2,145	—	—	(4,868)
Fittings	(982)	(91)	190	(5)	—	(888)
Vehicles	(85)	(13)	67	—	—	(31)
Computer equipment	(1,217)	(195)	14	(6)	—	(1,403)
Furniture	(251)	(12)	50	—	—	(213)
In progress	—	—	—	—	—	—
TOTAL - Accumulated depreciation	(11,090)	(2,789)	3,587	(11)	—	(10,304)
Accumulated impairment


Buildings on non-freehold land	(1,182)	—	679	—	—	(503)
Scientific equipment	(866)	—	779	—	—	(87)
Fittings	(93)	—	—	—	—	(93)
Vehicles	—	—	—	—	—	—
Computer equipment	(27)	—	15	—	—	(12)
Furniture	(3)	—	—	—	—	(3)
In progress	—	—	—	—	—	—
TOTAL - Accumulated impairment	(2,172)	—	1,473	—	—	(699)
TOTAL - Net	11,648	(2,302)	(394)	(11)	74	9,015


Property, plant and equipment - Variations	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	2021/12/31			adjustments		2022/12/31
Gross


Buildings on non-freehold land	10,311	610	—	—	—	10,921
Scientific equipment	6,320	228	(82)	—	—	6,467
Fittings	1,474	61	—	—	2	1,537
Vehicles	91	—	—	—	—	91
Computer equipment	1,542	98	(149)	—	8	1,500
Furniture	279	—	—	—	—	279
In progress	—	16	—	—	(16)	—
TOTAL - Gross	20,017	1,014	(230)	—	(7)	20,794











Accumulated depreciation


Buildings on non-freehold land	(2,900)	(1,033)	—	—	—	(3,934)
Scientific equipment	(4,868)	(697)	79	4	—	(5,481)
Fittings	(888)	(95)	—	(2)	—	(985)
Vehicles	(31)	(12)	—	—	—	(43)
Computer equipment	(1,403)	(105)	148	(5)	—	(1,365)
Furniture	(213)	(10)	—	—	—	(223)
In progress	—	—	—	—	—	—
TOTAL - Accumulated depreciation	(10,304)	(1,953)	227	(3)	—	(12,032)
Accumulated impairment


Buildings on non-freehold land	(503)	—	48	—	—	(455)
Scientific equipment	(87)	—	28	—	—	(59)
Fittings	(93)	—	69	—	—	(24)
Vehicles	—	—	—	—	—	—
Computer equipment	(12)	—	2	—	—	(10)
Furniture	(3)	—	—	—	—	(3)
In progress	—	—	—	—	—	—
TOTAL - Accumulated impairment	(699)	—	147	—	—	(552)
TOTAL - Net	9,015	(939)	144	(3)	(7)	8,210

Assets related to contracts that were originally classified as legacy finance leases are scientific equipment and are accounted for under IFRS 16. Their net carrying value as of December 31, 2021 and 2022 amounted to €114 and €27 respectively.

Amortization

Amortization of an asset starts when it becomes available for use. The asset should be in the location and condition that is required for it to be operating in the manner intended by management, which – in the case of in process research and development (IPR&D) acquired from Versantis, will happen once it receives regulatory and marketing approval. Until that point, it is tested for impairment annually in accordance with the requirements of IAS 36. The asset is tested for impairment by comparing its recoverable amount with its carrying amount once a year, at a minimum. An additional impairment test is required whenever there is an indication that an intangible asset may be impaired.

Impairment

If indicators of impairment are identified, amortizable intangible assets and depreciable tangible assets are subject to an impairment test under the provisions of IAS 36, Impairment of Assets.

The Group has considered that the discontinued use of some equipment following the termination of RESOLVE-IT as well as the decision to no longer use part of the leased premises were indicative of an impairment loss requiring the completion of an impairment test of property, plant and equipment or of the rights of use recognized in the statement of financial position for this equipment and lease agreements.

The recovery value of an asset is the higher value between the value in use and the fair value less costs of divestment. The value in use is evaluated in relation to the future forecasted cash flows, discounted at current interest rates, before tax, which reflects the current market appreciation of the time value of money and the risks specific to the asset. In the present case, the recovery value of the tested assets corresponds to their fair value less costs of divestment.

The impacts related to the impairment of tangible assets and rights of use related to equipment and premises that are no longer in use due to the discontinuation of the RESOLVE-IT study are recognized in the consolidated statement of operations under “Reorganization and restructuring costs”.

Impairment test of assets under IAS 36

Some equipment belonging to the Group and others under a leasing agreement were no longer in use following the reorganization of the group’s activities and the termination of the RESOLVE-IT trial decided in mid-2020.

This indication of loss of value led the Group to conduct an impairment test over owned and leased equipment, based on the value at which this equipment may be divested (on the basis of agreements with the lessors on the early purchase of the equipment and near-term purchase offers) in order to determine the recovery value.

In 2021, part of these elements, mainly scientific equipment, were sold. As a result the accumulated impairment for these equipments was reduced to €196, including:

•€87 for scientific equipment (of which €25 related to owned equipment and €62 of leased equipment),

•€93 for fittings, and

•€15 for computer equipment and furniture,

including associated liabilities.

In 2022, part of these elements, mainly scientific equipment, were sold. As a result the accumulated impairment for these equipments was reduced to €97, including:

•€59 for scientific equipment (of which €31 related to owned equipment and €28 of leased equipment),

•€24 for fittings, and

•€13 for computer equipment and furniture,

including associated liabilities.

Similarly, parts of the leased premises (a portion of the office space in Paris and of the former laboratories at headquarters) were no longer in use. The vacant space is segmented and separate from the premises that will continue to be occupied. An impairment test of the rights of use of this space has also been performed. The test of the rights of use pertaining to these premises in 2021 had resulted in the recognition of an accumulated impairment of €503.

In 2022, the corresponding accumulated impairment was reduced to €455 as of December 31, 2022.

Supplemental IFRS 16 Disclosures

Right of use assets and accumulated amortization

In accordance with IFRS 16, the Group has chosen not to present the right of use separately from other assets and has added them to the fixed assets of the same nature as the underlying leased assets.

Therefore, the right of use assets and related accumulated amortization as of December 31, 2021 included in the table above affect:

•The line item “Building on non-freehold land" amounting to €10,056 and €2,831, respectively;

•The line item "Scientific equipment", amounting to €1,369 and €1,255 respectively.

Therefore, the right of use assets and related accumulated amortization as of December 31, 2022 included in the table above affect:

•The line item “Building on non-freehold land" amounting to €10,665 and €3,839, respectively;

•The line item "Scientific equipment", amounting to €1,502 and €1,475 respectively.

Right of use additions

Right of use asset additions during 2022 amounted to: €743

Lease terminations - 2021

In 2021, GENFIT SA and GENFIT CORP terminated the respective lease agreements for their offices, respectively located in Paris, France and Cambridge, MA, which they both relocated to a coworking space. The rental of these office spaces, as a service contract, no longer falls under IFRS 16. The impact of this change in 2021 is limited as both relocations happened during the second half of the year.

Trade and Other Receivables

12 Months Ended

Dec. 31, 2022

Trade and other receivables [abstract]

Trade and Other Receivables

Trade and other receivables consisted of the following:


Trade and other receivables - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Trade receivables, net	57	3,188
Research tax credit	5,282	11,299
Social security costs receivables	4	1
VAT receivables	1,038	1,288
Grants receivables	5	4
Other receivables	852	126
TOTAL	7,239	15,906
Of which : Current	7,236	15,906
Of which : Non-current	3	—

Trade receivables, net

Trade receivables amounted to €3,188 as of December 31, 2022. The balance mainly corresponds to revenue related to the inventory purchase agreement with Ipsen.

Research tax credit

The research tax credit receivable for the year 2021 amounted to €5,282.

The research tax credit receivable for the year 2022 amounts to €11,299. This balance includes the 2021 balance as there is currently a tax inspection taking place by the French tax authorities.

VAT receivables

The VAT receivable amounted to €1,288 at December 31, 2022.

The VAT receivable amounted to €1,038 at December 31, 2021.

Other receivables

The line item “other receivables” primarily consists of credit notes from suppliers for €126 and €752, respectively, as of December 31, 2022 and December 31, 2021.

Other Financial Assets

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Financial Assets [Abstract]

Other Financial Assets

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

Financial detail

Other financial assets consisted of the following:


Financial assets - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Non consolidated equity investments	3,133	3,133
Other investments	—	483
Financial investments	—	4,550
Loans	388	428

Deposits and guarantees	397	335
Liquidity contract	513	534
TOTAL	4,431	9,464
Of which : Current	—	4,550
Of which : Non-current	4,431	4,914


Financial assets - Variations	As of	Increase	Decrease	As of
(in € thousands)	31/12/2021			31/12/2022
Non consolidated equity investments	3,133	—	—	3,133
Other investments	—	483	—	483
Financial investments	—	4,550	—	4,550
Loans	388	40	—	428

Deposits and guarantees	397	33	(95)	335
Liquidity contract	513	0	21	534
TOTAL	4,431	5,107	(74)	9,464

The total amount of financial assets of the Company was €4,431 at December 31, 2021, as is €9,464 at December 31, 2022. This change is mainly due to the short term financial asset with a term of 180 days.

Non-consolidated equity investments

As of December 31, 2022, the value of "Non-consolidated equity investments" totaled €3,133. The balance solely relates to our equity purchase in Genoscience Pharma which took place in 2021. The initial transaction amount in 2021 totaled €3,133.

We did not complete the equity purchase in Genoscience Pharma for trading purposes. Therefore, pursuant to IFRS 9, we elected to classify the equity in Genoscience Pharma we acquired in December 2021 as equity instruments recognized at fair value through other comprehensive income (OCI). At the time of initial recognition in 2021, this investment in equity instruments has been measured at fair value, inclusive of acquisition costs related to the purchase. The amount recognized on the balance sheet at December 31, 2021 corresponds to the subscription price agreed upon between the parties as representative of the value of Genoscience Pharma a few days before closing of the period. For future closings, changes in fair value on these equity instruments are recognized as OCI. This OCI may not be reused as profit or loss, including in the case of a sale. If applicable, only dividends related to the investment in equity instruments will be recognized as profit provided that all conditions are met.

For 2022, and in accordance with IFRS 13, we updated our estimated of the fair value of our equity stake in Genoscience Pharma, which was based on a valuation methodology including a royalty based income approach using discounted cash flow techniques for the company's main scientific research programs. The aforementioned income method utilizes management’s estimates of future operating results, cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions, and the expected success rate of each program. Based on our analysis performed as of December 31, 2022, the initial valuation of €3,133 is still appropriate and no loss or gain has been recognized in OCI.

Other investments

As of December 31, 2022, the value of "Other investments" totaled €483. The balance relates solely relates to our investment in CAPTECH SANTE.

On May 24, 2022, GENFIT undertook to subscribe for 50 units of the CAPTECH SANTE Professional Equity Fund (Fonds Professionnel de Capital Investissement – FPCI) in the amount of €500. On June 25, 2022, the management company made an initial call for funds from GENFIT in an amount equal to 35% of the subscription amount, i.e. €175, which GENFIT paid. The remaining subscription amount of €325 must be paid upon successive calls from the fund management company.

GENFIT’s investment in CAPTECH SANTE constitutes a debt instrument that does not meet the SPPI (solely payments of principal and interest) criterion test. It is therefore classified as a financial asset recognized at fair value through profit or loss. This investment is also consistent with a regular way purchase of a financial asset. GENFIT has opted to use the trade date as date of initial recognition. An amount of €500 was therefore recognized in the Group’s balance sheet on May 24, 2022.

As of December 31, 2022, a loss of €17 was recognized based on the net asset value of the units as of said date.

Financial investments

As of December 31, 2022, the value of "Financial investments" totaled €4,550. This relates solely to a short term investment whose term is 180 days.

Liquidity contract

The liquidity contract consists of a share buyback program contracted to investment service provider CM-CIC Market Solutions in order to facilitate the listing of the Group's shares.

As of December 31, 2022, the liquidity account had a cash balance of €534, and as of December 31, 2021 a cash balance of €513.

CM-CIC Market Solutions holds the following number of GENFIT shares on behalf of the Company, recorded as a deduction in equity:

Financial assets - Current

As of

2021/12/31

2022/12/31

Number of shares (recorded as a deduction from equity)

137,012

138,691

Summary of Other Financial Assets

Financial detail

Other financial assets consisted of the following:


Financial assets - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Non consolidated equity investments	3,133	3,133
Other investments	—	483
Financial investments	—	4,550
Loans	388	428

Deposits and guarantees	397	335
Liquidity contract	513	534
TOTAL	4,431	9,464
Of which : Current	—	4,550
Of which : Non-current	4,431	4,914


Financial assets - Variations	As of	Increase	Decrease	As of
(in € thousands)	31/12/2021			31/12/2022
Non consolidated equity investments	3,133	—	—	3,133
Other investments	—	483	—	483
Financial investments	—	4,550	—	4,550
Loans	388	40	—	428

Deposits and guarantees	397	33	(95)	335
Liquidity contract	513	0	21	534
TOTAL	4,431	5,107	(74)	9,464

Disclosure of significant accounting policies [text block]

SUMMARY OF MATERIAL ACCOUNTING INFORMATIONUse of estimates and judgments

When assessing going concern, the Group’s Board of Directors considers mainly the following factors:

Consolidation

Going concern

Consolidated entities

The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity.

The Group controls all the entities included in the scope of consolidation.

GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.

Foreign currency

4.3.1.Foreign currency transactions

The resulting exchange gains or losses are recognized in the statements of operations.

4.3.2.Translation of foreign subsidiary financial statements

The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

SEGMENT INFORMATION

The Board of Directors and Chief Executive Officer are the chief operating decision makers.

Revenues from contracts with customers

Accounting policy overview

•If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime;

•The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and

•Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.

Research tax credit

7.2.2.Government grants

Government grants

Subsidies received are non-refundable.

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

General and administrative expenses include:

•employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions;

•facility-related costs;

•marketing, legal, audit and accounting fees;

•press relations and communications firm fees;

•the cost of external employees seconded to the Company (such as security, reception, and accounting...);

•other service costs (recruitment, etc.); and

•intellectual property fees corresponding to the maintenance of the Group's patents.

Marketing and market access expenses include:

•employee-related costs for marketing and business development functions; and

•marketing, and market access firm fees.

Reorganization and restructuring expenses include:

•the accruals and provisions recognized within the scope of the reduction in force plan;

•the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT;

•the impairment of the right of use of the leased equipment and premises;

•the portion of the OCEANEs renegotiation expenses;

•the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.

Accounting policies

Evaluation models

Data and key assumptions used in evaluations

Consultants

Accounting policies

Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable.

Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities.

Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that:

•it is probable that future taxable profit will be available against which they can be used; or

•if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.

Earnings (loss) per share

CASH AND CASH EQUIVALENTS

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Goodwill

The company does not have any goodwill.

Intangible assets

Leases

TRADE AND OTHER RECEIVABLES

Accounting policies

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

INVENTORIES

The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements.

These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

TRADE AND OTHER PAYABLES

Accounting policies

ProvisionsAccounting policies

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

EQUITY

Accounting policies

Trade and other receivables

TRADE AND OTHER RECEIVABLES

Accounting policies

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

Other Assets	12 Months Ended
Other Assets	Dec. 31, 2022
Miscellaneous assets [abstract]
Other Assets	OTHER ASSETSOther assets of €1,998 at December 31, 2022 and €2,101 at December 31, 2021, and respectively consisted of prepaid expenses related to current operating expenses.

Loans and Borrowings

12 Months Ended

Dec. 31, 2022

Borrowing costs [abstract]

Loans and Borrowings

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

Breakdown of convertible loan

Introduction

On October 16, 2017, the Company issued 6,081,081 OCEANEs at par with a nominal unit value of €29.60 per bond for an aggregate nominal amount of €180 million. The original terms and conditions are summarized below:


			At origin (10/16/2017) :
			Number of bonds						6,081,081
			Nominal amount of the loan						179,999,997.60€
			Nominal unit value of the bonds						29.60€
			Conversion / exchange premium						30%
									To GENFIT's reference share price :
									22.77€
			Annual nominal interest rate						3.5%
									Payable semi-annually in arrears
			Annual nominal interest rate						7.2%
			Offering						10/16/2017
									At par
			Redemption						10/16/2022
									Redemption prior to maturity at the option of the Company from
									11/6/2020
									if the arithmetic volume-weighted average price of
									GENFIT's listed share price and the then prevailing conversion ratio over a
									20
									trading period exceeds
									150%
									of the nominal value of the OCEANEs.

2021 activity, buyback and amendment of terms

On November 23, 2020, GENFIT proposed to all OCEANEs bondholders a renegotiation offer involving two interdependent components:

•A partial buyback of the outstanding OCEANEs for a maximum amount of 3,048,780 OCEANEs at €16.40 per bond; and

•An amendment of the terms of the remaining OCEANEs allowing to extend their maturity (by 3 years) and increase the conversion ratio (to 5.5 ordinary shares per bond).

The completion of these commitments for partial repurchase, made in late 2020, remained entirely subject to approval of the new terms of the OCEANEs, by both the Shareholders’ and Bondholders’ Meetings, which on January 25, 2021, approved this renegotiation offer. Following the shareholders’ and bondholders’ decisions, GENFIT completed the partial buyback of 2,895,260 OCEANEs at a price of €16.40 (including accrued interest of €0.30) for a total buyback cost of €47.48 million. The settlement operations occurred on January 29, 2021. The repurchased OCEANEs were then cancelled by GENFIT.

For the non-cancelled, renegotiated OCEANEs (“OCEANEs 2022”) (i.e. 3,185,821 remaining OCEANEs), the maturity is extended to October 16, 2025 and the conversion ratio changed from 1 OCEANE for 1 share to 1 OCEANE for 5.5 shares. The nominal amount and the payout value of the remaining OCEANEs remains unchanged at €29.60 per bond.

This renegotiation operation of the OCEANEs has been recognized in the consolidated accounts for the half-year ended June 30, 2021, as:

•the derecognition of the full initial OCEANEs as of January 25, 2021 against a payment of €47.48 million, and

•the issuance of 3,185,821 new amended OCEANEs.

As the conversion option for the new OCEANEs (2025 maturity) fits the definition of an equity instrument under IAS 32 (Financial Instruments: Presentation), the components of this new OCEANEs (debt vs. equity) has been recognized separately on January 25, 2021, in accordance with the accounting rules and methods presented in this note.

The obligation and option components have been valued separately. The option component has been valued using a traditional binomial model.

The hypotheses considered to calculate the fair value of these new OCEANEs are the following:

•credit spread in the 874/976 bps interval;

•volatility: first level: 30% second level: 35%; and

•no-risk rate: 5-year Euros swap equals -0.45%.

On this basis, at January 25, 2021, the fair value of a new amended OCEANEs has been estimated at €27.80, of which a debt component of €24.12 and a €3.68 component that has been recognized in equity.

2021 accounting impacts of the debt renegotiation

On January 25, 2021 an amount of €94.8 million was derecognized and an amount of €76.8 million was recognized for the amended obligations, in exchange of:

•An increase in equity of €11.7 million before deferred taxes (corresponding to the recognition of the value of the conversion option of the amended OCEANEs);

•The payment of €47.5 million for the OCEANEs partial buyback; and

•The recognition of a financial gain (buyback bonus) of €35.6 million before tax.

2021 accounting impacts of the conversions completed following the debt renegotiation

Following the implementation of the partial buyback operation and the approval of the amendment of the terms of the OCEANEs:

•552,238 of the new OCEANEs were subject to a request for share conversion in January 2021. On February 4, 2021, as a result of these conversion requests, a capital increase of €759,327.25 has been recognized, corresponding to the creation of 3,037,309 new shares. This conversion of 552,238 new OCEANEs resulted in a reduction in financial debt for the Group of €13.32 million.

•483,330 of the new OCEANEs were subject to a request for share conversion in February 2021. On March 2, 2021, as a result of these conversion requests, a capital increase of €664,578.75 has been recognized, corresponding to the creation of 2,658,312 new shares. This conversion of 483,330 new OCEANEs resulted in a reduction in financial debt for the Group of €11.66 million.

•216,591 of the new OCEANEs were subject to a request for share conversion in March 2021. On April 6, 2021, as a result of these conversion requests, a capital increase of €297,812.50 has been recognized, corresponding to the creation of 1,191,250 new shares. This conversion of 216,591 new OCEANEs resulted in a reduction in financial debt for the Group of €5.2 million.

•10,000 of the new OCEANEs were subject to a request for share conversion in August 2021. On September 1, 2021, as a result of these conversion requests, a capital increase of €13,750 has been recognized, corresponding to the creation of 55,000 new shares. This conversion of 10,000 new OCEANEs resulted in a reduction in financial debt for the Group of €0.2 million.

The potential issuance of new shares upon conversion requests of the outstanding OCEANEs would represent 21.24% of the share capital of the Company at December 31, 2021 (representing a 17.52% dilution if all OCEANEs were converted).

All fees and commission paid in relation to this operation have been directly recognized as operating expenses. The fees disbursed have been recognized in the financial statements for a total of €745 in 2020 and €2,303 in 2021.

Updated balances after renegotiation

Following the renegotiation, and as of December 31, 2021 and 2022, number of bonds, nominal amount, nominal unit value and effective interest rate are as follows:


			After OCEANEs buyback :
			Number of bonds						3,185,821
			Nominal amount of the loan						94,300,301.60€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%
			As of 31/12/2021 :
			Number of bonds						1,923,662
			Nominal amount of the loan						56,940,395.20€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%
			As of 31/12/2022 :
			Number of bonds						1,923,662
			Nominal amount of the loan						56,940,395.20€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%

Final reimbursement is scheduled for October 16, 2025.

The potential issuance of new shares upon conversion requests of the outstanding OCEANEs would represent 21.29% of the share capital of the Company at December 31, 2022 (representing a 17.5% dilution if all OCEANEs were converted).

Conversion terms

There are no specific terms that need to be met for a holder of OCEANEs to convert their debt into GENFIT shares.

Deferred taxes

Deferred tax assets and deferred tax liabilities recognized on the balance sheet as of December 31, 2021 and 2022 related to the OCEANEs are disclosed in Note 11.2 "Deferred tax assets and liabilities ".

Current and non current balances

Convertible loans - Total

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

48,097

50,276

TOTAL

48,097

50,276

Convertible loans - Current

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

415

TOTAL

415

Convertible loans - Non current

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

47,682

49,861

TOTAL

47,682

49,861

Breakdown of other loans and borrowings

Other loans and borrowings consisted of the following:


Other loans and borrowings - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	3,229	3,229
Bank loans	15,824	15,196


Obligations under leases	7,069	6,559
Accrued interests	16	14
Other financial loans and borrowings	—	—

TOTAL	26,138	24,999


Other loans and borrowings - Current	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	—	—
Bank loans	667	3,619


Obligations under leases	1,089	1,032
Accrued interests	16	14
Other financial loans and borrowings	—	—

TOTAL	1,773	4,665


Other loans and borrowings - Non current	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	3,229	3,229
Bank loans	15,156	11,578


Obligations under leases	5,980	5,527
Accrued interests	—	—
Other financial loans and borrowings	—	—

TOTAL	24,365	20,334

20.2.1.Refundable and conditional advances

The following table summarizes advances outstanding at December 31, 2022 and 2021.


Refundable and conditional advances—general overview	Grant date	Total amount allocated	Receipts	Repayments	Effects of discounting	Net book value As of 2022/12/31
(in € thousands)
BPI FRANCE - IT-DIAB	12/23/2008	3,229	3,229	—	—	3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL		3,229	3,229	—	—	3,229


Refundable and conditional advances—general overview	Grant date	Total amount allocated	Receipts	Repayments	Effects of discounting	Net book value As of 2021/12/31
(in € thousands)
BPI FRANCE - IT-DIAB	12/23/2008	3,229	3,229	—	—	3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL		3,229	3,229	—	—	3,229


BPI FRANCE IT-DIAB			On December 23, 2008, the Group received an advance from Bpifrance (the BPI France IT-DIAB) as part of a framework innovation aid agreement involving several scientific partners and for which the Group was the lead partner. The contribution expected at each stage by each of the partners in respect of work carried out and results achieved is defined in the framework agreement. With respect to the Group, the aid consisted of a €3,229 conditional advance and a €3,947 non-repayable government grant.

			The conditional advance is not refundable except in the event of success. The program ended on December 31, 2014. In the event of success, defined as the commercial spin-offs of the IT-Diab program which involves products for the treatment or diagnosis of type 2 diabetes, in that case, the financial returns generated will be used initially to repay the €3,229 conditional advance and the agreement stipulates that the conditional advance will be regarded as repaid in full when the total payments made in this regards by the recipient, discounted at the rate of 5.19%, equal the total amount, discounted at the same rate, of the aid paid. Any further amounts will be classified as additional payments, up to a maximum amount of €14,800.

As provided in the project assistance contract, we sent a letter to Bpifrance in December 2019 in order to notify it of our Labcorp and Terns Pharmaceuticals contracts while indicating that elafibranor was now aimed at treating hepatic diseases and no longer type 2 diabetes as provided for in the aid agreement. We proposed to Bpifrance to establish a statement of abandonment of the IT-DIAB project on which the above advance is based. Following this letter, the parties met in March 2020 for the presentation of our arguments, and in June 2020 following the publication of the results of the RESOLVE-IT study, and a new letter was sent in November 2020. In this context, we are awaiting a proposal from Bpifrance on new financial terms related to this situation and a draft amendment to the repayable advance agreement. Until we receive a response from Bpifrance, we consider that the fair value of this liability corresponds to the amount paid by Bpifrance.

20.2.2.Bank loans

Introduction

In the context of the COVID-19 pandemic, the Company secured:

•A State-Guaranteed Loan (or "Prêt Garanti par l'Etat (PGE) Bancaire") for an amount of €11,000 (€10,919 net of fees), granted on June 24, 2021 by a syndicate of four French banks and paid out on June 29, 2021, 90% guaranteed by the French government with an initial term of one year with repayment options up to six years;

◦In the loan table below, this includes instruments "CDN PGE," "CIC PGE," "BNP PGE," and "NATIXIS PGE."

•A State-Guaranteed Loan (or "Prêt Garanti par l'Etat (PGE) Bpifrance") for an amount of €2,000 (€1,985 net of fees) granted on July 20, 2021 by BPI France and paid out on July 23, 2021, 90% guaranteed by the French government with an initial term of one year with repayment options up to six years;

◦In the loan table below this is represented by line "BPI PGE."

•A Subsidized Loan (or "BPI Prêt Taux Bonifié") for an amount of €2,250 (€2,250 net of fees) granted on November 23, 2021 by BPI France and paid out on November 26, 2021, with an initial term of six years.

◦In the loan table below this is represented by line "BPI PRÊT TAUX BONIFIE."

Accounting Treatment

The company has determined after analysis under IFRS that the subsidized loan should be treated in the same manner as the PGEs and that the review pursuant to IAS20 should not apply, in light of the facts, notably, that this subsidized loan:

•Constitutes Government Assistance under the "Umbrella" Scheme Notified by the French Government to the European Commission under the following references: State Aid SA.56985 (2020/N) - France - COVID-19: Temporary Framework to support companies;

•Has therefore not been granted to the Company in connection with research expenses on a particular project or investment;

•Supports the Company's cash position, similarly to the aforementioned PGEs, negotiated with and granted by Bpifrance in addition to these PGEs.

Conditions and interest rates

In 2022, as we were already planning to do in late 2021, GENFIT requested an extension of both the Bank PGE and the BPI France PGE. Both extensions were granted by the respective counterparties. Regarding the Bank PGE, the loan’s post-extension terms did not result in a revision of the maturity date of 29 June 2025 used at the time of the closing on 31 December 2021 (8 linear quarterly payments between September 29, 2023 and June 29, 2025), nor the amount of the “guarantee premiums” (which increases progressively from 0.25% in the first year to 1% in the third year and beyond). Only the interest rate for the second to fourth years was determined at the time of the extension and is therefore changed in relation to the assumptions used as of 31 December 2021. This annual interest rate is as follows (fixed):

•BNP PGE (loan of €4,900): 0.45%

•Natixis PGE (loan of €3,000): 0.40%

•CIC PGE (loan of €2,200): 0.75%

•CDN PGE (loan of €900): 1.36%

Regarding the BPI France PGE, the extension resulted in a one-year extension of the loan’s maturity compared with the assumption made as of 31 December 2021, i.e. 23 July 2027 (20 linear quarterly payments between October 23, 2022 and July 23, 2027) instead of 23 July 2026, as well as a change in the rate of the “guarantee premium” and a change in the interest rate of the loan. The revised terms from 1 August 2022 are as follows: the interest rate is 2.25% (including 1.00% under the French State guarantee).

Regarding the Subsidized Loan, the terms have remained unchanged since the time of closing in November 2021, providing for a 4-quarter deferment of capital amortization, followed by 20 equal quarterly payments (amortization and interest) between February 28, 2023 and November 30, 2027, at a fixed interest rate of 2.25% per annum

In accordance with the ANC recommendation (Recommendations and observations relating to the recognition of the consequences of COVID-19 in the accounts and positions prepared as from 1 January 2020), the accounting treatment relating to the extension of the two PGEs applied in the Group’s consolidated financial statements as of 30 June 2022 is as follows:

•Bank PGE: in the absence of a revision of the probable maturity, the revision of the interest rate of the non-guaranteed loan was accounted for prospectively as soon as the revised interest rate was known after agreement with the bank. The EIR after taking the extension into account is now as follows:

◦BNP PGE (loan of €4,900): 1.16% per annum

◦Natixis PGE (loan of €3,000): 1.11% per annum

◦CIC PGE (loan of €2,200): 1.46% per annum

◦CDN PGE (loan of €900): 2.08% per annum

For reference, the EIR was 0.75% per annum at December 31, 2021 for all Bank PGE.

• BPI France PGE: in view of the revision of the maturity of the PGE and the revision of the cost of the guarantee, the revision of the flows to be paid results, for the portion corresponding to the revision of the cost of the guarantee, in an increase in the debt in the amount of €44 against earnings, discounting new cash flows at the effective interest rate used for the closing as of 31 December 2021. Only the change in the revised interest rate has been accounted for prospectively. The EIR after taking the extension into account is now 1.65% per annum (1.95% at December 31, 2021).

Balances by loan

Bank loans consisted of the following as of December 31, 2022:


Bank loans	Loan	Facility	Interest		Available As of 2022/12/31	Installments	Outstanding As of 2021/12/31	Outstanding As of 2022/12/31
(in € thousands)	date	size	rate
CDN 3	April 2016	500	0.72	%	—	60 monthly	—	—
CDN 4	June 2017	600	0.36	%	—	48 monthly	—	—
CDN 5	November 2018	500	0.46	%	—	48 monthly	115	—
CIC 4	December 2016	265	0.69	%	—	60 monthly	4	—
CIC 5	July 2017	1,000	0.69	%	—	60 monthly	152	—
BNP 2	June 2016	500	0.80	%	—	20 quarterly	—	—
BNP 3	October 2016	1,050	0.80	%	—	20 quarterly	105	—
BNP 4	April 2017	800	0.87	%	—	60 monthly	217	54
AUTRES	-	—	—	%	—	0	20	17
CDN PGE	June 2021	900	1.36	%	—	8 quarterly	900	900
CIC PGE	June 2021	2,200	0.75	%	—	8 quarterly	2,200	2,200
BNP PGE	June 2021	4,900	0.45	%	—	8 quarterly	4,900	4,900
NATIXIS PGE	June 2021	3,000	0.40	%	—	8 quarterly	3,000	3,000
BPI PGE	July 2021	2,000	2.25	%	—	16 quarterly	2,000	1,900
BPI PRÊT TAUX BONIFIE	November 2021	2,250	2.25	%	—	20 quarterly	2,250	2,250
TOTAL		20,465			—		15,864	15,221

Maturities of financial liabilities


Maturity of financial liabilities	As of	Less than	Less than	Less than	Less than	Less than	More than
(in € thousands)	2022-12-31	1 year	2 years	3 years	4 years	5 years	5 years
BPI FRANCE - IT-DIAB	3,229	—	—	—	—	—	3,229
TOTAL - Refundable and conditional advances	3,229	—	—	—	—	—	3,229
Convertible loans	50,276	415	—	49,861	—	—	—
Bank loans	15,196	3,619	6,339	3,601	867	771	—


Leases	6,559	1,032	1,011	1,022	1,034	1,046	1,414
Accrued interests	14	14	—	—	—	—	—


TOTAL - Other loans and borrowings	72,046	5,080	7,350	54,485	1,901	1,817	1,414
TOTAL	75,275	5,080	7,350	54,485	1,901	1,817	4,643

Based on the nominal amount of €50,276 at December 31, 2022, the convertible bond results in the payment of yearly interest of €1,993 (payable in two biannual installments). Its repayment is due on October 16, 2025.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about financial instruments [abstract]

Fair Value of Financial Instruments

FAIR VALUE OF FINANCIAL INSTRUMENTS

Accounting policies

IFRS 9 “Financial Instruments” takes into account the following three aspects of booking financial instruments :

•Classification and measurement;

•Impairment and;

•Hedge accounting.

Loans and borrowings are initially measured at fair value and subsequently recorded at amortized cost.

Pursuant to IFRS 7 – Financial Instruments: Disclosures, the financial instruments are presented into three categories according to a hierarchical method used to establish their fair value.

If financial instruments are measured at fair value, they are measured according to a hierarchy comprising three levels of valuation inputs:

•Level 1: Fair value measured on the basis of quoted prices in active markets for identical assets or liabilities;

•Level 2: Fair value measured on the basis of valuation methods relying on quoted prices for similar assets, liabilities or observable inputs in active markets;

•Level 3: Fair value measured on the basis of valuation methods relying entirely or in part on unobservable inputs such as quoted prices in inactive markets or the valuation based on multiples for non-listed securities.

Financial detail

The following tables provide the financial assets and liabilities carrying values by category and fair values as of December 31, 2022 and December 31, 2021:


	As of 31/12/2021
	Carrying value				Fair value
	As per	Assets at	Assets at	Assets at	Debt at	Level 1	Level 2	Level 3
	statement of	fair value	fair value	amortized	amortized
	financial	through	through OCI	cost	cost
(in € thousands)	position	profit & loss
Assets
Equity investments	3,133		3,133					3,133

Financial investments	—
Loans	388			388			388

Deposits and guarantees	397			397			397
Trade receivables	57			57			57
Cash and cash equivalents	258,756	258,756				258,756
TOTAL - Assets	262,731	258,756	3,133	842	—	258,756	842	3,133
Liabilities
Conditional advances	3,229				3,229			3,229
Convertible loans	48,097				48,097		48,097
Bank loans	15,824				15,824		15,824


Obligations under finance leases	7,069				7,069		7,069
Accrued interests	16				16		16


Trade payables	12,304				12,304		12,304
Other payables	579				579		579
TOTAL - Liabilities	87,118	—	—	—	87,118	—	83,889	3,229


	As of 31/12/2022
	Carrying value				Fair value
	As per	Assets at	Assets at	Assets at	Debt at	Level 1	Level 2	Level 3
	statement of	fair value	fair value	amortized	amortized
	financial	through	through OCI	cost	cost
(in € thousands)	position	profit & loss
Assets
Equity investments	3,133		3,133					3,133
Other investments	483	483						483
Financial investments	4,550	4,550				4,550
Loans	428			428			428

Deposits and guarantees	335			335			335
Trade receivables	3,188			3,188			3,188
Cash and cash equivalents	136,001	136,001				136,001
TOTAL - Assets	148,119	141,034	3,133	3,951	—	140,551	3,951	3,617
Liabilities
Conditional advances	3,229				3,229			3,229
Convertible loans	50,276				50,276		52,708
Bank loans	15,196				15,196		15,196


Obligations under finance leases	6,559				6,559		6,559
Accrued interests	14				14		14


Trade payables	8,613				8,613		8,613
Other payables	1,325				1,325		1,325
TOTAL - Liabilities	85,214	—	—	—	85,214	—	84,416	3,229

Trade and Other Payables

12 Months Ended

Dec. 31, 2022

Disclosure Of Trade And Other Payables [Abstract]

Trade and Other Payables

TRADE AND OTHER PAYABLES

Accounting policies

Financial detail

Trade and other payables consisted of the following:


Trade and other payables - Total	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables (*)		12,304	8,613
Social security costs payables		4,087	4,838
VAT payables		23,725	200
Taxes payables		744	316
Other payables		579	1,325
TOTAL		41,438	15,293


Trade and other payables - Current	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables		12,304	8,613
Social security costs payables		4,087	4,838
VAT payables		23,725	200
Taxes payables		744	316
Other payables		128	877
TOTAL		40,988	14,845


Trade and other payables - Non current	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables		—	—
Social security costs payables		—	—
VAT payables		—	—
Taxes payables		—	—
Other payables		450	448
TOTAL		450	448

(*) Of which : Accrued expenses		6,201	3,924

At December 31, 2022, trade payables amounted to €8,613 (€12,304 at December 31, 2021). This change is due to a reduction in accrued expenses relating to yet unbilled amounts from the clinical trial sites via the Clinical Research Organizations (CROs) in charge of the Company's clinical trials. (€3,924 and €6,201 at December 31, 2022 and 2021 respectively). The timeframe in which those invoices will be received by the Company is unknown and may be spread out over a long period after the services have been performed.

The VAT debt amounted to €200 at December 31, 2022 (€23,725 at December 31, 2021). This decrease is related to the VAT amount collected on the upfront payment received from Ipsen in December 2021, paid in January 2022.

Trade and other payables

TRADE AND OTHER PAYABLES

Accounting policies

Disclosure of significant accounting policies [text block]

SUMMARY OF MATERIAL ACCOUNTING INFORMATIONUse of estimates and judgments

When assessing going concern, the Group’s Board of Directors considers mainly the following factors:

Consolidation

Going concern

Consolidated entities

The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity.

The Group controls all the entities included in the scope of consolidation.

GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.

Foreign currency

4.3.1.Foreign currency transactions

The resulting exchange gains or losses are recognized in the statements of operations.

4.3.2.Translation of foreign subsidiary financial statements

The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

SEGMENT INFORMATION

The Board of Directors and Chief Executive Officer are the chief operating decision makers.

Revenues from contracts with customers

Accounting policy overview

•If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime;

•The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and

•Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.

Research tax credit

7.2.2.Government grants

Government grants

Subsidies received are non-refundable.

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

General and administrative expenses include:

•employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions;

•facility-related costs;

•marketing, legal, audit and accounting fees;

•press relations and communications firm fees;

•the cost of external employees seconded to the Company (such as security, reception, and accounting...);

•other service costs (recruitment, etc.); and

•intellectual property fees corresponding to the maintenance of the Group's patents.

Marketing and market access expenses include:

•employee-related costs for marketing and business development functions; and

•marketing, and market access firm fees.

Reorganization and restructuring expenses include:

•the accruals and provisions recognized within the scope of the reduction in force plan;

•the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT;

•the impairment of the right of use of the leased equipment and premises;

•the portion of the OCEANEs renegotiation expenses;

•the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.

Accounting policies

Evaluation models

Data and key assumptions used in evaluations

Consultants

Accounting policies

Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable.

Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities.

Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that:

•it is probable that future taxable profit will be available against which they can be used; or

•if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.

Earnings (loss) per share

CASH AND CASH EQUIVALENTS

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Goodwill

The company does not have any goodwill.

Intangible assets

Leases

TRADE AND OTHER RECEIVABLES

Accounting policies

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

INVENTORIES

The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements.

These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

TRADE AND OTHER PAYABLES

Accounting policies

ProvisionsAccounting policies

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

EQUITY

Accounting policies

Deferred Income and Revenue	12 Months Ended
Deferred Income and Revenue	Dec. 31, 2022
Deferred Income and Revenue [Abstract]
Deferred Income and Revenue	DEFERRED INCOME AND REVENUE Out of the €120 million upfront payment received from Ipsen in application of the licensing agreement signed in December 2021, an amount of €40 million was recognized as Deferred income in 2021. The Deferred income is recognized as revenue as GENFIT carries out its part of the double-blind ELATIVE study, based on the progress made relative to the originally developed budget. As of December 31, 2022, the Company considers that this initial budget is still appropriate based on progress performed. In 2022, €15.9 million of said balance was recognized as revenue. As of December 31, 2022, €24.1 million of Deferred income remains, of which €14.4 million relates to Current deferred income and of which €9.7 million relates to Non-current deferred income, which was determined based on the original budget. See "Note 7 "Revenues and O ther income."

Provisions

12 Months Ended

Dec. 31, 2022

Provisions [abstract]

Provisions

ProvisionsAccounting policies

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

Financial detail

RESOLVE-IT

See Note 2.3 “Termination of RESOLVE -IT and the development program of elafibranor in NASH”.

Genoscience Pharma

On December 16, 2021, GENFIT completed the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma (CCA) in the United States, Canada and Europe, including the United Kingdom and Switzerland. GNS561 is a novel clinical-stage autophagy/PPT1 inhibitor developed by Genoscience Pharma and cholangiocarcinoma is an orphan disease.

Under the agreement, Genoscience Pharma is eligible for clinical and regulatory milestone payments for up to €50 million and tiered royalties. The first payable milestones are contingent on positive Phase 2 clinical trial results in CCA, and may total up to €20 million, if applicable.

The following payable milestones are contingent on positive Phase 3 results. These payments, when due, will be subject to a review to determine if they are eligible for activation pursuant to IAS 38. If so, they will be recorded as capital upon disbursement. Otherwise, they also constitute contingent liabilities which will be recognized when due.

In addition, we also have a right of first negotiation with respect to any license or assignment, or option for a license or an assignment, with any third party to develop or commercialize other Genoscience assets in the field of CCA, to the extent Genoscience is looking to partner the asset with a third party or receives a spontaneous offer for collaboration.

For the period commencing on the date of the agreement until the first regulatory approval of GNS561 for commercialization, Genoscience Pharma has the right to repurchase the license to GNS561 in CCA at a pre-determined price in the event that Genoscience Pharma receives an offer from a third party to acquire or obtain a license to GNS561 in all indications, provided that GENFIT shall first have the opportunity to negotiate the acquisition or license to GNS561 in all indications or match the offer from the third party.

Pursuant to IAS 37, our obligations under the terms of the agreement we entered into with Genoscience Pharma constitute contingent liabilities not recognized in the Company's consolidated financial statements at December 31, 2021 or December 31, 2022.

Versantis

See Note 2.1 "Acquisition of the Clinical-stage Biopharmaceutical Company Versantis"

At December 31, 2022 and at December 31, 2021, this line item amounted to €61 and €313, respectively.


Change in provisions	As of	Increase	Decrease	Decrease	As of
(in € thousands)	2021/12/31		(used)	(unused)	2022/12/31

Provision for litigation	87	0	(14)	(73)	0

Provision for charges	225	4	(92)	(77)	61
TOTAL	313	4	(106)	(150)	61

This change mainly reflects provision reversals recorded in 2022 related to:

•The estimated support costs related to the reduction in force plan (PSE) implemented starting in late 2020 (return-to-work bonuses, trainings, business start-up assistance and various other benefits): reversal of €169 (of which €92 was used), with the corresponding provision amounting to €61 at December 31, 2022.

Employee Benefits

12 Months Ended

Dec. 31, 2022

Disclosure of information about defined benefit plans [abstract]

Disclosure of benefit payments undere company's french retirement entity

The following assumed benefit payments under the Company's French retirement indemnity are expected to be paid as follows:


2023			0
2024			0
2025			37
2026			21
2027			78
Years 2028 and thereafter			646

Disclosure of employee benefits [text block]

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

Detailed breakdown

In France, pension funds are generally financed by employer and employee contributions and are accounted for as a defined contribution plan with the employer contributions recognized as expense as incurred. The Group has no actuarial liabilities in connection with these plans. Related expenses recorded for the years ended December 31, 2022, December 31, 2021, and December 31, 2020 amounted to €876, €774, and €923, respectively.

French law also requires payment of a lump sum retirement indemnity to employees based on years of service and annual compensation at retirement, which are accounted for as a defined benefit plan. Benefits do not vest prior to retirement. The liability is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final liability. At December 31, 2022 and December 31, 2021 pension provisions recorded were €782 and €864, respectively.

As part of the measurement of the retirement indemnity to employees, the following assumptions were used for all categories of employees in 2021 and 2022:


			Population			Permanent staff
			Retirement age			65
			Terms of retirement			Initiated by the employee
			Life expectancy			On the basis of the INSEE table (1)
			Probability of continued presence in the company at retirement age			On the basis of the DARES table

(1)INSEE is the French National Institute of Statistics; DARES is the French Bureau of Studies and Statistics


Rate	As of
(in € thousands)	2021/12/31		2022/12/31
Salary growth rate - in 2022	3.00	%	3.00	%
Salary growth rate - beyond	3.00	%	3.00	%
Discount rate (iboxx)	0.87	%	3.25	%

The discount rates are based on the market yield at December 31, 2021 and 2022 on high-quality corporate bonds.

The following table presents the changes in the present value of the defined benefit obligation:


			Changes in the present value of the defined benefit obligation
			(in € thousands)







			Defined benefit obligation as of January 01, 2021						922
			Current service cost						154
			Interest cost on benefit obligation						5
			Actuarial losses / (gains) on obligation						—
			Past service costs						(216)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2021						864
			Current service cost						169
			Interest cost on benefit obligation						8
			Actuarial losses / (gains) on obligation						—
			Past service costs						(258)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2022						782

Sensitivity of the Group’s retirement and post-employment benefits to a variation of the discount rate:

Retirement and post-employment benefits

Sensitivity of the Group's retirement and post-employment benefits

Changes in

Impact /

to a variation of the discount rate

assumptions /

present value of

(in € thousands)

discount rate

the undertaking

0.25

(23)

0.25

The following assumed benefit payments under the Company's French retirement indemnity are expected to be paid as follows:


2023			0
2024			0
2025			37
2026			21
2027			78
Years 2028 and thereafter			646

Disclosure of defined benefit plans [text block]

As part of the measurement of the retirement indemnity to employees, the following assumptions were used for all categories of employees in 2021 and 2022:


			Population			Permanent staff
			Retirement age			65
			Terms of retirement			Initiated by the employee
			Life expectancy			On the basis of the INSEE table (1)
			Probability of continued presence in the company at retirement age			On the basis of the DARES table

(1)INSEE is the French National Institute of Statistics; DARES is the French Bureau of Studies and Statistics


Rate	As of
(in € thousands)	2021/12/31		2022/12/31
Salary growth rate - in 2022	3.00	%	3.00	%
Salary growth rate - beyond	3.00	%	3.00	%
Discount rate (iboxx)	0.87	%	3.25	%

Disclosure of net defined benefit liability (asset) [text block]

The following table presents the changes in the present value of the defined benefit obligation:


			Changes in the present value of the defined benefit obligation
			(in € thousands)







			Defined benefit obligation as of January 01, 2021						922
			Current service cost						154
			Interest cost on benefit obligation						5
			Actuarial losses / (gains) on obligation						—
			Past service costs						(216)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2021						864
			Current service cost						169
			Interest cost on benefit obligation						8
			Actuarial losses / (gains) on obligation						—
			Past service costs						(258)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2022						782

Disclosure of sensitivity analysis for actuarial assumptions [text block]

Sensitivity of the Group’s retirement and post-employment benefits to a variation of the discount rate:

Retirement and post-employment benefits

Sensitivity of the Group's retirement and post-employment benefits

Changes in

Impact /

to a variation of the discount rate

assumptions /

present value of

(in € thousands)

discount rate

the undertaking

0.25

(23)

0.25

Disclosure of significant accounting policies [text block]

SUMMARY OF MATERIAL ACCOUNTING INFORMATIONUse of estimates and judgments

When assessing going concern, the Group’s Board of Directors considers mainly the following factors:

Consolidation

Going concern

Consolidated entities

The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity.

The Group controls all the entities included in the scope of consolidation.

GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.

Foreign currency

4.3.1.Foreign currency transactions

The resulting exchange gains or losses are recognized in the statements of operations.

4.3.2.Translation of foreign subsidiary financial statements

The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

SEGMENT INFORMATION

The Board of Directors and Chief Executive Officer are the chief operating decision makers.

Revenues from contracts with customers

Accounting policy overview

•If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime;

•The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and

•Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.

Research tax credit

7.2.2.Government grants

Government grants

Subsidies received are non-refundable.

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

General and administrative expenses include:

•employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions;

•facility-related costs;

•marketing, legal, audit and accounting fees;

•press relations and communications firm fees;

•the cost of external employees seconded to the Company (such as security, reception, and accounting...);

•other service costs (recruitment, etc.); and

•intellectual property fees corresponding to the maintenance of the Group's patents.

Marketing and market access expenses include:

•employee-related costs for marketing and business development functions; and

•marketing, and market access firm fees.

Reorganization and restructuring expenses include:

•the accruals and provisions recognized within the scope of the reduction in force plan;

•the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT;

•the impairment of the right of use of the leased equipment and premises;

•the portion of the OCEANEs renegotiation expenses;

•the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.

Accounting policies

Evaluation models

Data and key assumptions used in evaluations

Consultants

Accounting policies

Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable.

Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities.

Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that:

•it is probable that future taxable profit will be available against which they can be used; or

•if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.

Earnings (loss) per share

CASH AND CASH EQUIVALENTS

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Goodwill

The company does not have any goodwill.

Intangible assets

Leases

TRADE AND OTHER RECEIVABLES

Accounting policies

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

INVENTORIES

The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements.

These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

TRADE AND OTHER PAYABLES

Accounting policies

ProvisionsAccounting policies

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

EQUITY

Accounting policies

Description of accounting policy for employee benefits [text block]

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

Equity

12 Months Ended

Dec. 31, 2022

Disclosure of classes of share capital [abstract]

Disclosure of Detailed Information About Share Capital

Detailed breakdown

Share capital


Number of shares	As of
	2021/12/31	2022/12/31
Ordinary shares issued (€0.25 par value per share)	49,815,489	49,834,983
Convertible preferred shares registered	0	0
Total shares issued	49,815,489	49,834,983
Less treasury shares	0	0
Outstanding shares	49,815,489	49,834,983

Equity

EQUITY

Accounting policies

Disclosure of treasury shares [text block]

share buyback program

Disclosure of significant accounting policies [text block]

SUMMARY OF MATERIAL ACCOUNTING INFORMATIONUse of estimates and judgments

When assessing going concern, the Group’s Board of Directors considers mainly the following factors:

Consolidation

Going concern

Consolidated entities

The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity.

The Group controls all the entities included in the scope of consolidation.

GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.

Foreign currency

4.3.1.Foreign currency transactions

The resulting exchange gains or losses are recognized in the statements of operations.

4.3.2.Translation of foreign subsidiary financial statements

The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

SEGMENT INFORMATION

The Board of Directors and Chief Executive Officer are the chief operating decision makers.

Revenues from contracts with customers

Accounting policy overview

•If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime;

•The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and

•Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.

Research tax credit

7.2.2.Government grants

Government grants

Subsidies received are non-refundable.

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

General and administrative expenses include:

•employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions;

•facility-related costs;

•marketing, legal, audit and accounting fees;

•press relations and communications firm fees;

•the cost of external employees seconded to the Company (such as security, reception, and accounting...);

•other service costs (recruitment, etc.); and

•intellectual property fees corresponding to the maintenance of the Group's patents.

Marketing and market access expenses include:

•employee-related costs for marketing and business development functions; and

•marketing, and market access firm fees.

Reorganization and restructuring expenses include:

•the accruals and provisions recognized within the scope of the reduction in force plan;

•the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT;

•the impairment of the right of use of the leased equipment and premises;

•the portion of the OCEANEs renegotiation expenses;

•the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.

Accounting policies

Evaluation models

Data and key assumptions used in evaluations

Consultants

Accounting policies

Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable.

Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities.

Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that:

•it is probable that future taxable profit will be available against which they can be used; or

•if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.

Earnings (loss) per share

CASH AND CASH EQUIVALENTS

Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).

Goodwill

The company does not have any goodwill.

Intangible assets

Leases

TRADE AND OTHER RECEIVABLES

Accounting policies

Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss").

INVENTORIES

The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements.

These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.

OTHER FINANCIAL ASSETS

Accounting policies

A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss:

•Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets;

•Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount.

LOANS AND BORROWINGS

Accounting policies

Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method.

The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire.

TRADE AND OTHER PAYABLES

Accounting policies

ProvisionsAccounting policies

The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation.

Provisions are discounted when the time value effect is material.

EMPLOYEE BENEFITS

Accounting policies

The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans.

25.1.Defined benefit plans

Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss.

25.2.Defined contribution plans

25.3.Short-term employee benefits

EQUITY

Accounting policies

Equity

EQUITY

Accounting policies

Detailed breakdown

Share capital


Number of shares	As of
	2021/12/31	2022/12/31
Ordinary shares issued (€0.25 par value per share)	49,815,489	49,834,983
Convertible preferred shares registered	0	0
Total shares issued	49,815,489	49,834,983
Less treasury shares	0	0
Outstanding shares	49,815,489	49,834,983

Ordinary shares are classified under shareholders' equity. Any shareholder, regardless of nationality, whose shares are fully paid-in and registered for at least two years, is entitled to double voting rights under the conditions prescribed by law (Article 32 of the Company's bylaws).

Changes in share capital in 2022

The Chief Executive Officer, acting on the decision and delegation of the Board of Directors on July 18, 2019, noted on September 16, 2022 that some of the performance and attendance conditions linked to the AGA D 2019 and AGA S 2019 free shares were met at the end of the year. 19,494 free shares were thus definitively acquired and as many new shares were created. The share capital was increased accordingly.

At December 31, 2022, the remaining unused authorizations to issue additional share-based compensation or other share-based instruments (stock options, free shares and share warrants) represent a total of 306,435 shares.

Changes in share capital in 2021

On February 4, 2021, as a result of share conversion requests in January 2021, a capital increase of €759,327.25 has been recognized, corresponding to the creation of 3,037,309 new shares.

On March 2, 2021, as a result of share conversion requests in February 2021, a capital increase of €664,578.75 has been recognized, corresponding to the creation of 2,658,312 new shares.

On April 6, 2021, as a result of share conversion requests in March 2021, a capital increase of €297,812.50 has been recognized, corresponding to the creation of 1,191,250 new shares.

On September 1, 2021, as a result of share conversion requests in August 2021, a capital increase of €13,750 has been recognized, corresponding to the creation of 55,000 new shares.

The Chief Executive Officer, acting on a decision and delegation from the Board of Directors on December 16, 2021, recognized on December 22, 2021 the execution of a capital increase for the benefit of Ipsen Pharma SAS. 3,985,239 new shares were created (and €28 million was collected from Ipsen Pharma SAS) on this occasion. The share capital was increased accordingly.

At December 31, 2021, the total number of shares comprising the share capital, taking into account the above, was 49,815,489 shares.

At December 31, 2021, the remaining unused authorizations to issue additional share-based compensation or other share-based instruments (stock options, free shares and share warrants) represent a total of 323,125 shares.

Operating Income

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Income [Abstract]

Operating Income

REVENUES AND OTHER INCOME

Financial statement line item detail

In 2022, the total revenues and other income amounted to €26,566 (€85,579 in 2021, and €7,758 in 2020).

Revenue amounted to €20,195 in 2022 (€80,069 in 2021, and €765 in 2020).

Revenue is primarily composed of:

1.Licensing Agreement (Ipsen). In December 2021, GENFIT and Ipsen entered into an exclusive licensing agreement for elafibranor, a Phase 3 asset evaluated in Primary Biliary Cholangitis (PBC), as part of a long-term global partnership ("Collaboration and License Agreement").

◦In 2022, €15.9 million was attributable to the partial recognition of deferred revenue of €40 million from 2021 as noted immediately below, in line with the progress in the ELATIVE clinical study and expenses incurred during the period.

◦In 2021, €80 million was attributable to the recognition of the initial payment received from Ipsen pursuant to the license agreement entered into in December 2021 (of the total amount of €120 million). The remaining balance of the initial payment, i.e. 40 million euros, was recorded as deferred income.

2.Transition Services Agreement (Ipsen). In 2022, GENFIT and Ipsen entered into a Service Transition Agreement, which describes the scope of the services provided by GENFIT to Ipsen in order to facilitate the transition of certain activities related to the Phase 3 clinical trial, evaluating elafibranor in PBC.

◦In 2022, the services provided under this contract generated €1.0 million in revenue.

3.Inventory Purchase Agreement (Ipsen). GENFIT and Ipsen also entered into an Inventory Purchase Agreement in 2022, which provided for the purchase by Ipsen of batches of active ingredients and elafibranor products during the second half of 2022.

◦In 2022, inventory sold to Ipsen under this contract generated €3.3 million in revenue.

4.Other revenue

◦In 2022, other revenue was not significant.

◦In 2021, other revenue recognized relates to license agreements with Labcorp for the deployment of NIS4 diagnostic technology in the field of NASH, amounting to €69.

◦In 2020, revenue of €765 mainly originated from the income generated by the license agreements with Labcorp and one-off revenue resulting from the sale of goods and services notably within the scope of the license and collaboration agreement with Terns Pharmaceuticals.

Application of IFRS 15 to the Ipsen License Agreement signed in 2021

Pursuant to IFRS 15, 27, 28 and 29, we have identified that the agreement provides for four distinct performance obligations:

•The license for elafibranor,

•The completion of the ELATIVE Phase 3 trial until the end of the double-blind period,

•The knowledge transfer related to elafibranor, as well as support for Ipsen in future undertakings and processes, and

•The provision of drug tablets that may be needed by Ipsen to conduct their clinical trials.

The compensation under this agreement consists of an upfront payment, milestone payments, and royalties on future sales of elafibranor by Ipsen. Besides, it must be noted that, with respect to (i) support services other than the knowledge transfer and (ii) the provision of drug tablets, the agreement provides for separate prices covering all costs borne by the Company to provide those goods and services, therefore constituting in each case an individual and distinct sale price for the relevant goods or service, which is not included in the aforementioned price elements.

We estimate the individual sale price of the clinical trial phase to be €40 million, including forecasted external costs, personnel expenses for the relevant staff, indirect costs pertaining to the work environment of such staff, augmented of a customary margin rate for CRO (Clinical Research Organization) contracting. This calculation of the individual sale price for the clinical trial phase reflects observable price conditions as recommended under IFRS 15.79.c. We used the same method to calculate the individual sale price of the knowledge transfer.

Regarding the calculation of the individual sale price of the license, we have analyzed recommended methods under IFRS 15.79 and determined that method (c) is the most relevant, considering in particular that the amount of this individual sale price is variable and partly uncertain. Thus, we applied the "residual" method, which stipulates that the individual sale price of the license corresponds to the difference between the total amount of the price and the individual sale prices of the knowledge transfer and the clinical trial phase. Moreover, referring to IFRS 15.B61, we determined that the date of transfer of control over the license corresponds to the date of the knowledge transfer, i.e. December 16, 2021, when key elements of the know-how were made available to Ipsen.

Regarding the recognition of revenue related to the license, we have chosen the following methods:

•The upfront payment, minus the portion of prices allocated to knowledge transfer services and clinical phase execution, has been recognized at the date of transfer of control, i.e. December 16, 2021 according to the above, as it is a static license (without implication or associated service provision);

•Milestone payments constitute variable and uncertain income, which would be, if applicable, recognized in revenue at the time they become highly probable, which means, in this case, due by Ipsen;

•Royalties would be progressively recognized in revenue as sales are completed by Ipsen, in accordance with the IFRS 15 exception for royalties constituting variable income.

Regarding the recognition of revenue related to the Phase 3 ELATIVE trial until the end of the double-blind period, we have chosen the following method:

•The part of the upfront payment allocated to this service will be recognized progressively as completion progresses.

Regarding the recognition of revenue related to the knowledge transfer, we have chosen the following method:

•The part of the upfront payment allocated to this service has been recognized on December 16, 2021 in accordance with the above.

It must be noted that the 8% equity purchase by Ipsen in the Company mentioned in Note 2.2 under the terms of which Ipsen is represented in the Company's Board of Directors, has been completed on the basis of a subscription price agreed upon by the parties as representative of the value of GENFIT at the time, as we had secured future financing and created favorable conditions for the completion of the development and commercial launch of our main program. Therefore, the amount paid by Ipsen for its equity purchase does not interfere in the determination of the price of the licensing and collaboration agreement signed in December 2021 (including the Upfront Payment and other payments due for milestones identified above) and has been entirely recognized in the Group's equity.

Application of IFRS 15 to the Ipsen Transition Services Agreement and Inventory Purchase Agreement signed in 2022

Other income

The breakdown of Other income is as follows:


Other income	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
CIR tax credit	6,020	5,282	6,017
Other operating income	968	223	320
Government grants and subsidies	5	5	34
TOTAL	6,993	5,510	6,371

The research tax credit (CIR) amounted to €6,017 in 2022 (€5,282 in 2021), due to the reduction in research and development expenses.

In comparison, the 2020 Research Tax Credit amounted to €7,911, partially balanced with the expense amounting to €1,892 corresponding to the resolution of the dispute on the 2010, 2011, 2012 and 2014 Research Tax Credit.

During 2022, the Group recognized €320 in “Other operating income” (€968 in 2020 and €223 in 2021), mainly comprised of exchange gains on trade receivables.

Operating Expense

12 Months Ended

Dec. 31, 2022

Operating Expense [Abstract]

Operating Expense

OPERATING EXPENSES


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2020/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(59,097)	(1,876)	(39,216)	(11,554)	(5,465)	(985)	—
General and administrative expenses	(14,270)	(202)	(92)	(6,936)	(6,545)	(495)	—
Marketing and market access expenses	(11,216)	(7)	(2)	(1,298)	(9,818)	(90)	—
Reorganization and restructuring income (expenses)	(5,308)	—	—	8	(2,141)	(3,175)	—
Other operating expenses	(764)	—	—	—	(684)	—	(80)
TOTAL	(90,655)	(2,085)	(39,310)	(19,779)	(24,655)	(4,746)	(80)


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2021/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(35,166)	(1,305)	(18,808)	(8,192)	(4,593)	(2,247)	(19)
General and administrative income (expenses)	(16,153)	(161)	(85)	(7,379)	(8,003)	(541)	15
Marketing and market access expenses	(1,539)	(1)	(1)	(783)	(741)	(13)	—
Reorganization and restructuring income (expenses)	(142)	(5)	—	—	(2,343)	2,206	—
Other operating income (expenses)	(763)	—	—	—	(338)	4	(429)
TOTAL	(53,763)	(1,472)	(18,895)	(16,354)	(16,019)	(591)	(433)


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2022/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(35,818)	(1,876)	(17,407)	(10,029)	(5,177)	(1,328)	—
General and administrative expenses	(16,405)	(248)	(71)	(6,772)	(9,168)	(146)	—
Marketing and market access expenses	(992)	(3)	(1)	(565)	(416)	(6)	—
Reorganization and restructuring income (expenses)	11	—	—	—	—	11	—
Other operating income (expenses)	(652)	—	—	—	(667)	—	16
TOTAL	(53,855)	(2,128)	(17,479)	(17,366)	(15,429)	(1,469)	16

Research and development expenses at each reporting date take into account estimates for ongoing activities subcontracted as part of the clinical trials and not yet invoiced, on the basis of detailed information provided by subcontractors and reviewed by the Group’s internal departments. The accuracy of these estimates for some types of expenses improves with the progression of the trials and the review of their determination methods. For regulatory reasons, research services for clinical trials and the production of active ingredients and therapeutic units are contracted out to third parties.

The "Other expenses (maintenance, fees, travel, taxes...)" mainly includes:

•Legal fees, audit and accounting fees;

•Advisor fees (banking, press relations, communication, IT, market access, marketing, scientific advising);

•Intellectual property expenses, including in particular the charges and fees incurred by the Company for patent applications and maintenance;

•Expenses related to insurance, notably those triggered by the Company listing on the Nasdaq since 2019;

•Expenses related to the rental, use, and maintenance of the Group's premises;

•Expenses related to external personnel contracted out to the company (safety and security, front desk, clinical and IT services); and

•Expenses related to travel and conferences, including mainly employee travel costs as well as scientific, medical, financial and business development conference registration fees.

2022 Activity

Research and Development Expenses

The increase in research and development costs is generally explained by the increase in costs related to new programs and product candidates, in particular NTZ, VS-01 and GNS 561, offset by the sharp reduction in study costs related to RESOLVE-IT.

General and Administrative Expenses

The increase in general and administrative expenses is broadly explained by the increase in costs related to liability insurance, the increase in costs related to consulting fees, and other charges in the normal course of business.

Marketing and Market Access Expenses

This decrease is mainly explained by the decrease in marketing activity in the United States and France.

Reorganization and Restructuration Expenses

For the year ended December 31, 2022, reorganization and restructuration expenses were not significant.

Employee expenses

Employee expenses and number of employees were as follows:


Employee expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Wages and salaries	(13,570)	(10,328)	(12,188)
Social security costs	(5,047)	(4,775)	(4,765)
Changes in pension provision	74	(154)	(169)
Employee profit-sharing	—	(628)	—
Share-based compensation	(1,236)	(470)	(245)
TOTAL	(19,779)	(16,354)	(17,366)


Number of employees at year-end	Year ended
	2020/12/31	2021/12/31	2022/12/31
Average number of employees	193	122	133
Number of employees
Research and development	66	55	73
Services related to research and development	16	18	18
Administration and management	43	47	55
Marketing and commercial	5	2	2
TOTAL	130	122	148

The increase in employee expenses resulted mainly from an increase in workforce of the average headcount from 122 in 2021 to 133 in 2022.

As the Company recorded a net profit in 2021, it granted a profit-sharing plan to its employees in accordance with the French Law, totaling €(628). As the Company recorded a net loss in 2022, there was no profit sharing in said year.

Research and development expenses

Accounting policies

Research and development expenses

Research expenses are recorded in the financial statements as expenses.

In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met:

•Technical feasibility necessary for the completion of the development project;

•Intention on the Group's part to complete the project and to utilize it;

•Capacity to utilize the intangible asset;

•Proof of the probability of future economic benefits associated with the asset;

•Availability of the technical, financial, and other resources for completing the project; and

•Reliable evaluation of the expenses attributed to the intangible asset during its development.

As of the date of these financial statements these criteria have not all been met.

Classification of operating expenses

Research and development expenses include:

•employee-related costs;

•costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…);

•lab supplies and facility costs;

•fees paid to scientific advisers and contracted research and development activities conducted by third parties;

•intellectual property fees corresponding to the filing of the Group's patents, and

•provision and reversals of provisions in relation to the Research Tax Credit dispute.

Share-Based Compensation

12 Months Ended

Dec. 31, 2022

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Disclosure of number and weighted average exercise prices of other equity instruments [text block]

Information on share warrants activity is as follows for 2022:


Grant Date	Type	BSAs issued	BSAs outstanding as of January 1, 2022	BSAs awarded	BSAs exercised	BSAs cancelled/forfeited	BSAs outstanding as of December 31, 2022	BSAs exercisable as of December 31, 2022
31/10/2019	BSA 2019	35,070	35,070	0	0	0	35,070	35,070
06/12/2017	BSA 2017-A	18,345	18,345	0	0	18,345	0	0
06/12/2017	BSA 2017-B	18,345	18,345	0	0	18,345	0	0
TOTAL			71,760	0	0	36,690	35,070	35,070

Information on share warrants activity is as follows for 2021:


Grant Date	Type	BSAs issued	BSAs outstanding as of January 1, 2021	BSAs awarded	BSAs exercised	BSAs cancelled/forfeited	BSAs outstanding as of December 31, 2021	BSAs exercisable as of December 31, 2021
31/10/2019	BSA 2019	35,070	35,070	0	0	0	35,070	35,070
06/12/2017	BSA 2017-A	18,345	18,345	0	0	0	18,345	18,345
06/12/2017	BSA 2017-B	18,345	18,345	0	0	0	18,345	18,345
TOTAL			71,760	0	0	0	71,760	71,760

Disclosure of share-based payment arrangements [text block]

Share-based compensation

Financial detail

Share-based compensation granted to employees and executive officers corresponds to stock options and free shares.

Share-based compensation granted to board members and consultants corresponds to share warrants. For the measurement of this share-based compensation, the Group determined that under IFRS its consultants were not equivalent to employees.

Under these programs, holders of vested instruments are entitled to subscribe to shares of the Company at a pre-determined exercise price. All of the plans are equity settled.

In 2022, only SO and AGA plans were granted as share-based compensation.

The expense recognized during 2022 pursuant to IFRS 2 was €245 (compared to €470 at December 31, 2021 and €1,236 at December 31, 2020).

The table below shows the share-based compensation by plan:


Share-based compensation - expense	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
AGA S 2016-1	—	—	—
AGA S 2016-2	—	—	—
AGA D 2016-1	21	—	—
AGA D 2016-2	6	—	—
SO 2016-1	49	—	—
SO 2016-2	13	—	—
SO US 2016-1	—	—	—
SO US 2016-2	—	—	—
AGA S 2017-1	—	—	—
AGA S 2017-2	13	—	—
AGA D 2017-1	—	—	—
AGA D 2017-2	4	—	—
SO 2017-1	335	—	—
SO 2017-2	110	—	—
SO US 2017-1	—	—	—
SO US 2017-2	—	—	—
BSA-2017-A	—	—	—
BSA-2017-B	—	—	—
AGA S 2018	62	—	—
AGA D 2018	65	—	—
SO 2018	225	186	—
SO US 2018	24	24	—
AGA S 2019	55	39	50
AGA D 2019	63	16	6
SO 2019	123	105	(21)
SO 2019 - US	35	(11)	(16)
BSA 2019	20	—	—
SO US 2019	14	(7)	—
SO D 2020	—	14	14
SO C 2020	—	40	40
SO US 2020	—	19	19
AGA S 2021	—	29	32
AGA D 2021	—	5	7
SO D 2021	—	2	13
SO C2021	—	9	55
SO US 2021	—	2	9
AGA S 2022	—	—	11
AGA D 2022	—	—	2
SO D 2022	—	—	4
SO C 2022	—	—	17
SO US 2022	—	—	4
SO SU 2022	—	—	—
TOTAL	1,236	470	245

9.1. Share warrants

The following table summarizes the data relating to share warrants and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:


Share warrants (BSA)	2019		2017
	BSA 2019		BSA 2017-A		BSA 2017-B
Option pricing model	Black Scholes
Fair value per IFRS 2	€0.75		€3.78		€3.81
Issue price	€1.23		€2.00		€2.00
Exercise price	€12.32		€19.97		€19.97
Expected volatility	40.0	%	36.4	%	35.7	%
End of exercise period	5/31/2024		6/30/2022		7/15/2022
Expected dividends	0	%	0	%	0	%
Risk free interest rate	0	%	0	%	0	%
Conversion ratio	1:1		1:1		1:1

The services performed by the consultants are mainly:

•to evaluate product development plans and propose, if necessary, changes to strategic or technical approaches;

•to advise the Company's management and the Scientific Board in identifying strategies and selecting drug candidates, based in particular on the scientific results obtained by the Group (new therapeutic targets, new compounds); and

•to assist and advise the Group in its alliance strategies, such as external growth-supporting synergies (acquisition of new competencies and the purchase of operating rights, drug candidates and innovative technologies, etc.)

Information on share warrants activity is as follows for 2022:


Grant Date	Type	BSAs issued	BSAs outstanding as of January 1, 2022	BSAs awarded	BSAs exercised	BSAs cancelled/forfeited	BSAs outstanding as of December 31, 2022	BSAs exercisable as of December 31, 2022
31/10/2019	BSA 2019	35,070	35,070	0	0	0	35,070	35,070
06/12/2017	BSA 2017-A	18,345	18,345	0	0	18,345	0	0
06/12/2017	BSA 2017-B	18,345	18,345	0	0	18,345	0	0
TOTAL			71,760	0	0	36,690	35,070	35,070

Information on share warrants activity is as follows for 2021:


Grant Date	Type	BSAs issued	BSAs outstanding as of January 1, 2021	BSAs awarded	BSAs exercised	BSAs cancelled/forfeited	BSAs outstanding as of December 31, 2021	BSAs exercisable as of December 31, 2021
31/10/2019	BSA 2019	35,070	35,070	0	0	0	35,070	35,070
06/12/2017	BSA 2017-A	18,345	18,345	0	0	0	18,345	18,345
06/12/2017	BSA 2017-B	18,345	18,345	0	0	0	18,345	18,345
TOTAL			71,760	0	0	0	71,760	71,760

Free shares (actions gratuites attribuées or AGA)

The following table summarizes the data relating to free shares and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:


Free Shares (AGA)	2022		2021				2019		2018		2017		2016
	AGA D & S 2022		AGA S 2021		AGA D 2021		AGA D & S 2019		AGA D & S 2018		AGA D & S, 2017-1 & 2017-2		AGA D & S, 2016-1 & 2016-2
Option pricing model	Monte Carlo
Fair value per IFRS 2	€4.08		€4.00		€4.15		€17.06		€20.02		€21.95		€20.78
Grant date	10/14/2022		03/30/2021		03/17/2021		07/18/2019		11/22/2018		12/06/2017		12/15/2016
Share price at grant date	€4.08		€4.00		€4.15		€17.06		€20.02		€21.95		€20.78
Expected volatility	50	%	51	%	51	%	40.2	%	38	%	53.7	%	63	%
Vesting period	From 14/10/2022 to 16/10/2025		From 30/03/2021 to 31/03/2024		From 17/03/2021 to 31/03/2024		From 18/07/2019 to 16/09/2022		From 18/07/2019 to 16/09/2022		From 06/12/2017 to 31/12/2020		From 15/12/2016 to 15/12/2019
Expected dividends	0	%	0	%	0	%	0	%	0	%	0	%	0	%
Risk free interest rate	2.24	%	-0.59	%	-0.59	%	0	%	0	%	0	%	0	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	15	%	15	%	15	%

The final allocation of free shares is subject to continued employment with the Group and performance conditions.

Information on free shares activity is as follows for 2022:


Grant Date	Type	AGAs issued	AGAs outstanding as of January 1, 2022	AGAs awarded	AGAs vested	AGAs cancelled/ forfeited	AGAs outstanding as of December 31, 2022
14/10/2022	AGA S 2022	39,200		39,200		300	38,900
14/10/2022	AGA D 2022	20,000		20,000			20,000
30/03/2021	AGA S 2021	32,400	29,000			2,700	26,300
17/03/2021	AGA D 2021	15,000	15,000				15,000
18/07/2019	AGA S 2019	17,556	10,782		10,782		0
18/07/2019	AGA D 2019	19,070	13,068		8,712	4,356	0
TOTAL			67,850	59,200	19,494	7,356	100,200

Information on free shares activity is as follows for 2021:


Grant Date	Type	AGAs issued	AGAs outstanding as of January 1, 2021	AGAs awarded	AGAs vested	AGAs cancelled/ forfeited	AGAs outstanding as of December 31, 2021
30/03/2021	AGA S 2021	32,400		32,400		3,400	29,000
17/03/2021	AGA D 2021	15,000		15,000			15,000
18/07/2019	AGA S 2019	17,556	12,330			1,548	10,782
18/07/2019	AGA D 2019	19,070	15,710			2,642	13,068
TOTAL			28,040	47,400	-	7,590	67,850

Stock options (options de souscription d'actions or SO)

The following table summarizes the data relating to stock options and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:


Stock options (SO)	2022								2021
	SO SU 2022		SO D 2022		SO C 2022		SO US 2022		SO D 2021		SO C 2021		SO US 2021
Option pricing model	Black Scholes
Fair value per IFRS 2	€1.40		€1.57		€1.90		€1.56		€1.06		€1.30		€1.07
Grant date	12/2/2022		10/17/2022		10/17/2022		10/17/2022		10/20/2021		10/20/2021		10/20/2021
Share price at grant date	€3.46		€4.16		€4.16		€4.16		€3.24		€3.24		€3.24
Exercise price	€2.95		€3.91		€3.12		€3.94		€3.26		€2.61		€3.22
Expected volatility	49.0	%	50.0	%	50.0	%	50.0	%	50.0	%	50.0	%	50.0	%
Vesting period	From 3/12/2022 to 3/12/2025		Du 17/10/2022 au 17/10/2025						Du 20/10/2021 au 20/10/2024
Exercise period	From 3/12/2022 to 3/12/2032		Du 18/10/2025 au 17/10/2032						Du 21/10/2024 au 21/10/2031
Expected dividends	0	%	0	%	0	%	0	%	0	%	0	%	0	%
Risk free interest rate	2.1	%	2.24	%	2.24	%	2.24	%	-0.6	%	-0.6	%	-0.6	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	0	%	0	%	0	%


Stock options (SO)	2020						2019
	SO D 2020		SO C 2020		SO US 2020		SO 2019		SO US 1 2019		SO US 2 2019
Option pricing model	Black Scholes
Fair value per IFRS 2	€1.16		€1.46		€1.12		€4.59		€3.67		€3.23
Grant date	12/31/2020		12/31/2020		12/31/2020		7/18/2019		7/18/2019		11/27/2019
Share price at grant date	€3.99		€3.99		€3.99		€17.06		€17.06		€14.50
Exercise price	€4.38		€3.50		€4.52		€13.99		€16.90		€14.31
Expected volatility	49.0	%	49.0	%	49.0	%	40.0	%	40.0	%	40.0	%
Vesting period	Du 31/12/2020 au 31/12/2023						Du 18/07/2019 au 16/09/2022				Du 27/11/2019 au 16/01/2023
Exercise period	Du 01/01/2024 au 31/12/2027						Du 17/09/2022 au 17/09/2029				Du 17/01/2023 au 17/01/2030
Expected dividends	0.0	%	0.0	%	0.0	%	0.0	%	0.0	%	0.0	%
Risk free interest rate	-0.7	%	-0.7	%	-0.7	%	0.0	%	0.0	%	0.0	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	0	%	0	%


Stock options (SO)	2018				2017		2016
	SO 2018		SO US 2018		SO 2017		SO 2016
Option pricing model	Black Scholes
Fair value per IFRS 2	€9.32		€6.90		€9.32		€10.30
Grant date	11/7/2018		11/7/2018		12/6/2017		12/15/2016
Share price at grant date	€22.10		€22.10		€21.95		€20.79
Exercise price	€16.00		€21.65		€17.91		€15.79
Expected volatility	44.1	%	44.1	%	53.7	%	63.0	%
Vesting period	Du 07/11/2018 au 31/12/2021				Du 06/12/2017 au 31/12/2020		Du 15/12/2016 au 15/12/2019
Exercise period	Du 01/01/2022 au 31/12/2028				Du 01/01/2021 au 31/12/2027		Du 16/12/2019 au 16/12/2026
Expected dividends	0	%	0	%	0	%	0	%
Risk free interest rate	0.0	%	0.0	%	0.0	%	0.0	%
Conversion ratio	1:1		1:1		1:1		1:1
Expected employee turnover	15	%	15	%	15	%	15	%

Definitive vesting is subject to continued employment with the Group and performance conditions.

Information on stock options activity is as follows for 2022:


Grant Date	Type	SO issued	SO outstanding as of January 1, 2022	SO awarded	SO cancelled/ forfeited	SO exercised	SO outstanding as of December 31, 2022	SO exercisable as of December 31, 2022
02/12/2022	SO SU 2022	8,750		8,750			8,750	0
17/10/2022	SO D 2022	35,000		35,000			35,000	0
17/10/2022	SO C 2022	131,000		131,000			131,000	0
17/10/2022	SO US 2022	34,625		34,625			34,625	0
20/10/2021	SO D 2021	35,000	35,000				35,000	0
20/10/2021	SO C 2021	134,375	134,375		10,000		124,375	0
20/10/2021	SO US 2021	32,500	25,000				25,000	0
31/12/2020	SO D 2020	35,000	35,000				35,000	0
31/12/2020	SO C 2020	103,750	81,250				81,250	0
31/12/2020	SO US 2020	56,250	50,000				50,000	0
18/07/2019	SO 2019	107,880	77,015		25,672		51,343	51,343
18/07/2019	SO US 1 2019	30,620	7,670		2,557		5,113	5,113
07/11/2018	SO 2018	122,000	68,329				68,329	68,329
07/11/2018	SO US 2018	17,500	9,713				9,713	9,713
06/12/2017	SO 2017-1	64,164	43,212				43,212	43,212
06/12/2017	SO 2017-2	32,086	17,765				17,765	17,765
15/12/2016	SO 2016-1	41,917	34,398				34,398	34,398
15/12/2016	SO 2016-2	20,958	15,308				15,308	15,308
TOTAL			634,035	209,375	38,229	0	805,181	245,181

Information on stock options activity is as follows for 2021:


Grant Date	Type	SO issued	SO outstanding as of January 1, 2021	SO awarded	SO cancelled/ forfeited	SO exercised	SO outstanding as of December 31, 2021	SO exercisable as of December 31, 2021
20/10/2021	SO D 2021	35 000		35 000			35 000	-
20/10/2021	SO C 2021	134 375		134 375			134 375	-
20/10/2021	SO US 2021	32 500		32 500	7 500		25 000	-
31/12/2020	SO D 2020	35 000	35 000				35 000	-
31/12/2020	SO C 2020	103 750	103 750		22 500		81 250	-
31/12/2020	SO US 2020	56 250	56 250		6 250		50 000	-
18/07/2019	SO 2019	107 880	94 530		17 515		77 015	-
18/07/2019	SO US 1 2019	30 620	23 620		15 950		7 670	-
27/11/2019	SO US 2 2019	13 350	8 900		8 900		-	-
07/11/2018	SO 2018	122 000	71 678		3 349		68 329	68 329
07/11/2018	SO US 2018	17 500	9 713				9 713	9 713
06/12/2017	SO 2017-1	64 164	43 212				43 212	43 212
06/12/2017	SO 2017-2	32 086	17 765				17 765	17 765
15/12/2016	SO 2016-1	41 917	34 398				34 398	34 398
15/12/2016	SO 2016-2	20 958	15 308				15 308	15 308
TOTAL			514 124	201 875	81 964	0	634 035	188 725

Performance conditions

The SO and SO US stock option plans as well as certain free share plans (AGA "D") implemented in 2016, 2017, 2018 and 2019 are subject to internal performance conditions related to the progress of the Group's research and development programs, and to external performance conditions related to the evolution of the Company's stock price.

The other free share plans (AGA "S") and SO plans implemented starting in 2020 are subject only to internal performance conditions.

Performance conditions of 2022 plans


Plans			Nature of performance conditions
SO D 2022 SO C 2022 SO US 2022 SO SU 2022 AGA S 2022 AGA D 2022 Evaluation date for performance conditions: - 10/17/2025 for SO D 2022/SO C 2022/SO US 2022/AGA S 2022/AGA D 2022 - 12/3/2025 for SO SU 2022			Internal conditions - a) 50% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 10,000 of the Free Shares for the AGA D 2022 will vest, if during the 2022 financial year and then at any time during the Vesting Period, 3 new R&D programs (at the rate of one third of these 2022 instruments per new program) complete the Company's R&D program portfolio (as it was at 12/31/2021); that these programs are at the so-called clinical development stage when this addition is made or that they reach this stage afterwards and that this addition originates: (i) a business-development operation (licensing-in, M&A, etc.), or (ii) the identification of new opportunities resulting from internal research (repositioning). b) 25% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 5,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following three conditions relating to the development of the elafibranor development program is fulfilled: (i) obtaining the main results of the first part of the ELATIVE trial in the second quarter of 2023; (ii) filing of a Marketing Authorization Application for elafibranor in the second half of 2023; (iii) marketing authorization for elafibranor in 2024. c) 15% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 3,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following two conditions relating to the development of the NTZ program in the ACLF is fulfilled: (i) First clinical results in 2022; (ii) Start of a Phase 2 clinical trial in the first half of 2023. d) 10% of instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 2,000 of the Free Shares for the AGA D 2022 will vest, if as part of the development of the GNS561 program, a Phase 2b trial starts in the first half of 2023. External conditions - Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2022 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2022 definitively allocated will be equal to:[(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2022 instruments (c) All AGA D 2022 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.

Performance conditions of 2021 plans


Plans			Nature of performance conditions
SO D 2021 SO C 2021 SO US 2021 Evaluation date for performance conditions: 10/20/2024			a) 50% of the Stock Options will be exercisable if at least one of the following three conditions relating to the development of elafibranor in PBC and to the ELATIVE clinical trial is fulfilled: (i) ELATIVE topline results are released to the market before or during the second quarter of 2023; (ii) a new drug application is filed for elafibranor in PBC with the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in the second half of 2023 or before; (iii) elafibranor is approved by a regulatory authority in 2024. b) 15% of the Stock Options will be exercisable if at least one of the following two conditions relating to the development of NTZ and the ACLF franchise is fulfilled: (i) a Phase 2 clinical study or a more advanced clinical study evaluating NTZ is in ongoing or was carried out; (ii) the Company develops or acquires the rights to a new molecule (including through repositioning) for development in ACLF. c) 15% of the Stock Options will be exercisable if at least one of the following two conditions relating to the NIS4 diagnostic technology is fulfilled: (i) if a research and development partnership agreement relating to the implementation of the NIS4 diagnostic technology into an IVD test with at least one major NASH player (“big pharma”, biotech company, institution, etc.) is entered into by the Company; (ii) Labcorp’s NASHnext LDT is reimbursed by at least three payers in the United States (insurance, integrated system, etc). d) 20% of the Stock Options will be exercisable if at least one of the following two conditions relating to the development of the product pipeline of the Company is fulfilled: (i) At least one new molecule (excluding elafibranor and NTZ) is developed by the Company or the Company has acquired development rights to a new molecule outside of the ACLF franchise (performance already covered by b(ii) above); (ii) At least two Phase 2 clinical studies or more advanced clinical studies are ongoing or have been completed ; not including a Phase 2 clinical study or more advanced clinical study in NTZ (performance already covered by b(i) above).


Plans			Nature of performance conditions
AGA S 2021 AGA D 2021 Evaluation date for performance conditions: 3/31/2024			Internal conditions - a) 50% of the Free Shares AGA S 2021 will be exercisable, and 7,500 of the Free Shares AGA D 2021 will be exercisable, if at least one of the following three conditions relating to PBC and ELATIVE is fulfilled: (i) “Last Patient Visit” in ELATIVE in the fourth quarter of 2022 or earlier; (ii) If the results of ELATIVE are released to the market before or during the first half of 2023; (iii) if a registration request is filed for elafibranor in PBS with the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in 2023. b) 25% of the Free Shares AGA S 2021 will be exercisable, and of the Free Shares AGA D 2021 will be exercisable, if at least one of the following two conditions relating to the NIS4 diagnostic is fulfilled: (i) if a research and development partnership agreement with at least one major NASH player (“big pharma”, biotech company, institution, etc.) is entered into by the Company; (ii) the NIS4 diagnostic is used in at least 20 clinical studies. c) 25% of the Free Shares AGA S 2021 will be exercisable, and 3,750 of the Free Shares AGA D 2021 will be exercisable, if at least one of the following two conditions relating to the product pipeline of the Company is fulfilled: (i) initiation of a clinical study for a new indication with elafibranor or NTZ; (ii) if the Company develops or acquires the rights to a new molecule. External conditions - Each applicable portion of all 15,000 Free Shares under the AGA D 2021 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all Free Shares under the AGA D 2021 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2021 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2021 definitively allocated will be equal to:[(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2021 instruments (c) All AGA D 2021 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.

Financial Income and Expenses

12 Months Ended

Dec. 31, 2022

Financial Income And Expenses [Abstract]

Financial Income and Expenses

FINANCIAL INCOME AND EXPENSES


Financial income and expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31


Interest income	1,442	274	137
Foreign exchange gain	4,983	8,876	7,470
Financial income from renegotiating the convertible bond debt OCEANE	0	35,578	0
Other financial income	119	52	605
TOTAL - Financial income	6,544	44,780	8,212
Financial expenses
Interest expenses	(11,643)	(4,846)	(4,341)
Interest expenses for leases	(134)	(109)	(69)
Foreign exchange losses	(13,508)	(2,163)	(340)
Other financial expenses	(11)	(5)	(8)
TOTAL - Financial expenses	(25,296)	(7,122)	(4,758)
FINANCIAL GAIN (LOSS)	(18,752)	37,658	3,453

As a reminder, financial income in 2021 included notably the one-time buyback bonus of €35.6 million issued from the renegotiation of the OCEANEs completed in said year.

Income Tax

12 Months Ended

Dec. 31, 2022

Deferred tax expense (income) [abstract]

Income Tax

INCOME TAX

Financial detail

For 2022, the corporate income tax payable of the Parent company GENFIT SA amounted to €4,906, which is recognized as "Other current tax liabilities" in the consolidated financial statements.

It is of note that we benefited from a reduced tax rate on part of the income from the licensing agreement signed with Ipsen pursuant to Article 238 of the French Tax Code.

The determination of the income tax expense recognized in the consolidated financial statements, which amounted to (a gain) of €(116) for 2021, is summarized in the table "Effective tax rate" hereunder.

Breakdown of deferred taxes by nature


	As of	Impact on	Impact on the	As of
(in € thousands)	12/31/2020	equity	profit/loss	12/31/2021












Deferred tax liabilities	(2,050)	(2,721)	2,455	(2,315)
Deferred tax assets	1,282	—	430	1,712
TOTAL	(767)	(2,721)	2,885	(602)


	As of	Impact on	Impact on the	As of
(in € thousands)	12/31/2021	equity	profit/loss	12/31/2022












Deferred tax liabilities	(2,315)	—	545	(1,770)
Deferred tax assets	1,712	—	(453)	1,260
TOTAL	(602)	—	93	(510)

Effective tax rate


	Year ended
(in € thousands)	2020/12/31		2021/12/31		2022/12/31
Profit (loss) for the period	(101,221)		67,259		(23,719)
Tax gain (expense)	428		(2,215)		116
Profit (loss) for the period before taxes	(101,649)		69,474		(23,836)
Tax rate in France	28.92	%	27.37	%	25.00	%
Theoretical tax expense calculated at the French tax rate	29,401		(19,018)		5,959
Increase / decrease in tax benefit arising from :
Tax credits	1,739		1,512		1,504
Permanent differences	(404)		833		(31)
Differences between rates	172		7,323		(67)
Tax losses for the period, unrecognised as deferred tax assets	(28,603)		0		(7,037)
Utilisation of previously unrecognised tax losses	0		5,590		0
IFRS adjustments without tax incidence	(358)		(129)		(61)
Non recognition of deffered tax assets related to temporary differences	(775)		(24)		331
Recognition of deferred tax assets against deferred tax liabilities	(706)		430		(453)
Tax effects related to the renegociation of the convertible debt	0		1,370		0
Others	(39)		(102)		(29)

Income tax expense recognised in profit or loss	428		(2,215)		116
Effective income rate	(0.42)	%	(3.19)	%	(0.49)	%

Tax Inspection

We are subject to a tax audit by the French revenue service on our tax returns or operations subject to review on the 2019 and 2020 periods (including the Research Tax Credit claimed for these periods), which started on December 10, 2021 and is still ongoing at the date of this document.

The research tax credit receivable from amounted to €11,299 as of December 31, 2022, €6,017 of which relates to 2022. The balance for 2021 has not yet been reimbursed in 2022 given the ongoing tax audit. The amount of the balance for 2021 is €5,282.

Losses available for offsetting against future taxable income

At December 31, 2020, 2021 and 2022, the tax loss carry forwards for the Company amounted to €483,356, €449,679 and €477,149, respectively.

Such carry forwards can be offset against future taxable profit within a limit of €1.0 million per year plus 50% of the profit exceeding this limit. Remaining unused losses will continue to be carried forward indefinitely.

In 2021, the amount of tax loss carry forwards used to offset taxable profit were €33.7 million.

Deferred tax assets and liabilities

The Group's main sources of deferred tax assets and liabilities as of December 31, 2021 and 2022 related to:

•Tax loss carry forwards: €449,679 and €477,149 respectively;

•Temporary differences related to:

◦the OCEANEs: a deferred tax liability for €2,315 and €1,770 as of December 31, 2021 and 2022, respectively, and a deferred tax asset for €1,712 and €1,260 as of December 31, 2021 and 2022,

◦Post-employment benefits: a deferred tax liability for €287 and €216, as of December 31, 2021 and 2022, respectively, each offset by a deferred tax asset of the same amount.

The Company offsets its deferred tax assets and liabilities (€1,260 and €1,770, respectively), as permitted by IAS 12, resulting in a net deferred tax liability of €510 as of December 31, 2022.

Other than as it relates to deferred tax assets recognized based on the available deferred tax liabilities, no other deferred tax asset has been recognized as it is not probable that taxable profit will be available to offset deductible temporary differences and tax loss carry forwards.

Earnings (Loss) Per Share

12 Months Ended

Dec. 31, 2022

Earnings per share [abstract]

Earnings (Loss) Per Share

Earnings (loss) per share

The components of the earnings (loss) per share computation are as follows:


Earnings per share	Year ended
	2020/12/31	2021/12/31	2022/12/31

Profit (loss) for the period (in € thousands)	(101,221)	67,259	(23,719)
Weighted average number of ordinary shares used to calculate basic earnings (loss) per share	38,858,617	44,739,756	49,673,936
Basic earnings (loss) per share (€/share)	(2.60)	1.51	(0.48)


Weighted average number of ordinary shares used to calculate diluted earnings (loss) per share	38,858,617	55,613,634	49,673,936
Diluted earnings (loss) per share (€/share)	(2.60)	1.23	(0.48)

The weighted average numbers of ordinary shares as noted above exclude shares held by Genfit.

The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:

Potential common shares not included in the computation of diluted earnings per share

Year ended

2022/12/31

BSA

35,070

STOCK OPTIONS

637,726

AGA

53,887

OCEANES

10,580,141

Litigation and Contingent Liabilities	12 Months Ended
Litigation and Contingent Liabilities	Dec. 31, 2022
Disclosure of contingent liabilities [abstract]
Litigation and Contingent Liabilities	LITIGATION AND CONTINGENT LIABILITIES Class Action In May 2020, following the Group announcement on the interim results of our RESOLVE-IT Phase 3 clinical trial in which elafibranor had not achieved the primary or key secondary endpoints, a purported shareholder class action complaint was filed in state court in the Commonwealth of Massachusetts, naming the Group, the board of directors and certain members of the senior management as defendants, alleging that defendants made materially misleading statements about the development of elafibranor in connection with our U.S. initial public offering in violation of U.S. federal securities laws. In October 2020, the plaintiff voluntarily dismissed the Commonwealth of Massachusetts action, but in December 2020, the same plaintiff filed a purported shareholder class action complaint in state court in the State of New York, alleging claims substantially similar to those in the previous complaint against the same defendants, as well as the underwriters of our U.S. initial public offering. In March 2021, the Company and the other defendants filed a motion to dismiss. In August 2021, the Supreme Court of the State of New York, New York County, granted the motion and dismissed the complaint with prejudice. The plaintiff appealed and in December 2022, the Supreme Court, Appellate Division, First Department affirmed the dismissal of the complaint, except that it deleted the phrase “with prejudice” from the Supreme Court’s judgment. The time to appeal the decision of the Appellate Division has expired.

Related Parties

12 Months Ended

Dec. 31, 2022

Disclosure of transactions between related parties [abstract]

Related Parties

RELATED PARTIES

Compensation of key management personnel

The aggregate compensation of the members of the Company’s Board of Directors (including the Chairman of the Board) and to the Chief Executive Officer includes the following:


	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Fixed compensation owed	518	518	585
Variable compensation owed	71	163	169
Attendance fees - board of Directors	456	488	421
Contributions in-kind	26	23	21
Share-based payments	41	58	74
Employer contributions	405	443	410
Consulting fees	0	0	0
TOTAL	1,517	1,693	1,680

Biotech Avenir

Jean-François Mouney, the Chairman of the Company, is also the Chairman of Biotech Avenir SAS.

At December 31, 2022, Biotech Avenir SAS held 3.79% of the share capital of the Company.

The Company did not carry out any transactions with Biotech Avenir in 2022, 2021, or 2020, with the exception of the domiciliation without charge.

Ipsen Pharma SAS

See note 7.1 "Revenue s and oth er income ".

Compensation of Corporate Officers

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Of Corporate Officers [Abstract]

Compensation of Corporate Officers

Compensation of key management personnel

The aggregate compensation of the members of the Company’s Board of Directors (including the Chairman of the Board) and to the Chief Executive Officer includes the following:


	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Fixed compensation owed	518	518	585
Variable compensation owed	71	163	169
Attendance fees - board of Directors	456	488	421
Contributions in-kind	26	23	21
Share-based payments	41	58	74
Employer contributions	405	443	410
Consulting fees	0	0	0
TOTAL	1,517	1,693	1,680

Commitments	12 Months Ended
Commitments	Dec. 31, 2022
Disclosure Of Commitments [Abstract]
Commitments	COMMITMENTS Obligations under the terms of subcontracting agreements The Group enters into contracts for its business needs with clinical research organizations (CROs) for clinical trials, as well as with Contract Manufacturing Organizations (CMOs) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Group’s agreements generally provide for termination with specified periods of advance notice. Such agreements are generally cancellable contracts and not included in the description of the Group’s contractual obligations and commitments. Obligations under the terms of license and collaboration agreements The Company has entered into a licensing agreement with Genoscience Pharma whereby we are obligated to pay royalties and milestone payments based on future events that are uncertain and therefore they constitute contingent liabilities not recognized in the Company's consolidated financial statements for the period ending December 31, 2022. Refer to N ote 24 "Provisions ". Obligations related to the Versantis acquisition The company entered into an agreement with the former shareholders of Versantis whereby we are obligated to pay milestone payments based on future events that are uncertain and there therefore they constitute contingent liabilities not recognized in the Company's consolidated financial statements for the period ending December 31, 2022. Refer to Note 2.1. Obligations under the terms of lease agreements The Company has guaranteed its rental payment obligation under the lease agreement for the headquarters in Loos, France in the amount of €600 at December 31, 2022, €600 at December 31, 2021. Contingent assets The Company has entered into a licensing agreement with Terns Pharma whereby we could receive milestone payments based on future events that are uncertain and therefore they constitute contingent assets not recognized in the Company's consolidated financial statements for the period ending December 31, 2022. Milestones include Development Milestone Payments upon the achievement of the development milestones for the licensed product and Commercial Milestone Payments upon the achievement of commercial milestones depending on reaching certain aggregate thresholds. There are also potential mid-teen royalties based on sales by Terns Pharmaceuticals in Greater China. The potential Development and Commercial Milestone payments may represent up to $193 million . .

Cash flow statement	12 Months Ended
Cash flow statement	Dec. 31, 2022
Cash Flow Information [Abstract]
Disclosure of cash flow statement [text block]	SUPPLEMENTAL CASH FLOW INFORMATION Supplemental cash flow information Disclosure of non-cash financing and investing activities Accrued property, plant and equipment, 2022: €142 Accrued property, plant and equipment, 2021: €76 Accrued property, plant and equipment, 2020: €83 Other non-cash items On the Consolidated Statements of Cash Flows, "Other non-cash items" includes the bonus generated by the partial buyback following the renegotiation completed in January 2021 for the amount of €35,578, for 2021. Similarly, on the Consolidated Statements of Operations, this amount was included in "Financial Income" in 2021.

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2022
Disclosure of voluntary change in accounting policy [abstract]
Use of estimates and judgments	Use of estimates and judgments In preparing these consolidated financial statements, management makes judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, incomes and expenses. Actual amounts may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The estimates and underlying assumptions mainly relate to research tax credits (see Note 7.2 "O ther income ", employee benefits (see Note 25 "Employee benefits"), leases (see Note 15 “Property, plant and equipment including Leases”), share-based payments (see Note 9 "Share-based compensation"), accruals related to clinical trials (see Note 8 "Operating expenses"), convertible loans (see Note 20.1 "Breakdown of convertible loan"), accounting judgments related to the Versantis acquisition (see Note 2.1 "Acquisition of the Clinical-stage Biopharmaceutical Company Versantis "), the valuation of our investment in Genoscience (See Note 18 "Other fi nancial assets "), and the allocation of income to the performance obligations provided for in the agreement entered into with Ipsen (see Note 7 "Revenues and Other Income"). When assessing going concern, the Group’s Board of Directors considers mainly the following factors: The liquidity available at the statement of financial position date, the cash spend projections for next 12-month period as from the date of the financial statements are issued and the availability of other funding.
Consolidation	Consolidation Going concern The consolidated financial statements were prepared on a going concern basis. The Group believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Consolidated entities The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity. The Group controls all the entities included in the scope of consolidation. GENFIT Pharmaceuticals SAS was dissolved on December 23, 2022 in accordance with article 1844-5 of the Civil Code in France. All assets and liabilities of the company was transferred to GENFIT SA.
Foreign currency	Foreign currency 4.3.1.Foreign currency transactions Transactions in foreign currencies are translated into the respective functional currencies of the entities of the Group at the exchange rates applicable at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the reporting date. The resulting exchange gains or losses are recognized in the statements of operations. 4.3.2.Translation of foreign subsidiary financial statements The assets and liabilities of foreign operations having a functional currency different from the euro are translated into euros at the closing exchange rate. The income and expenses of foreign operations are translated into euros at the exchange rates effective at the transaction dates or using the average exchange rate for the reporting period unless this method cannot be applied due to significant exchange rate fluctuations. Gains and losses arising from foreign operations are recognized in the statement of other comprehensive loss. When a foreign operation is partly or fully divested, the associated share of gains and losses recognized in the currency translation reserve is transferred to the statements of operations. The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A.
Revenues from ongoing activities under client agreements	Revenues from contracts with customers Accounting policy overview Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, i.e., when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service. Under this standard, each contract must be analyzed, on a case-by-case basis, in order to verify whether it contains performance obligations towards third parties, and, if applicable, to identify their nature in order to determine the appropriate accounting of amounts that the Company has received or is entitled to receive from third parties, for example: •The transfer of control over the intellectual property, via a license granted by the Company, as it exists at the time of the sale, the date of which will determine that of the revenue recognition; •If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime; •The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; and •Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale.
Intangible assets	Goodwill The company does not have any goodwill. Intangible assets Intangible assets mainly consist of software and operating licenses acquired by the Group. They are recognized at cost less accumulated amortization and impairment. Amortization expense is recorded on a straight-line basis over the estimated useful lives of the intangible assets.
Leases	Leases IFRS 16 introduces for the lessee a single model of accounting on the balance sheet for leases. The lessee recognizes a "right of use" asset which represents its right to use the underlying asset, and a lease liability for its obligation to pay the rent. The Group recognizes a "right of use" asset and a lease liability at the start of the lease term. The "right of use" asset is initially measured at cost and then at cost less any amortization and accumulated impairment losses. The amount can be adjusted based on certain revaluations of the lease liability. The lease liability is initially measured at the discounted value of the rents owed and not yet paid at the start date of the contract. The discount rate used is the implicit interest rate of the contract or, if it cannot be easily determined, the Company’s incremental borrowing rate of the lessee. The Group generally uses the latter as the discount rate. The lease liability is then adjusted by the interest expense minus the amounts of rent paid. It is revalued in the event of a change in future rents following a change in the index or rate, a new estimate of the amount to be paid under a residual value guarantee or, where applicable, a revaluation of the exercise of an option to purchase or to extend, or the non-exercise of an option to terminate (which then becomes reasonably certain). The Group has exercised its judgment in determining the term of the lease agreements that provide for extension options. The fact that the Group has determined that it is reasonably certain to exercise such options has an impact on the lease term used and has a significant impact on the amount of lease debt and the "right of use" asset in the accounts. The amount of short term or low value leases which are not included in the IFRS 16 model is not material.
Inventories	INVENTORIES The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements. These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.
Trade and other receivables	TRADE AND OTHER RECEIVABLES Accounting policies Trade and other receivables are recognized at fair value, which is the nominal value of invoices unless payment terms require a material adjustment for the time value discounting effect at market interest rates. Trade receivables are subsequently measured at amortized cost. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables . Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date, according to IFRS 9 standards ("expected credit loss"). OTHER FINANCIAL ASSETS Accounting policies A financial asset is initially recognized as measured at amortized cost, at fair value through other comprehensive income - debt instrument, at fair value through other comprehensive income - equity instrument, or at fair value through profit or loss. Financial assets will not be reclassified after initial recognition, unless we change our economic model of financial asset management. If so, all affected financial assets would be reclassified as of the first day of the first reporting period following the change in economic model. A financial asset is measured at amortized cost if both of the following conditions are met, and if it is not measure at fair value through profit or loss: •Its ownership is part of an economic model of which the objective is to hold assets in order to receive its contractual cash flows; •Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount. A debt instrument is measured at fair value through other comprehensive income if both of the following conditions are met, and if it is not measure at fair value through profit or loss: •Its ownership is part of an economic model of which the goal is met through both the receipt of contractual cash flows and the sale of financial assets; •Its contractual conditions provide for cash flows at defined dates, which correspond only to principal payments and interest on the remaining principal amount. At the time of initial recognition of an equity instrument that is not held for trading, we may irrevocably choose to present future changes in fair value in other comprehensive income. This choice is made for each investment. All financial assets that are not categorized as measured at amortized cost or at fair value through other comprehensive income as previously described are measured at fair value through profit or loss.
Cash and cash equivalents	CASH AND CASH EQUIVALENTS Cash and cash equivalents comprise cash on hand, bank accounts and term deposits, together with short-term deposits and highly liquid investments. They are readily convertible to a known amount of cash and thus present a negligible risk of a change in value. They also include Undertakings for Collective Investments in Transferable Securities (UCITs) whose characteristics allow them to be classified as cash and cash equivalents. Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).
Equity	EQUITY Accounting policies Share capital comprises ordinary shares and ordinary shares with double voting rights classified in equity. Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium. The liquidity agreement consists of a share buyback program contracted to an investment service provider. Purchases and sales of the Company's shares carried out under the contract are recognized directly in shareholders’ equity under treasury shares. See N ote 18 “Other financial assets”
Loans and borrowings	LOANS AND BORROWINGS Accounting policies Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method. The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire. The bonds convertible or exchangeable into new or existing shares (OCEANEs—see Note 20 .1 "Breakdown of convertible loan ") are recognized as follows: in accordance with IAS 32, Financial Instruments—Presentation, if a financial instrument has different components and the characteristics indicate that some should be classified as liabilities and others as equity, the issuer must recognize the different components separately. The liability component is measured, at the date of issuance, at its fair value on the basis of future contractual cash flows discounted at market rates (taking into consideration the issuer's credit risk) of a debt having similar characteristics but without the conversion option. The value of the conversion option is measured by the difference between the bond's issue price and the fair value of the liability component. After deduction of the pro rata portion of expenses related to the transaction, this amount is recognized in the line item "Share premium" under shareholders' equity and is subject to a calculation of deferred tax according to IAS 12.28. The liability component (after deduction of the pro rata portion of the transaction expenses attributed to the liability and the conversion option) is measured at amortized cost. A non-monetary interest expense, recorded in net loss is calculated using an effective interest rate to progressively bring the debt component up to the amount which will be repaid (or converted) at maturity. A deferred tax liability is calculated on the basis of this amount. The shareholders' equity component is not remeasured.
Trade and other payables	TRADE AND OTHER PAYABLES Accounting policies Trade and other payables are initially recognized at the fair value of the amount due. This value is usually the nominal value, due to the relatively short period of time between the recognition of the instrument and its repayment.
Provisions	ProvisionsAccounting policies In accordance with IAS 37, Provisions Contingent Liabilities and Contingent Assets, provisions are recognized when the Group has a present obligation (legal, regulatory, contractual or constructive) as a result of a past event, for which it is probable that an outflow of resources will be required to settle the obligation, and of which the amount can be estimated reliably. The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation. Provisions are discounted when the time value effect is material. A provision for reorganization is recognized when the Group has approved a formal and detailed plan for its reorganization and has either started to implement it or publicly disclosed it. A provision for onerous contract is estimated at the actual value of the lowest expected cost of either the cancellation or the execution of the contract, the latter being established on the basis of the additional costs required to fulfill the obligations stipulated by the contract. Before a provision is established, the Group recognizes any impairment loss that occurred on the assets dedicated to this contract. Future milestone and revenue based royalty payments may be recorded pursuant to Contingent liability under IAS 37 or intangible asset under IAS 38. Under IAS 38, we record a provision when we have a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources. Under IAS 38, we record intangible asset when it is probable that the expected future economic benefits that are attributes to the assets will flow to us and the cost of asset can be measured reliably.
Description of accounting policy for employee benefits [text block]	EMPLOYEE BENEFITS Accounting policies The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans. 25.1.Defined benefit plans Defined benefit plans relate to French retirement benefit plans under which the Group is committed to guaranteeing a specific amount or level of contractually defined benefits. The obligation arising from these plans is measured on an actuarial basis using the projected unit credit method. The method consists of measuring the obligation based on a projected end-of-career salary and vested rights at the measurement date, according to the provisions of the collective bargaining agreement, corporate agreements and applicable law. Actuarial assumptions are used to determine the benefit obligations. The amount of future payments is determined on the basis of demographic and financial assumptions such as mortality, staff turnover, pay increases and age at retirement, and then discounted to their present value. The discount rate used is the yield at the reporting date on AA credit-rated bonds with maturity dates that approximate the expected payments for the Group's obligations. Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss. The Group determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. 25.2.Defined contribution plans Under defined contribution plans, the management of plans is performed by an external organization, to which the Group pays regular contributions. Payments made by the Group in respect of these plans are recognized as an expense for the period in the statements of operations. 25.3.Short-term employee benefits A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee, and the obligation can be estimated reliably.
Other income	Research tax credit The Research Tax Credit ("Crédit d'Impôt Recherche," or "CIR") is granted to entities by the French tax authorities in order to encourage them to conduct technical and scientific research. Entities that demonstrate that their research expenditures meet the required CIR criteria receive a tax credit that may be used for the payment of their income tax due for the fiscal year in which the expenditures were incurred, as well as in the next three years. If taxes due are not sufficient to cover the full amount of tax credit at the end of the three-year period, the difference is paid in cash to the entity by the tax authorities. If a company meets certain criteria in terms of sales, headcount or assets to be considered a small/mid-size company, immediate payment of the Research Tax Credit can be requested. The Group meets such criteria. The Group applies for CIR for research expenditures incurred in each fiscal year and recognizes the amount claimed in the line item "Other income" in the statements of operations in the same fiscal year. In the notes to the financial statements, the amount claimed is recognized under the heading "Research tax credit" (see Note 16, "Trade and other receivables" and the table below). 7.2.2.Government grants Government grants The Group received until 2016 various forms of government grants. This government aid is provided for and managed by French state-owned entities, and specifically "BPI France" ("Banque Publique d'Investissement"), formerly named "OSEO Innovation". Subsidies received are non-refundable.
Research and development expenses	Accounting policies Research and development expenses Research expenses are recorded in the financial statements as expenses. In accordance with IAS 38, Intangible Assets, development expenses are recognized as intangible assets only if all the following criteria are met: •Technical feasibility necessary for the completion of the development project; •Intention on the Group's part to complete the project and to utilize it; •Capacity to utilize the intangible asset; •Proof of the probability of future economic benefits associated with the asset; •Availability of the technical, financial, and other resources for completing the project; and •Reliable evaluation of the expenses attributed to the intangible asset during its development. As of the date of these financial statements these criteria have not all been met. Classification of operating expenses Research and development expenses include: •employee-related costs; •costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…); •lab supplies and facility costs; •fees paid to scientific advisers and contracted research and development activities conducted by third parties; •intellectual property fees corresponding to the filing of the Group's patents, and •provision and reversals of provisions in relation to the Research Tax Credit dispute.
Classification of operating expenses	Classification of operating expenses Research and development expenses include: •employee-related costs; •costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…); •lab supplies and facility costs; •fees paid to scientific advisers and contracted research and development activities conducted by third parties; •intellectual property fees corresponding to the filing of the Group's patents, and •provision and reversals of provisions in relation to the Research Tax Credit dispute. Contracted research and development activities conducted by third parties include services subcontracted to research partners for technical and/or regulatory reasons. In particular, this includes the production of active ingredients and therapeutic units, all or a part of clinical trials and preclinical trials that are necessary to the development of GENFIT's drug candidates and biomarker candidates. General and administrative expenses include: •employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions; •facility-related costs; •marketing, legal, audit and accounting fees; •press relations and communications firm fees; •the cost of external employees seconded to the Company (such as security, reception, and accounting...); •other service costs (recruitment, etc.); and •intellectual property fees corresponding to the maintenance of the Group's patents. Marketing and market access expenses include: •employee-related costs for marketing and business development functions; and •marketing, and market access firm fees. Reorganization and restructuring expenses include: •the accruals and provisions recognized within the scope of the reduction in force plan; •the extraordinary amortization, loss of value and impairment of fixed assets recognized within the scope of the reorganization of GENFIT; •the impairment of the right of use of the leased equipment and premises; •the portion of the OCEANEs renegotiation expenses; •the provision recognized for some of the costs of the closing process for the RESOLVE-IT study, which, after detailed analysis, do not have any future economic advantage for the PBC program.
Share-based compensation	Accounting policies The fair value of equity-settled share-based compensation granted to employees, officers, board members and consultants as determined on the grant date is recognized as a compensation expense with a corresponding increase in equity, over the vesting period. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market performance conditions are expected to be met. Evaluation models The fair value of equity-settled share-based compensation granted to employees are measured using i) the Black-Scholes model for share warrants ("Bons de Souscriptions d'Actions" or "BSA") and stock options ("SO") and ii) the Monte Carlo model for free shares ("actions gratuites" or "AGA"). Data and key assumptions used in evaluations For evaluating BSAs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: issue price, exercise price, expected volatility, exercise period, expected dividends, risk free interest rate (based on government bonds), and conversion ratio. For evaluating AGAs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: grant date, share price at grant date, expected volatility, vesting period, expected dividends, risk free interest rate (based on government bonds), conversion ratio, and expected employee turnover. For evaluating SOs, the following data and key assumptions are utilized in accordance with IFRS 2 - Share based payment: grant date, share price at grant date, exercise price, expected volatility, vesting period, exercise period, expected dividends, risk free interest rate (based on government bonds), conversion ratio, and expected employee turnover. Regarding SOs and AGAs, market conditions are taken into account in the determination of the fair value of the plans award. For share-based compensation awards with non-vesting conditions, the grant date fair value of the share-based compensation is measured to reflect such conditions and there is no adjustment for differences between expected and actual outcomes. Volatility assumptions in the above tables are determined by reference to the Company's historical share price observed on the grant date over a two- and three-year period prior to the grant date, adjusted for extreme variations, if any. Consultants GENFIT may also grant equity-settled share-based compensation in exchange for services to consultants who are not considered employees. In such cases, the value of the services is measured when they are rendered by the consultants and the share-based compensation exchanged for the services is measured at an equal amount. If the value of the services cannot be measured reliably, then such value is measured with reference to the fair value of the equity instruments granted.
Income tax	Accounting policies Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable. Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities. Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that: •it is probable that future taxable profit will be available against which they can be used; or •if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share are calculated by dividing profit or loss attributable to the Company's ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share are calculated by adjusting profit attributable to ordinary shareholders and the average number of ordinary shares outstanding weighted for the effects of all potentially dilutive instruments (share warrants, redeemable share warrants, free shares, stock options and bonds convertible into new and/or existing shares).
Operating segments	SEGMENT INFORMATION The Board of Directors and Chief Executive Officer are the chief operating decision makers. The Board of Directors and the Chief Executive Officer oversee the operations and manage the business as one segment with a single activity; namely, the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of voluntary change in accounting policy [abstract]

Summary of Functional Currency


	Year ended
Ratio : 1 US dollars (USD) = x euros (EUR)	2020/12/31	2021/12/31	2022/12/31
Exchange rate at period end	0.81493	0.88292	0.93756
Average exchange rate for the period	0.87755	0.84542	0.95105

The functional currency of Versantis AG is the Swiss Franc. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows:

Ratio : 1 CH franc (CHF) = x euros (EUR)

Year ended

2020/12/31

2021/12/31

2022/12/31

Exchange rate at period end

N/A

1.01554

Average exchange rate for the period

N/A

1.01710

Note that the average rate immediately above is based on the period between September 29, 2022 and December 31, 2022.

Operating segments (Tables)

12 Months Ended

Dec. 31, 2022

Segment information [Abstract]

Disclosure of non-curent assets by geographical area

Non-current assets break down by geographical area as follows:

NON-CURRENT ASSETS

As of December 31, 2021

As of December 31, 2022

(thousands of euros)

France

Switzerland

Total

France

Switzerland

Total

TOTAL

13,623

12,923

44,158

57,081

Disclosure of revenue breakdown by geographical area

Revenue breakdown by geographical area


Revenue by destination	Year ended
(in € thousands)	12/31/2020		12/31/2021		12/31/2022
Revenue from France	100	%	100	%	100	%
Revenue from other countries	—	%	—	%	—	%
TOTAL	100	%	100	%	100	%

Financial Risks Management (Tables)

12 Months Ended

Dec. 31, 2022

Foreign exchange rates [abstract]

Summary of Sensitivity of Cash and Cash Equivalents and Expenses to Variation of Ten Percent of the US Dollars Against the Euro

The following table shows the sensitivity of the Group's cash and cash equivalent and expenses in U.S. dollars to a variation of 10% of the U.S. dollar against the euro in 2020, 2021 and 2022.


Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10%	As of
of the US dollar against the euro
(in € thousands or in US dollar thousands, as applicable)	2021/12/31	2022/12/31
Cash and cash equivalents denominated in US dollars	81,713	34,192
Equivalent in euros, on the basis of the exchange rate described below	72,146	32,057
Equivalent in euros, in the event of an increase of 10% of US dollar vs euro	80,163	35,619
Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro	65,588	29,143


Sensitivity of the Group's expenses to a variation of +/- 10%	Year ended
of the US dollar against the euro
(in € thousands or in US dollar thousands, as applicable)	2020/12/31	2021/12/31	2022/12/31
Expenses denominated in US dollars	47,277	12,566	14,884
Equivalent in euros, on the basis of the exchange rate described below	38,528	11,095	13,955
Equivalent in euros, in the event of an increase of 10% of US dollar vs euro	42,808	12,328	15,506
Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro	35,025	10,086	12,686

Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory

Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10%

As of

of the CH franc against the euro

(in € thousands or in CH franc thousands, as applicable)

2020/12/31

2021/12/31

2022/12/31

Cash and cash equivalents denominated in CH franc

N/A

2,321

Equivalent in euros, on the basis of the exchange rate described below

N/A

2,357

Equivalent in euros, in the event of an increase of 10% of CH franc vs euro

N/A

2,618

Equivalent in euros, in the event of a decrease of 10% of CH franc vs euro

N/A

2,142

Sensitivity of the Group's expenses to a variation of +/- 10%

Year ended

of the CH franc against the euro

(in € thousands or in CH franc thousands, as applicable)

2020/12/31

2021/12/31

2022/12/31

Expenses denominated in CH franc

N/A

2,016

Equivalent in euros, on the basis of the exchange rate described below

N/A

2,048

Equivalent in euros, in the event of an increase of 10% of CH franc vs euro

N/A

2,275

Equivalent in euros, in the event of a decrease of 10% of CH franc vs euro

N/A

1,862

Summary of Cash, Cash Equivalents and Financial Assets


Cash, cash equivalents and financial assets	As of
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
At origin, denominated in EUR
Cash and cash equivalents	80,391	186,609	101,536
Current and non current financial assets	1,391	4,355	9,456
Total	81,782	190,964	110,993
At origin, denominated in USD
Cash and cash equivalents	90,637	72,147	32,057
Current and non current financial assets	67	76	7
Total	90,704	72,223	32,064
At origin, denominated in CHF
Cash and cash equivalents	—	—	2,358
Current and non current financial assets	—	—	—
Total	—	—	2,358
Total, in EUR
Cash and cash equivalents	171,029	258,756	136,001
Current and non current financial assets	1,458	4,431	9,464
Total	172,486	263,187	145,464

Cash and Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2022

Cash and cash equivalents [abstract]

Summary of Cash and Cash Equivalents

These investments, summarized in the tables below, are short-term, highly liquid and subject to insignificant risk of changes in value.


Cash and cash equivalents	As of
(in € thousands)	2021/12/31	2022/12/31
Short-term deposits	69,045	119,090
Cash on hand and bank accounts	189,711	16,910
TOTAL	258,756	136,001

Short-term deposits

As of

(in € thousands)

2021/12/31

2022/12/31

TERM ACCOUNTS

69,045

119,090

TOTAL

69,045

119,090

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about intangible assets [abstract]

Schedule of Variations in Intangible Assets

The following tables show the variations in intangible assets for the years ended December 31, 2021 and 2022:


	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	12/31/2020			adjustments		12/31/2021
Gross


Software	1,440	126	(255)	—	(17)	1,294
Patents	91	—	(21)	—	—	70

Other intangibles	—	—	(17)	—	17	—
TOTAL—Gross	1,531	127	(294)	—	—	1,364
Accumulated depreciation and impairment


Software	(1,213)	(152)	176	—	—	(1,190)
Patents	(21)	—	21	—	—	—

Other intangibles	—	—	—	—	—	—
TOTAL - Accumulated depreciation and impairment	(1,234)	(152)	197	—	—	(1,190)
TOTAL - Net	297	(26)	(97)	—	—	174


	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	12/31/2021			adjustments		2022/12/31
Gross


Software	1,294	81	(398)	—	—	977
Patents	70	281	—	—	—	351

Other intangibles	—	43,569	—	—	—	43,569
TOTAL—Gross	1,364	43,931	(398)	—	—	44,897
Accumulated depreciation and impairment


Software	(1,190)	(79)	329	—	—	(940)
Patents	—	—	—	—	—	—

Other intangibles	—	—	—	—	—	—
TOTAL - Accumulated depreciation and impairment	(1,190)	(79)	329	—	—	(940)
TOTAL - Net	174	43,852	(69)	—	—	43,957

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about property, plant and equipment [abstract]

Summary of Variations in Tangible Assets

The following tables show the variations in tangible assets for the years ended December 31, 2021 and 2022:


Property, plant and equipment - Variations	As of As of	Increase	Decrease	Translation	Reclassification	As of As of
(in € thousands)	As of 2020/12/31			adjustments		As of 2021/12/31
Gross


Buildings on non-freehold land	12,167	—	(1,912)	—	56	10,311
Scientific equipment	9,080	71	(2,831)	—	—	6,320
Fittings	1,703	(4)	(234)	—	9	1,474
Vehicles	99	60	(67)	—	—	91
Computer equipment	1,534	30	(18)	—	(4)	1,542
Furniture	329	—	(50)	—	—	279
In progress	—	330	(342)	—	12	—
TOTAL - Gross	24,911	487	(5,454)	—	74	20,017











Accumulated depreciation


Buildings on non-freehold land	(2,603)	(1,417)	1,120	—	—	(2,900)
Scientific equipment	(5,952)	(1,061)	2,145	—	—	(4,868)
Fittings	(982)	(91)	190	(5)	—	(888)
Vehicles	(85)	(13)	67	—	—	(31)
Computer equipment	(1,217)	(195)	14	(6)	—	(1,403)
Furniture	(251)	(12)	50	—	—	(213)
In progress	—	—	—	—	—	—
TOTAL - Accumulated depreciation	(11,090)	(2,789)	3,587	(11)	—	(10,304)
Accumulated impairment


Buildings on non-freehold land	(1,182)	—	679	—	—	(503)
Scientific equipment	(866)	—	779	—	—	(87)
Fittings	(93)	—	—	—	—	(93)
Vehicles	—	—	—	—	—	—
Computer equipment	(27)	—	15	—	—	(12)
Furniture	(3)	—	—	—	—	(3)
In progress	—	—	—	—	—	—
TOTAL - Accumulated impairment	(2,172)	—	1,473	—	—	(699)
TOTAL - Net	11,648	(2,302)	(394)	(11)	74	9,015


Property, plant and equipment - Variations	As of	Increase	Decrease	Translation	Reclassification	As of
(in € thousands)	2021/12/31			adjustments		2022/12/31
Gross


Buildings on non-freehold land	10,311	610	—	—	—	10,921
Scientific equipment	6,320	228	(82)	—	—	6,467
Fittings	1,474	61	—	—	2	1,537
Vehicles	91	—	—	—	—	91
Computer equipment	1,542	98	(149)	—	8	1,500
Furniture	279	—	—	—	—	279
In progress	—	16	—	—	(16)	—
TOTAL - Gross	20,017	1,014	(230)	—	(7)	20,794











Accumulated depreciation


Buildings on non-freehold land	(2,900)	(1,033)	—	—	—	(3,934)
Scientific equipment	(4,868)	(697)	79	4	—	(5,481)
Fittings	(888)	(95)	—	(2)	—	(985)
Vehicles	(31)	(12)	—	—	—	(43)
Computer equipment	(1,403)	(105)	148	(5)	—	(1,365)
Furniture	(213)	(10)	—	—	—	(223)
In progress	—	—	—	—	—	—
TOTAL - Accumulated depreciation	(10,304)	(1,953)	227	(3)	—	(12,032)
Accumulated impairment


Buildings on non-freehold land	(503)	—	48	—	—	(455)
Scientific equipment	(87)	—	28	—	—	(59)
Fittings	(93)	—	69	—	—	(24)
Vehicles	—	—	—	—	—	—
Computer equipment	(12)	—	2	—	—	(10)
Furniture	(3)	—	—	—	—	(3)
In progress	—	—	—	—	—	—
TOTAL - Accumulated impairment	(699)	—	147	—	—	(552)
TOTAL - Net	9,015	(939)	144	(3)	(7)	8,210

Trade and Other Receivables (Tables)

12 Months Ended

Dec. 31, 2022

Trade and other receivables [abstract]

Summary of Trade and Other Receivables

Trade and other receivables consisted of the following:


Trade and other receivables - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Trade receivables, net	57	3,188
Research tax credit	5,282	11,299
Social security costs receivables	4	1
VAT receivables	1,038	1,288
Grants receivables	5	4
Other receivables	852	126
TOTAL	7,239	15,906
Of which : Current	7,236	15,906
Of which : Non-current	3	—

Other Financial Assets (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Financial Assets [Abstract]

Summary of Other Financial Assets

Financial detail

Other financial assets consisted of the following:


Financial assets - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Non consolidated equity investments	3,133	3,133
Other investments	—	483
Financial investments	—	4,550
Loans	388	428

Deposits and guarantees	397	335
Liquidity contract	513	534
TOTAL	4,431	9,464
Of which : Current	—	4,550
Of which : Non-current	4,431	4,914


Financial assets - Variations	As of	Increase	Decrease	As of
(in € thousands)	31/12/2021			31/12/2022
Non consolidated equity investments	3,133	—	—	3,133
Other investments	—	483	—	483
Financial investments	—	4,550	—	4,550
Loans	388	40	—	428

Deposits and guarantees	397	33	(95)	335
Liquidity contract	513	0	21	534
TOTAL	4,431	5,107	(74)	9,464

Loans and Borrowings (Tables)

12 Months Ended

Oct. 16, 2017

Dec. 31, 2022

Borrowing costs [abstract]

Summary of Bonds


			At origin (10/16/2017) :
			Number of bonds						6,081,081
			Nominal amount of the loan						179,999,997.60€
			Nominal unit value of the bonds						29.60€
			Conversion / exchange premium						30%
									To GENFIT's reference share price :
									22.77€
			Annual nominal interest rate						3.5%
									Payable semi-annually in arrears
			Annual nominal interest rate						7.2%
			Offering						10/16/2017
									At par
			Redemption						10/16/2022
									Redemption prior to maturity at the option of the Company from
									11/6/2020
									if the arithmetic volume-weighted average price of
									GENFIT's listed share price and the then prevailing conversion ratio over a
									20
									trading period exceeds
									150%
									of the nominal value of the OCEANEs.


			After OCEANEs buyback :
			Number of bonds						3,185,821
			Nominal amount of the loan						94,300,301.60€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%
			As of 31/12/2021 :
			Number of bonds						1,923,662
			Nominal amount of the loan						56,940,395.20€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%
			As of 31/12/2022 :
			Number of bonds						1,923,662
			Nominal amount of the loan						56,940,395.20€
			Nominal unit value of the bonds						29.60€
			Effective interest rate						8.8%

Summary of Convertible Loans

Convertible loans - Total

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

48,097

50,276

TOTAL

48,097

50,276

Convertible loans - Current

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

415

TOTAL

415

Convertible loans - Non current

As of

(in € thousands)

2021/12/31

2022/12/31

Convertible loans

47,682

49,861

TOTAL

47,682

49,861

Other Loans and Borrowings

Other loans and borrowings consisted of the following:


Other loans and borrowings - Total	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	3,229	3,229
Bank loans	15,824	15,196


Obligations under leases	7,069	6,559
Accrued interests	16	14
Other financial loans and borrowings	—	—

TOTAL	26,138	24,999


Other loans and borrowings - Current	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	—	—
Bank loans	667	3,619


Obligations under leases	1,089	1,032
Accrued interests	16	14
Other financial loans and borrowings	—	—

TOTAL	1,773	4,665


Other loans and borrowings - Non current	As of
(in € thousands)	2021/12/31	2022/12/31
Refundable and conditional advances	3,229	3,229
Bank loans	15,156	11,578


Obligations under leases	5,980	5,527
Accrued interests	—	—
Other financial loans and borrowings	—	—

TOTAL	24,365	20,334

Summary of Refundable and Conditional Advances

The following table summarizes advances outstanding at December 31, 2022 and 2021.


Refundable and conditional advances—general overview	Grant date	Total amount allocated	Receipts	Repayments	Effects of discounting	Net book value As of 2022/12/31
(in € thousands)
BPI FRANCE - IT-DIAB	12/23/2008	3,229	3,229	—	—	3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL		3,229	3,229	—	—	3,229


Refundable and conditional advances—general overview	Grant date	Total amount allocated	Receipts	Repayments	Effects of discounting	Net book value As of 2021/12/31
(in € thousands)
BPI FRANCE - IT-DIAB	12/23/2008	3,229	3,229	—	—	3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL		3,229	3,229	—	—	3,229

Summary of Bank Loans

Bank loans consisted of the following as of December 31, 2022:


Bank loans	Loan	Facility	Interest		Available As of 2022/12/31	Installments	Outstanding As of 2021/12/31	Outstanding As of 2022/12/31
(in € thousands)	date	size	rate
CDN 3	April 2016	500	0.72	%	—	60 monthly	—	—
CDN 4	June 2017	600	0.36	%	—	48 monthly	—	—
CDN 5	November 2018	500	0.46	%	—	48 monthly	115	—
CIC 4	December 2016	265	0.69	%	—	60 monthly	4	—
CIC 5	July 2017	1,000	0.69	%	—	60 monthly	152	—
BNP 2	June 2016	500	0.80	%	—	20 quarterly	—	—
BNP 3	October 2016	1,050	0.80	%	—	20 quarterly	105	—
BNP 4	April 2017	800	0.87	%	—	60 monthly	217	54
AUTRES	-	—	—	%	—	0	20	17
CDN PGE	June 2021	900	1.36	%	—	8 quarterly	900	900
CIC PGE	June 2021	2,200	0.75	%	—	8 quarterly	2,200	2,200
BNP PGE	June 2021	4,900	0.45	%	—	8 quarterly	4,900	4,900
NATIXIS PGE	June 2021	3,000	0.40	%	—	8 quarterly	3,000	3,000
BPI PGE	July 2021	2,000	2.25	%	—	16 quarterly	2,000	1,900
BPI PRÊT TAUX BONIFIE	November 2021	2,250	2.25	%	—	20 quarterly	2,250	2,250
TOTAL		20,465			—		15,864	15,221

Summary of Maturities of Financial Liabilities


Maturity of financial liabilities	As of	Less than	Less than	Less than	Less than	Less than	More than
(in € thousands)	2022-12-31	1 year	2 years	3 years	4 years	5 years	5 years
BPI FRANCE - IT-DIAB	3,229	—	—	—	—	—	3,229
TOTAL - Refundable and conditional advances	3,229	—	—	—	—	—	3,229
Convertible loans	50,276	415	—	49,861	—	—	—
Bank loans	15,196	3,619	6,339	3,601	867	771	—


Leases	6,559	1,032	1,011	1,022	1,034	1,046	1,414
Accrued interests	14	14	—	—	—	—	—


TOTAL - Other loans and borrowings	72,046	5,080	7,350	54,485	1,901	1,817	1,414
TOTAL	75,275	5,080	7,350	54,485	1,901	1,817	4,643

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about financial instruments [abstract]

Disclosure of financial assets and liabilities carrying values by category and fair values

Financial detail

The following tables provide the financial assets and liabilities carrying values by category and fair values as of December 31, 2022 and December 31, 2021:


	As of 31/12/2021
	Carrying value				Fair value
	As per	Assets at	Assets at	Assets at	Debt at	Level 1	Level 2	Level 3
	statement of	fair value	fair value	amortized	amortized
	financial	through	through OCI	cost	cost
(in € thousands)	position	profit & loss
Assets
Equity investments	3,133		3,133					3,133

Financial investments	—
Loans	388			388			388

Deposits and guarantees	397			397			397
Trade receivables	57			57			57
Cash and cash equivalents	258,756	258,756				258,756
TOTAL - Assets	262,731	258,756	3,133	842	—	258,756	842	3,133
Liabilities
Conditional advances	3,229				3,229			3,229
Convertible loans	48,097				48,097		48,097
Bank loans	15,824				15,824		15,824


Obligations under finance leases	7,069				7,069		7,069
Accrued interests	16				16		16


Trade payables	12,304				12,304		12,304
Other payables	579				579		579
TOTAL - Liabilities	87,118	—	—	—	87,118	—	83,889	3,229


	As of 31/12/2022
	Carrying value				Fair value
	As per	Assets at	Assets at	Assets at	Debt at	Level 1	Level 2	Level 3
	statement of	fair value	fair value	amortized	amortized
	financial	through	through OCI	cost	cost
(in € thousands)	position	profit & loss
Assets
Equity investments	3,133		3,133					3,133
Other investments	483	483						483
Financial investments	4,550	4,550				4,550
Loans	428			428			428

Deposits and guarantees	335			335			335
Trade receivables	3,188			3,188			3,188
Cash and cash equivalents	136,001	136,001				136,001
TOTAL - Assets	148,119	141,034	3,133	3,951	—	140,551	3,951	3,617
Liabilities
Conditional advances	3,229				3,229			3,229
Convertible loans	50,276				50,276		52,708
Bank loans	15,196				15,196		15,196


Obligations under finance leases	6,559				6,559		6,559
Accrued interests	14				14		14


Trade payables	8,613				8,613		8,613
Other payables	1,325				1,325		1,325
TOTAL - Liabilities	85,214	—	—	—	85,214	—	84,416	3,229

Trade and Other Payables (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Trade And Other Payables [Abstract]

Schedule of Trade and Other Payables

Financial detail

Trade and other payables consisted of the following:


Trade and other payables - Total	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables (*)		12,304	8,613
Social security costs payables		4,087	4,838
VAT payables		23,725	200
Taxes payables		744	316
Other payables		579	1,325
TOTAL		41,438	15,293


Trade and other payables - Current	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables		12,304	8,613
Social security costs payables		4,087	4,838
VAT payables		23,725	200
Taxes payables		744	316
Other payables		128	877
TOTAL		40,988	14,845


Trade and other payables - Non current	As of
(in € thousands)		2021/12/31	2022/12/31
Trade payables		—	—
Social security costs payables		—	—
VAT payables		—	—
Taxes payables		—	—
Other payables		450	448
TOTAL		450	448

(*) Of which : Accrued expenses		6,201	3,924

Other provisions, contingent liabilities and contingent assets (Tables)

12 Months Ended

Dec. 31, 2022

Changes in other provisions [abstract]

Disclosure of change in provision


Change in provisions	As of	Increase	Decrease	Decrease	As of
(in € thousands)	2021/12/31		(used)	(unused)	2022/12/31

Provision for litigation	87	0	(14)	(73)	0

Provision for charges	225	4	(92)	(77)	61
TOTAL	313	4	(106)	(150)	61

Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of information about defined benefit plans [abstract]

Disclosure of benefit payments undere company's french retirement entity

The following assumed benefit payments under the Company's French retirement indemnity are expected to be paid as follows:


2023			0
2024			0
2025			37
2026			21
2027			78
Years 2028 and thereafter			646

Disclosure of defined benefit plans [text block]

As part of the measurement of the retirement indemnity to employees, the following assumptions were used for all categories of employees in 2021 and 2022:


			Population			Permanent staff
			Retirement age			65
			Terms of retirement			Initiated by the employee
			Life expectancy			On the basis of the INSEE table (1)
			Probability of continued presence in the company at retirement age			On the basis of the DARES table

(1)INSEE is the French National Institute of Statistics; DARES is the French Bureau of Studies and Statistics


Rate	As of
(in € thousands)	2021/12/31		2022/12/31
Salary growth rate - in 2022	3.00	%	3.00	%
Salary growth rate - beyond	3.00	%	3.00	%
Discount rate (iboxx)	0.87	%	3.25	%

Disclosure of net defined benefit liability (asset) [text block]

The following table presents the changes in the present value of the defined benefit obligation:


			Changes in the present value of the defined benefit obligation
			(in € thousands)







			Defined benefit obligation as of January 01, 2021						922
			Current service cost						154
			Interest cost on benefit obligation						5
			Actuarial losses / (gains) on obligation						—
			Past service costs						(216)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2021						864
			Current service cost						169
			Interest cost on benefit obligation						8
			Actuarial losses / (gains) on obligation						—
			Past service costs						(258)
			Service paid to employees						—
			Defined benefit obligation as of December 31, 2022						782

Disclosure of sensitivity analysis for actuarial assumptions [text block]

Sensitivity of the Group’s retirement and post-employment benefits to a variation of the discount rate:

Retirement and post-employment benefits

Sensitivity of the Group's retirement and post-employment benefits

Changes in

Impact /

to a variation of the discount rate

assumptions /

present value of

(in € thousands)

discount rate

the undertaking

0.25

(23)

0.25

Operating Income (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Income [Abstract]

Schedule of Other Income

The breakdown of Other income is as follows:


Other income	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
CIR tax credit	6,020	5,282	6,017
Other operating income	968	223	320
Government grants and subsidies	5	5	34
TOTAL	6,993	5,510	6,371

Operating Expense (Tables)

12 Months Ended

Dec. 31, 2022

Operating Expense [Abstract]

Summary of Operating Expenses and Other Operating Income


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2020/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(59,097)	(1,876)	(39,216)	(11,554)	(5,465)	(985)	—
General and administrative expenses	(14,270)	(202)	(92)	(6,936)	(6,545)	(495)	—
Marketing and market access expenses	(11,216)	(7)	(2)	(1,298)	(9,818)	(90)	—
Reorganization and restructuring income (expenses)	(5,308)	—	—	8	(2,141)	(3,175)	—
Other operating expenses	(764)	—	—	—	(684)	—	(80)
TOTAL	(90,655)	(2,085)	(39,310)	(19,779)	(24,655)	(4,746)	(80)


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2021/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(35,166)	(1,305)	(18,808)	(8,192)	(4,593)	(2,247)	(19)
General and administrative income (expenses)	(16,153)	(161)	(85)	(7,379)	(8,003)	(541)	15
Marketing and market access expenses	(1,539)	(1)	(1)	(783)	(741)	(13)	—
Reorganization and restructuring income (expenses)	(142)	(5)	—	—	(2,343)	2,206	—
Other operating income (expenses)	(763)	—	—	—	(338)	4	(429)
TOTAL	(53,763)	(1,472)	(18,895)	(16,354)	(16,019)	(591)	(433)


Operating expenses and other operating income (expenses)	Year ended	Of which :
	2022/12/31	Raw	Contracted	Employee	Other	Depreciation,	Gain /
		materials	research and	expenses	expenses	amortization	(loss) on
		and	development		(maintenance,	and	disposal of
		consumables	activities		fees, travel,	impairment	property,
		used	conducted by		taxes…)	charges	plant and
(in € thousands)			third parties				equipment
Research and development expenses	(35,818)	(1,876)	(17,407)	(10,029)	(5,177)	(1,328)	—
General and administrative expenses	(16,405)	(248)	(71)	(6,772)	(9,168)	(146)	—
Marketing and market access expenses	(992)	(3)	(1)	(565)	(416)	(6)	—
Reorganization and restructuring income (expenses)	11	—	—	—	—	11	—
Other operating income (expenses)	(652)	—	—	—	(667)	—	16
TOTAL	(53,855)	(2,128)	(17,479)	(17,366)	(15,429)	(1,469)	16

Summary of Employee Expenses and Number of Employees

Employee expenses and number of employees were as follows:


Employee expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Wages and salaries	(13,570)	(10,328)	(12,188)
Social security costs	(5,047)	(4,775)	(4,765)
Changes in pension provision	74	(154)	(169)
Employee profit-sharing	—	(628)	—
Share-based compensation	(1,236)	(470)	(245)
TOTAL	(19,779)	(16,354)	(17,366)


Number of employees at year-end	Year ended
	2020/12/31	2021/12/31	2022/12/31
Average number of employees	193	122	133
Number of employees
Research and development	66	55	73
Services related to research and development	16	18	18
Administration and management	43	47	55
Marketing and commercial	5	2	2
TOTAL	130	122	148

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Share-based Compensation Under Each Plan According to Change in Estimate

The table below shows the share-based compensation by plan:


Share-based compensation - expense	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
AGA S 2016-1	—	—	—
AGA S 2016-2	—	—	—
AGA D 2016-1	21	—	—
AGA D 2016-2	6	—	—
SO 2016-1	49	—	—
SO 2016-2	13	—	—
SO US 2016-1	—	—	—
SO US 2016-2	—	—	—
AGA S 2017-1	—	—	—
AGA S 2017-2	13	—	—
AGA D 2017-1	—	—	—
AGA D 2017-2	4	—	—
SO 2017-1	335	—	—
SO 2017-2	110	—	—
SO US 2017-1	—	—	—
SO US 2017-2	—	—	—
BSA-2017-A	—	—	—
BSA-2017-B	—	—	—
AGA S 2018	62	—	—
AGA D 2018	65	—	—
SO 2018	225	186	—
SO US 2018	24	24	—
AGA S 2019	55	39	50
AGA D 2019	63	16	6
SO 2019	123	105	(21)
SO 2019 - US	35	(11)	(16)
BSA 2019	20	—	—
SO US 2019	14	(7)	—
SO D 2020	—	14	14
SO C 2020	—	40	40
SO US 2020	—	19	19
AGA S 2021	—	29	32
AGA D 2021	—	5	7
SO D 2021	—	2	13
SO C2021	—	9	55
SO US 2021	—	2	9
AGA S 2022	—	—	11
AGA D 2022	—	—	2
SO D 2022	—	—	4
SO C 2022	—	—	17
SO US 2022	—	—	4
SO SU 2022	—	—	—
TOTAL	1,236	470	245

Share Warrants

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Key Terms and Conditions of Share-Based Compensation Based


Share warrants (BSA)	2019		2017
	BSA 2019		BSA 2017-A		BSA 2017-B
Option pricing model	Black Scholes
Fair value per IFRS 2	€0.75		€3.78		€3.81
Issue price	€1.23		€2.00		€2.00
Exercise price	€12.32		€19.97		€19.97
Expected volatility	40.0	%	36.4	%	35.7	%
End of exercise period	5/31/2024		6/30/2022		7/15/2022
Expected dividends	0	%	0	%	0	%
Risk free interest rate	0	%	0	%	0	%
Conversion ratio	1:1		1:1		1:1

Free Shares

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The following table summarizes the data relating to free shares and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:


Free Shares (AGA)	2022		2021				2019		2018		2017		2016
	AGA D & S 2022		AGA S 2021		AGA D 2021		AGA D & S 2019		AGA D & S 2018		AGA D & S, 2017-1 & 2017-2		AGA D & S, 2016-1 & 2016-2
Option pricing model	Monte Carlo
Fair value per IFRS 2	€4.08		€4.00		€4.15		€17.06		€20.02		€21.95		€20.78
Grant date	10/14/2022		03/30/2021		03/17/2021		07/18/2019		11/22/2018		12/06/2017		12/15/2016
Share price at grant date	€4.08		€4.00		€4.15		€17.06		€20.02		€21.95		€20.78
Expected volatility	50	%	51	%	51	%	40.2	%	38	%	53.7	%	63	%
Vesting period	From 14/10/2022 to 16/10/2025		From 30/03/2021 to 31/03/2024		From 17/03/2021 to 31/03/2024		From 18/07/2019 to 16/09/2022		From 18/07/2019 to 16/09/2022		From 06/12/2017 to 31/12/2020		From 15/12/2016 to 15/12/2019
Expected dividends	0	%	0	%	0	%	0	%	0	%	0	%	0	%
Risk free interest rate	2.24	%	-0.59	%	-0.59	%	0	%	0	%	0	%	0	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	15	%	15	%	15	%

Information on free shares activity is as follows for 2022:


Grant Date	Type	AGAs issued	AGAs outstanding as of January 1, 2022	AGAs awarded	AGAs vested	AGAs cancelled/ forfeited	AGAs outstanding as of December 31, 2022
14/10/2022	AGA S 2022	39,200		39,200		300	38,900
14/10/2022	AGA D 2022	20,000		20,000			20,000
30/03/2021	AGA S 2021	32,400	29,000			2,700	26,300
17/03/2021	AGA D 2021	15,000	15,000				15,000
18/07/2019	AGA S 2019	17,556	10,782		10,782		0
18/07/2019	AGA D 2019	19,070	13,068		8,712	4,356	0
TOTAL			67,850	59,200	19,494	7,356	100,200

Information on free shares activity is as follows for 2021:


Grant Date	Type	AGAs issued	AGAs outstanding as of January 1, 2021	AGAs awarded	AGAs vested	AGAs cancelled/ forfeited	AGAs outstanding as of December 31, 2021
30/03/2021	AGA S 2021	32,400		32,400		3,400	29,000
17/03/2021	AGA D 2021	15,000		15,000			15,000
18/07/2019	AGA S 2019	17,556	12,330			1,548	10,782
18/07/2019	AGA D 2019	19,070	15,710			2,642	13,068
TOTAL			28,040	47,400	-	7,590	67,850

Stock Options

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The following table summarizes the data relating to stock options and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:


Stock options (SO)	2022								2021
	SO SU 2022		SO D 2022		SO C 2022		SO US 2022		SO D 2021		SO C 2021		SO US 2021
Option pricing model	Black Scholes
Fair value per IFRS 2	€1.40		€1.57		€1.90		€1.56		€1.06		€1.30		€1.07
Grant date	12/2/2022		10/17/2022		10/17/2022		10/17/2022		10/20/2021		10/20/2021		10/20/2021
Share price at grant date	€3.46		€4.16		€4.16		€4.16		€3.24		€3.24		€3.24
Exercise price	€2.95		€3.91		€3.12		€3.94		€3.26		€2.61		€3.22
Expected volatility	49.0	%	50.0	%	50.0	%	50.0	%	50.0	%	50.0	%	50.0	%
Vesting period	From 3/12/2022 to 3/12/2025		Du 17/10/2022 au 17/10/2025						Du 20/10/2021 au 20/10/2024
Exercise period	From 3/12/2022 to 3/12/2032		Du 18/10/2025 au 17/10/2032						Du 21/10/2024 au 21/10/2031
Expected dividends	0	%	0	%	0	%	0	%	0	%	0	%	0	%
Risk free interest rate	2.1	%	2.24	%	2.24	%	2.24	%	-0.6	%	-0.6	%	-0.6	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	0	%	0	%	0	%


Stock options (SO)	2020						2019
	SO D 2020		SO C 2020		SO US 2020		SO 2019		SO US 1 2019		SO US 2 2019
Option pricing model	Black Scholes
Fair value per IFRS 2	€1.16		€1.46		€1.12		€4.59		€3.67		€3.23
Grant date	12/31/2020		12/31/2020		12/31/2020		7/18/2019		7/18/2019		11/27/2019
Share price at grant date	€3.99		€3.99		€3.99		€17.06		€17.06		€14.50
Exercise price	€4.38		€3.50		€4.52		€13.99		€16.90		€14.31
Expected volatility	49.0	%	49.0	%	49.0	%	40.0	%	40.0	%	40.0	%
Vesting period	Du 31/12/2020 au 31/12/2023						Du 18/07/2019 au 16/09/2022				Du 27/11/2019 au 16/01/2023
Exercise period	Du 01/01/2024 au 31/12/2027						Du 17/09/2022 au 17/09/2029				Du 17/01/2023 au 17/01/2030
Expected dividends	0.0	%	0.0	%	0.0	%	0.0	%	0.0	%	0.0	%
Risk free interest rate	-0.7	%	-0.7	%	-0.7	%	0.0	%	0.0	%	0.0	%
Conversion ratio	1:1		1:1		1:1		1:1		1:1		1:1
Expected employee turnover	0	%	0	%	0	%	0	%	0	%	0	%


Stock options (SO)	2018				2017		2016
	SO 2018		SO US 2018		SO 2017		SO 2016
Option pricing model	Black Scholes
Fair value per IFRS 2	€9.32		€6.90		€9.32		€10.30
Grant date	11/7/2018		11/7/2018		12/6/2017		12/15/2016
Share price at grant date	€22.10		€22.10		€21.95		€20.79
Exercise price	€16.00		€21.65		€17.91		€15.79
Expected volatility	44.1	%	44.1	%	53.7	%	63.0	%
Vesting period	Du 07/11/2018 au 31/12/2021				Du 06/12/2017 au 31/12/2020		Du 15/12/2016 au 15/12/2019
Exercise period	Du 01/01/2022 au 31/12/2028				Du 01/01/2021 au 31/12/2027		Du 16/12/2019 au 16/12/2026
Expected dividends	0	%	0	%	0	%	0	%
Risk free interest rate	0.0	%	0.0	%	0.0	%	0.0	%
Conversion ratio	1:1		1:1		1:1		1:1
Expected employee turnover	15	%	15	%	15	%	15	%

Definitive vesting is subject to continued employment with the Group and performance conditions.

Information on stock options activity is as follows for 2022:


Grant Date	Type	SO issued	SO outstanding as of January 1, 2022	SO awarded	SO cancelled/ forfeited	SO exercised	SO outstanding as of December 31, 2022	SO exercisable as of December 31, 2022
02/12/2022	SO SU 2022	8,750		8,750			8,750	0
17/10/2022	SO D 2022	35,000		35,000			35,000	0
17/10/2022	SO C 2022	131,000		131,000			131,000	0
17/10/2022	SO US 2022	34,625		34,625			34,625	0
20/10/2021	SO D 2021	35,000	35,000				35,000	0
20/10/2021	SO C 2021	134,375	134,375		10,000		124,375	0
20/10/2021	SO US 2021	32,500	25,000				25,000	0
31/12/2020	SO D 2020	35,000	35,000				35,000	0
31/12/2020	SO C 2020	103,750	81,250				81,250	0
31/12/2020	SO US 2020	56,250	50,000				50,000	0
18/07/2019	SO 2019	107,880	77,015		25,672		51,343	51,343
18/07/2019	SO US 1 2019	30,620	7,670		2,557		5,113	5,113
07/11/2018	SO 2018	122,000	68,329				68,329	68,329
07/11/2018	SO US 2018	17,500	9,713				9,713	9,713
06/12/2017	SO 2017-1	64,164	43,212				43,212	43,212
06/12/2017	SO 2017-2	32,086	17,765				17,765	17,765
15/12/2016	SO 2016-1	41,917	34,398				34,398	34,398
15/12/2016	SO 2016-2	20,958	15,308				15,308	15,308
TOTAL			634,035	209,375	38,229	0	805,181	245,181

Information on stock options activity is as follows for 2021:


Grant Date	Type	SO issued	SO outstanding as of January 1, 2021	SO awarded	SO cancelled/ forfeited	SO exercised	SO outstanding as of December 31, 2021	SO exercisable as of December 31, 2021
20/10/2021	SO D 2021	35 000		35 000			35 000	-
20/10/2021	SO C 2021	134 375		134 375			134 375	-
20/10/2021	SO US 2021	32 500		32 500	7 500		25 000	-
31/12/2020	SO D 2020	35 000	35 000				35 000	-
31/12/2020	SO C 2020	103 750	103 750		22 500		81 250	-
31/12/2020	SO US 2020	56 250	56 250		6 250		50 000	-
18/07/2019	SO 2019	107 880	94 530		17 515		77 015	-
18/07/2019	SO US 1 2019	30 620	23 620		15 950		7 670	-
27/11/2019	SO US 2 2019	13 350	8 900		8 900		-	-
07/11/2018	SO 2018	122 000	71 678		3 349		68 329	68 329
07/11/2018	SO US 2018	17 500	9 713				9 713	9 713
06/12/2017	SO 2017-1	64 164	43 212				43 212	43 212
06/12/2017	SO 2017-2	32 086	17 765				17 765	17 765
15/12/2016	SO 2016-1	41 917	34 398				34 398	34 398
15/12/2016	SO 2016-2	20 958	15 308				15 308	15 308
TOTAL			514 124	201 875	81 964	0	634 035	188 725

Performance Conditions

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

Performance conditions of 2022 plans


Plans			Nature of performance conditions
SO D 2022 SO C 2022 SO US 2022 SO SU 2022 AGA S 2022 AGA D 2022 Evaluation date for performance conditions: - 10/17/2025 for SO D 2022/SO C 2022/SO US 2022/AGA S 2022/AGA D 2022 - 12/3/2025 for SO SU 2022			Internal conditions - a) 50% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 10,000 of the Free Shares for the AGA D 2022 will vest, if during the 2022 financial year and then at any time during the Vesting Period, 3 new R&D programs (at the rate of one third of these 2022 instruments per new program) complete the Company's R&D program portfolio (as it was at 12/31/2021); that these programs are at the so-called clinical development stage when this addition is made or that they reach this stage afterwards and that this addition originates: (i) a business-development operation (licensing-in, M&A, etc.), or (ii) the identification of new opportunities resulting from internal research (repositioning). b) 25% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 5,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following three conditions relating to the development of the elafibranor development program is fulfilled: (i) obtaining the main results of the first part of the ELATIVE trial in the second quarter of 2023; (ii) filing of a Marketing Authorization Application for elafibranor in the second half of 2023; (iii) marketing authorization for elafibranor in 2024. c) 15% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 3,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following two conditions relating to the development of the NTZ program in the ACLF is fulfilled: (i) First clinical results in 2022; (ii) Start of a Phase 2 clinical trial in the first half of 2023. d) 10% of instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 2,000 of the Free Shares for the AGA D 2022 will vest, if as part of the development of the GNS561 program, a Phase 2b trial starts in the first half of 2023. External conditions - Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2022 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2022 definitively allocated will be equal to:[(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2022 instruments (c) All AGA D 2022 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.

Performance conditions of 2021 plans


Plans			Nature of performance conditions
SO D 2021 SO C 2021 SO US 2021 Evaluation date for performance conditions: 10/20/2024			a) 50% of the Stock Options will be exercisable if at least one of the following three conditions relating to the development of elafibranor in PBC and to the ELATIVE clinical trial is fulfilled: (i) ELATIVE topline results are released to the market before or during the second quarter of 2023; (ii) a new drug application is filed for elafibranor in PBC with the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in the second half of 2023 or before; (iii) elafibranor is approved by a regulatory authority in 2024. b) 15% of the Stock Options will be exercisable if at least one of the following two conditions relating to the development of NTZ and the ACLF franchise is fulfilled: (i) a Phase 2 clinical study or a more advanced clinical study evaluating NTZ is in ongoing or was carried out; (ii) the Company develops or acquires the rights to a new molecule (including through repositioning) for development in ACLF. c) 15% of the Stock Options will be exercisable if at least one of the following two conditions relating to the NIS4 diagnostic technology is fulfilled: (i) if a research and development partnership agreement relating to the implementation of the NIS4 diagnostic technology into an IVD test with at least one major NASH player (“big pharma”, biotech company, institution, etc.) is entered into by the Company; (ii) Labcorp’s NASHnext LDT is reimbursed by at least three payers in the United States (insurance, integrated system, etc). d) 20% of the Stock Options will be exercisable if at least one of the following two conditions relating to the development of the product pipeline of the Company is fulfilled: (i) At least one new molecule (excluding elafibranor and NTZ) is developed by the Company or the Company has acquired development rights to a new molecule outside of the ACLF franchise (performance already covered by b(ii) above); (ii) At least two Phase 2 clinical studies or more advanced clinical studies are ongoing or have been completed ; not including a Phase 2 clinical study or more advanced clinical study in NTZ (performance already covered by b(i) above).


Plans			Nature of performance conditions
AGA S 2021 AGA D 2021 Evaluation date for performance conditions: 3/31/2024			Internal conditions - a) 50% of the Free Shares AGA S 2021 will be exercisable, and 7,500 of the Free Shares AGA D 2021 will be exercisable, if at least one of the following three conditions relating to PBC and ELATIVE is fulfilled: (i) “Last Patient Visit” in ELATIVE in the fourth quarter of 2022 or earlier; (ii) If the results of ELATIVE are released to the market before or during the first half of 2023; (iii) if a registration request is filed for elafibranor in PBS with the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in 2023. b) 25% of the Free Shares AGA S 2021 will be exercisable, and of the Free Shares AGA D 2021 will be exercisable, if at least one of the following two conditions relating to the NIS4 diagnostic is fulfilled: (i) if a research and development partnership agreement with at least one major NASH player (“big pharma”, biotech company, institution, etc.) is entered into by the Company; (ii) the NIS4 diagnostic is used in at least 20 clinical studies. c) 25% of the Free Shares AGA S 2021 will be exercisable, and 3,750 of the Free Shares AGA D 2021 will be exercisable, if at least one of the following two conditions relating to the product pipeline of the Company is fulfilled: (i) initiation of a clinical study for a new indication with elafibranor or NTZ; (ii) if the Company develops or acquires the rights to a new molecule. External conditions - Each applicable portion of all 15,000 Free Shares under the AGA D 2021 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all Free Shares under the AGA D 2021 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2021 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2021 definitively allocated will be equal to:[(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2021 instruments (c) All AGA D 2021 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.

Financial Income and Expenses (Tables)

12 Months Ended

Dec. 31, 2022

Financial Income And Expenses [Abstract]

Summary of Financial Income and Expenses


Financial income and expenses	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31


Interest income	1,442	274	137
Foreign exchange gain	4,983	8,876	7,470
Financial income from renegotiating the convertible bond debt OCEANE	0	35,578	0
Other financial income	119	52	605
TOTAL - Financial income	6,544	44,780	8,212
Financial expenses
Interest expenses	(11,643)	(4,846)	(4,341)
Interest expenses for leases	(134)	(109)	(69)
Foreign exchange losses	(13,508)	(2,163)	(340)
Other financial expenses	(11)	(5)	(8)
TOTAL - Financial expenses	(25,296)	(7,122)	(4,758)
FINANCIAL GAIN (LOSS)	(18,752)	37,658	3,453

Income Tax (Tables)

12 Months Ended

Dec. 31, 2022

Deferred tax expense (income) [abstract]

Breakdown of deferred taxes by nature


	As of	Impact on	Impact on the	As of
(in € thousands)	12/31/2020	equity	profit/loss	12/31/2021












Deferred tax liabilities	(2,050)	(2,721)	2,455	(2,315)
Deferred tax assets	1,282	—	430	1,712
TOTAL	(767)	(2,721)	2,885	(602)


	As of	Impact on	Impact on the	As of
(in € thousands)	12/31/2021	equity	profit/loss	12/31/2022












Deferred tax liabilities	(2,315)	—	545	(1,770)
Deferred tax assets	1,712	—	(453)	1,260
TOTAL	(602)	—	93	(510)

Schedule of effective tax rate


	Year ended
(in € thousands)	2020/12/31		2021/12/31		2022/12/31
Profit (loss) for the period	(101,221)		67,259		(23,719)
Tax gain (expense)	428		(2,215)		116
Profit (loss) for the period before taxes	(101,649)		69,474		(23,836)
Tax rate in France	28.92	%	27.37	%	25.00	%
Theoretical tax expense calculated at the French tax rate	29,401		(19,018)		5,959
Increase / decrease in tax benefit arising from :
Tax credits	1,739		1,512		1,504
Permanent differences	(404)		833		(31)
Differences between rates	172		7,323		(67)
Tax losses for the period, unrecognised as deferred tax assets	(28,603)		0		(7,037)
Utilisation of previously unrecognised tax losses	0		5,590		0
IFRS adjustments without tax incidence	(358)		(129)		(61)
Non recognition of deffered tax assets related to temporary differences	(775)		(24)		331
Recognition of deferred tax assets against deferred tax liabilities	(706)		430		(453)
Tax effects related to the renegociation of the convertible debt	0		1,370		0
Others	(39)		(102)		(29)

Income tax expense recognised in profit or loss	428		(2,215)		116
Effective income rate	(0.42)	%	(3.19)	%	(0.49)	%

Earnings (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings per share [abstract]

Summary of Earnings (Loss) Per Share

The components of the earnings (loss) per share computation are as follows:


Earnings per share	Year ended
	2020/12/31	2021/12/31	2022/12/31

Profit (loss) for the period (in € thousands)	(101,221)	67,259	(23,719)
Weighted average number of ordinary shares used to calculate basic earnings (loss) per share	38,858,617	44,739,756	49,673,936
Basic earnings (loss) per share (€/share)	(2.60)	1.51	(0.48)


Weighted average number of ordinary shares used to calculate diluted earnings (loss) per share	38,858,617	55,613,634	49,673,936
Diluted earnings (loss) per share (€/share)	(2.60)	1.23	(0.48)

Compensation of Corporate Officers (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Of Corporate Officers [Abstract]

Summary of Compensation Paid to Officers

Compensation of key management personnel

The aggregate compensation of the members of the Company’s Board of Directors (including the Chairman of the Board) and to the Chief Executive Officer includes the following:


	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Fixed compensation owed	518	518	585
Variable compensation owed	71	163	169
Attendance fees - board of Directors	456	488	421
Contributions in-kind	26	23	21
Share-based payments	41	58	74
Employer contributions	405	443	410
Consulting fees	0	0	0
TOTAL	1,517	1,693	1,680

Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors

Compensation of key management personnel

The aggregate compensation of the members of the Company’s Board of Directors (including the Chairman of the Board) and to the Chief Executive Officer includes the following:


	Year ended
(in € thousands)	2020/12/31	2021/12/31	2022/12/31
Fixed compensation owed	518	518	585
Variable compensation owed	71	163	169
Attendance fees - board of Directors	456	488	421
Contributions in-kind	26	23	21
Share-based payments	41	58	74
Employer contributions	405	443	410
Consulting fees	0	0	0
TOTAL	1,517	1,693	1,680

Major Events in the Period and Events After the Period - Termination of RESOLVE-IT and the development program of elafibranor in NASH (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
ReorganizationAndReductionInForce	21	171	523
Impact On Subcontracting Costs		€ 1,100
Owned equipment
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Losses on disposals of property, plant and equipment	€ 27	25	€ 363
Leased equipment
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Losses on disposals of property, plant and equipment	28	62	503
Premises
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Losses on disposals of property, plant and equipment	€ 479	€ 596	€ 1,275

Major Events in the Period and Events After the Period - Acquisition of the Clinical-stage Biopharmaceutical Company Versantis (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Sep. 29, 2022 EUR (€)	Sep. 19, 2022 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure of net assets and liabilities of Business Combination [Line Items]
Other current tax liabilities	€ 4,906,000	€ 4,906,000	€ 5,051,000
Current provisions	61,000	61,000	313,000
Current trade and other payables	14,845,000	14,845,000	40,988,000
Other non-current financial assets	4,914,000	4,914,000	4,431,000
Property, plant and equipment	8,210,000	8,210,000	9,015,000	€ 11,648,000
Current trade and others receivables	15,906,000	15,906,000	7,236,000
Cash and cash equivalents	136,001,000	136,001,000	258,756,000	171,029,000			€ 276,748,000
General and administrative expense		16,405,000	16,153,000	14,270,000
Research and development expense		35,818,000	35,166,000	59,097,000
ClosingForeignExchangeRateCHFEuro			1.01554
ClosingForeignExchangeRateUSDEuro	€ 0.93756	€ 0.93756	0.88292	0.81493
Exchange Rate CHF Euro used for Versantis acquisition conversion			1.04843
Exchange Rate USD Euro used for Versantis acquisition conversion			0.9706
Closing foreign exchange rate \| shares	1	1
Purchase of interests in associates		€ 41,525,000	€ 0
Versantis
Disclosure of net assets and liabilities of Business Combination [Line Items]
Name of acquiree		Versantis AG
Date of acquisition		Sep. 29, 2022
Cash transferred						€ 41,900,000
Net cash adjustment payment						2,900,000
Description of primary reasons for business combination		1.Consolidating GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)2.Significantly expanding GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-HAC, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE), and3.Combining Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development
Acquisition costs						€ 1,800,000
Assets (liabilities)	€ 43,939,000	€ 43,939,000
Total acquired liabilities	2,601,000	2,601,000			€ 4,425,000
Lease liabilities	282,000	282,000			302,000
Other current tax liabilities	33,000	33,000			63,000
Current provisions	672,000	672,000			858,000
Current trade and other payables	1,614,000	1,614,000			3,202,000
Total acquired assets	46,540,000	46,540,000			51,026,000
Other non-current financial assets	13,000	13,000			14,000
Property, plant and equipment	295,000	295,000			326,000
Intangible assets and goodwill	43,850,000	43,850,000			45,323,000
Other current assets	197,000	197,000			78,000
Current trade and others receivables	17,000	17,000			209,000
Cash and cash equivalents	2,168,000	2,168,000			5,076,000
General and administrative expense		228,000
Research and development expense	€ 1,187,000
Total purchase price					€ 46,601,000
Purchase of interests in associates		41,500,000
Percentage of fair value in asset value						90.00%
Versantis \| Estimated
Disclosure of net assets and liabilities of Business Combination [Line Items]
Research and development expense		€ 5,833,000
Versantis \| Switzerland, Francs
Disclosure of net assets and liabilities of Business Combination [Line Items]
Cash transferred						€ 40,000,000
Net cash adjustment payment						2,800,000
Additional milestone payments						€ 65,000,000

Major Events in the Period and Events After the Period - Additional Information (Details)
€ in Thousands

12 Months Ended

Dec. 22, 2021

EUR (€)

Sep. 01, 2021

EUR (€)

Apr. 06, 2021

EUR (€)

Mar. 02, 2021

EUR (€)

Feb. 04, 2021

EUR (€)

Jan. 25, 2021

EUR (€)

euroPerBond

oCEANE

Nov. 23, 2020

euroPerBond

oCEANE

Oct. 16, 2017

EUR (€)

euroPerBond

oCEANE

Dec. 31, 2022

EUR (€)

Dec. 31, 2021

EUR (€)

Dec. 31, 2020

EUR (€)

Dec. 16, 2021

EUR (€)

Dec. 01, 2021

EUR (€)

Nov. 23, 2021

EUR (€)

Jun. 24, 2021

EUR (€)

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Expense of restructuring activities

€ (11)

€ 142

€ 5,308

Impairment loss

196

Increase in capital

€ 54,791

€ (59,680)

11,129

New shares created (in shares) | shares

49,834,983

49,815,489

Property, plant and equipment

€ 8,210

€ 9,015

11,648

Number of shares outstanding | shares

49,834,983

49,815,489

Fee and commission expense

€ 2,303

745

Number of shares issued during period (in shares) | shares

3,985,239

+ Proceeds from issue of share capital (net)

€ 28,000

€ 5

27,972

Purchase of interests in associates

€ 41,525

€ 0

ReorganizationAndReductionInForce

171

523

Revenue

€ 26,566

€ 85,579

€ 7,758

Major Events in the Period and Events After the Period

MAJOR EVENTS IN THE PERIOD AND EVENTS AFTER THE PERIODAcquisition of the Clinical-stage Biopharmaceutical Company Versantis

1.Consolidating GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)

3.Combining Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development

The deal closed effective September 29, 2022.

Total purchase price and contingent milestone payments

This transaction includes:

•an initial payment of 40 million CHF (€41.9 million) due and paid at the date of closing,

•a net cash adjustment payment of 2.8 million CHF (€2.9 million) at the end of the year in accordance with the terms of the acquisition agreement

•additional milestone payments of up to 65 million CHF contingent on the following outcomes:

◦positive Phase 2 results related to VS-01-ACLF,

◦regulatory approval of VS-01-ACLF, and

◦positive Phase 2 results related to VS-02.

Acquisition costs totaled €1.8 million.

Accounting treatment - IFRS 3

Accounting treatment - IAS 21

Supplementary information

The consolidated value of net assets acquired of Versantis AG and Versantis, Inc. on September 29, 2022 is as follows :


Total acquired assets and liabilities, in thousands of euros			29/9/2022
Cash and cash equivalents			5,076
Current trade and others receivables			209
Other current assets			78
Intangible assets			45,323
Property, plant and equipment			326
Other non-current financial assets			14
Total acquired assets			51,026

Current trade and other payables			3,202
Current provisions			858
Other current tax liabilities			63
Lease liabilities			302
Total acquired liabilities			4,425

Total purchase price			46,601

The net book value of assets and liabilities as of December 31, 2022 is as follows, per the application of IAS 21:


Net assets, in thousands of euros			31/12/2022
Cash and cash equivalents			2,168
Current trade and others receivables			17
Other current assets			197
Intangible assets			43,850
Property, plant and equipment			295
Other non-current financial assets			13
Total assets			46,540

Current trade and other payables			1,614
Current provisions			672
Other current tax liabilities			33
Lease liabilities			282
Total liabilities			2,601

Net assets			43,939

General and administrative expenses for the period between September 29, 2022 and December 31, 2022 attributable to Versantis total €228 thousand.

For further information, refer to N ote 14 - "Goodwill and Intangible Assets"

Agreements and partnership with Ipsen

2021 Collaboration and License Agreement

The Collaboration and License Agreement qualifies as a contract under IFRS 15, and meets the criteria under IFRS 15.9.

Under this agreement:

Ipsen Ownership Stake in GENFIT

2022 Follow-on Agreements: Transition Services Agreement and Inventory Purchase Agreement

Regarding the application of IFRS15, see Note 7 "Revenue s and other income.".

Termination of RESOLVE-IT and the development program of elafibranor in NASH

Impact on subcontracting costs

In 2022, the residual impact of the RESOLVE-IT study are based on two main topics:

•Secondly, the Company reversed 2021 accruals, amounting of €1.1 million, based on communication with the CRO (in particular as it relates to investigator costs).

Finally, the Company benefited in 2022 from an "end of study" credit note, ending the study in July, and bringing the provision recognized in the balance sheet for RESOLVE-IT to zero.

Impact on scientific equipment leased and owned

Leased equipment

Owned equipment

Premises

See Note 8 - “Property, Plant and Equipment”.

Reorganization and reduction in force

Genfit | Ipsen

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Proportion of ownership interest in associate (as a percent)

8.00%

Account Reversal

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

ReorganizationAndReductionInForce

Genoscience Pharma

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Milestone payments

€ 50,000

Contingent milestone payments

€ 20,000

Ipsen

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Contract liabilities

€ 40,000

€ 120,000

Revenue from contracts with customers

€ 1,000

80,000

Number of shares issued during period (in shares) | shares

3,985,239

Payment from collaboration, up-front cash payment, VAT

24,000

+ Proceeds from issue of share capital (net)

€ 28,000

Revenue from sales of inventories

3,300

Deferred income

40,000

Revenue

15,900

Ipsen | Collaboration and License Agreement

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Revenue from collaboration, potential milestone payments

€ 360,000

Royalty income, percent of collaborative sales

20.00%

Impairment

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Property, plant and equipment

(552)

€ (699)

€ (2,172)

OCEANE

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Extension of maturity

3 years

Buyback amount

€ 47,480

Accrued interest portion of buyback amount (in EUR per share) | euroPerBond

0.30

Number of debt instruments issued | oCEANE

2,895,260

3,048,780

6,081,081

Nominal value per unit (in EUR per bond) | euroPerBond

16.40

29.60

Debt component of a new amended OCEANE (in EUR per bond) | euroPerBond

24.12

Payment for partial buyback

€ 47,500

New shares created (in shares) | shares

55,000

1,191,250

2,658,312

Reduction in financial debt

€ 200

€ 5,200

€ 11,660

€ 13,320

Conversion Exchange Premium

550.00%

Number of shares issued during period (in shares) | shares

3,037,309

Aggregate nominal amount

€ 180,000

Pret Garanti Par L etat (PGE) Bancaire

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Notional amount

€ 11,000

Subsidized Loan

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Notional amount

€ 2,250

Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E

Disclosure Of Major Events In The Period And Events After The Period [Line Items]

Aggregate nominal amount

€ 57,000

Major Events in the Period and Events After the Period - Signature of a Licensing and Partnership Agreement with Ipsen (Details) - EUR (€) € in Thousands		12 Months Ended
	Dec. 22, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Major Events In The Period And Events After The Period [Line Items]
New shares created (in shares)		49,834,983	49,815,489
+ Proceeds from issue of share capital (net)	€ 28,000	€ 5	€ 27,972	€ 7
Genfit \| Ipsen
Disclosure Of Major Events In The Period And Events After The Period [Line Items]
Proportion of ownership interest in associate (as a percent)		8.00%	8.00%
Ipsen
Disclosure Of Major Events In The Period And Events After The Period [Line Items]
Payment from collaboration, up-front cash payment, VAT			€ 24,000
+ Proceeds from issue of share capital (net)		€ 28,000
Ipsen \| Collaboration and License Agreement
Disclosure Of Major Events In The Period And Events After The Period [Line Items]
Revenue from collaboration, potential milestone payments			€ 360,000
Royalty income, percent of collaborative sales			20.00%

Basis of Presentation (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Provisions for employee benefits	€ 782	€ 864
Equity	€ 94,528	€ 119,097	€ (16,430)	€ 84,065

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2022 EUR (€) shares bond	Dec. 31, 2022 EUR (€) shares USD ($)	Dec. 31, 2022 EUR (€) shares CHF (SFr)	Dec. 31, 2021 EUR (€) USD ($)	Dec. 31, 2020 EUR (€) USD ($)
Disclosure of voluntary change in accounting policy [abstract]
Closing foreign exchange rate \| shares	1	1	1	1
Average foreign exchange rate	1		1.0666	0.9847	1.1326	1.2271
ClosingForeignExchangeRateUSDEuro	€ 0.93756	€ 0.93756	€ 0.93756	€ 0.93756	€ 0.88292	€ 0.81493
ClosingForeignExchangeRateCHFEuro					1.01554
AverageForeignExchangeRateUSDEuro	0.95105				0.84542	€ 0.87755
AverageForeignExchangeRateCHFEuro					1.01710
Non Current Assets By Geographical	57,081,000				13,623,000
Disclosure of intangible assets with indefinite useful life [table]
Non Current Assets By Geographical	57,081,000				13,623,000
Number of segment \| bond		1
FRANCE
Disclosure of voluntary change in accounting policy [abstract]
Non Current Assets By Geographical	12,923,000				13,623,000
Disclosure of intangible assets with indefinite useful life [table]
Non Current Assets By Geographical	12,923,000				13,623,000
SWITZERLAND
Disclosure of voluntary change in accounting policy [abstract]
Non Current Assets By Geographical	44,158,000				0
Disclosure of intangible assets with indefinite useful life [table]
Non Current Assets By Geographical	€ 44,158,000				€ 0

Summary of Significant Accounting Policies - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) bond	Dec. 31, 2021 EUR (€)	Dec. 31, 2020
Disclosure of voluntary change in accounting policy [line items]
Number of segment \| bond	1
Impairment loss	€ 97	€ 196
Research tax credit, carryforward period (in years)	3 years
Revenue By Destination	1	1	1
Revenue From France
Disclosure of voluntary change in accounting policy [line items]
Revenue By Destination	1	1	1
Revenue From Other Countries
Disclosure of voluntary change in accounting policy [line items]
Revenue By Destination	0	0	0
Computer software [member] \| Top of Range
Disclosure of voluntary change in accounting policy [line items]
Estimated useful lives of software and license agreements	8 years
Leased equipment
Disclosure of voluntary change in accounting policy [line items]
Impairment loss	€ 28	€ 62

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Building on Non-Freehold Land
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	10 years
Fixtures and fittings [member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	9 years
Fixtures and fittings [member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	25 years
Scientific Equipment [Member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	2 years
Scientific Equipment [Member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	12 years
Computer equipment [member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	2 years
Computer equipment [member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	5 years
Furniture [Member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	4 years
Furniture [Member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	10 years
Vehicles [member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	4 years
Vehicles [member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives for property, plant and equipment	6 years
Computer software [member] \| Bottom of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of software and license agreements	1 year
Computer software [member] \| Top of Range
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of software and license agreements	8 years

Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 EUR (€)
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	€ 136,001,000			€ 258,756,000		€ 171,029,000					€ 276,748,000
Euros equivalent to USD or CHF	1	1.0666	0.9847	1	1.1326	1	1.2271
Denominated in USD
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	€ 32,057,000			€ 72,147,000		€ 90,637,000		$ 34,192,000		$ 81,713,000
Expenses \| $		$ 14,884,000			$ 12,566,000		$ 47,277,000
Denominated In C H F
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	2,358,000			0		0			SFr 2,321,000
Expenses \| SFr			SFr 2,016,000
10% Increase (Decrease) in US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	32,057,000			72,146,000
Expenses	13,955,000			11,095,000		38,528,000
10% Increase of US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	35,619,000			80,163,000
Expenses	15,506,000			12,328,000		42,808,000
10% Decrease of US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	29,143,000			65,588,000
Expenses	€ 12,686,000			€ 10,086,000		€ 35,025,000

Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of CHF against Euro (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)
Ten Percent Increase Decrease In C H F Vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	€ 2,357
Operating expense	2,048
Ten Percent Increase Of C H F Vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	2,618
Operating expense	2,275
Ten Percent Decrease Of C H F Vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	2,142
Operating expense	€ 1,862

Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details) € in Thousands, SFr in Thousands, $ in Thousands	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	€ 136,001			€ 258,756		€ 171,029	€ 276,748
Current and non current financial assets	9,464			4,431		1,458
Total	145,464			263,187		172,486
Denominated in EUR
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	101,536			186,609		80,391
Current and non current financial assets	9,456			4,355		1,391
Total	110,993			190,964		81,782
Denominated in USD
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	32,057	$ 34,192		72,147	$ 81,713	90,637
Current and non current financial assets	7			76		67
Total	32,064			72,223		90,704
Denominated In C H F
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	2,358		SFr 2,321	0		0
Current and non current financial assets	0			0		0
Total	€ 2,358			€ 0		€ 0

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References + Details

Financial Risks Management - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Oct. 16, 2017
Foreign Exchange Rates [Line Items]
Fluctuation in currency (in percent)	10.00%
Cash and cash equivalents and other financial assets	€ 145,464	€ 263,187	€ 172,486
OCEANE
Foreign Exchange Rates [Line Items]
Aggregate nominal amount				€ 180,000
Interest Rate Risk
Foreign Exchange Rates [Line Items]
Financial liabilities	€ 75,300	€ 74,200

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalent [line items]
Short-term deposits, classified as cash equivalents	€ 119,090	€ 69,045
Cash	16,910	189,711
Total cash and cash equivalents	136,001	258,756	€ 171,029	€ 276,748
Term Accounts [Member]
Cash and cash equivalent [line items]
Short-term deposits, classified as cash equivalents	€ 119,090	€ 69,045

Intangible Assets - Schedule of Variations in Intangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 29, 2022
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	€ 174	€ 297
Increase	43,852	(26)
Decrease	(69)	(97)
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	€ 43,957	174
Versantis
Disclosure of detailed information about intangible assets [line items]
Total purchase price			€ 46,601
Computer software [member] \| Top of Range
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives of software and license agreements	8 years
Acquisition of Versantis
Disclosure of detailed information about intangible assets [line items]
Increase (decrease) in intangible assets and goodwill	€ 43,900
Total purchase price			€ 46,600
Patents
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives of software and license agreements	20 years
Gross
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	€ 1,364	1,531
Increase	43,931	127
Decrease	(398)	(294)
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	44,897	1,364
Gross \| Computer software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	1,294	1,440
Increase	81	126
Decrease	(398)	(255)
Translation adjustments	0	0
Reclassification	0	(17)
Intangible assets other than goodwill Period End	977	1,294
Gross \| Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	70	91
Increase	281	0
Decrease	0	(21)
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	351	70
Gross \| Other Intangibles
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	0	0
Increase	43,569	0
Decrease	0	(17)
Translation adjustments	0	0
Reclassification	0	17
Intangible assets other than goodwill Period End	43,569	0
Accumulated Depreciation and Impairment
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	(1,190)	(1,234)
Increase	(79)	(152)
Decrease	329	197
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	(940)	(1,190)
Accumulated Depreciation and Impairment \| Computer software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	(1,190)	(1,213)
Increase	(79)	(152)
Decrease	329	176
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	(940)	(1,190)
Accumulated Depreciation and Impairment \| Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	0	(21)
Increase	0	0
Decrease	0	21
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	0	0
Accumulated Depreciation and Impairment \| Other Intangibles
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill Period Start	0	0
Increase	0	0
Decrease	0	0
Translation adjustments	0	0
Reclassification	0	0
Intangible assets other than goodwill Period End	€ 0	€ 0

Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	€ 9,015	€ 11,648
Increase	(939)	(2,302)
Decrease	144	(394)
Translation adjustments	(3)	(11)
Reclassification	(7)	74
Ending balance	8,210	9,015
Gross
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	20,017	24,911
Increase	1,014	487
Decrease	(230)	(5,454)
Translation adjustments	0	0
Reclassification	(7)	74
Ending balance	20,794	20,017
Gross \| Buildings On Non Freehold Land [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	10,311	12,167
Increase	610	0
Decrease	0	(1,912)
Translation adjustments	0	0
Reclassification	0	56
Ending balance	10,921	10,311
Gross \| Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	6,320	9,080
Increase	228	71
Decrease	(82)	(2,831)
Translation adjustments	0	0
Reclassification	0	0
Ending balance	6,467	6,320
Gross \| Fixtures and fittings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,474	1,703
Increase	61	(4)
Decrease	0	(234)
Translation adjustments	0	0
Reclassification	2	9
Ending balance	1,537	1,474
Gross \| Vehicles [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	91	99
Increase	0	60
Decrease	0	(67)
Translation adjustments	0	0
Reclassification	0	0
Ending balance	91	91
Gross \| Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,542	1,534
Increase	98	30
Decrease	(149)	(18)
Translation adjustments	0	0
Reclassification	8	(4)
Ending balance	1,500	1,542
Gross \| Furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	279	329
Increase	0	0
Decrease	0	(50)
Translation adjustments	0	0
Reclassification	0	0
Ending balance	279	279
Gross \| Construction in progress [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Increase	16	330
Decrease	0	(342)
Translation adjustments	0	0
Reclassification	(16)	12
Ending balance	0	0
Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(10,304)	(11,090)
Increase	(1,953)	(2,789)
Decrease	227	3,587
Translation adjustments	(3)	(11)
Reclassification	0	0
Ending balance	(12,032)	(10,304)
Accumulated Depreciation \| Buildings On Non Freehold Land [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(2,900)	(2,603)
Increase	(1,033)	(1,417)
Decrease	0	1,120
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(3,934)	(2,900)
Accumulated Depreciation \| Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(4,868)	(5,952)
Increase	(697)	(1,061)
Decrease	79	2,145
Translation adjustments	4	0
Reclassification	0	0
Ending balance	(5,481)	(4,868)
Accumulated Depreciation \| Fixtures and fittings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(888)	(982)
Increase	(95)	(91)
Decrease	0	190
Translation adjustments	(2)	(5)
Reclassification	0	0
Ending balance	(985)	(888)
Accumulated Depreciation \| Vehicles [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(31)	(85)
Increase	(12)	(13)
Decrease	0	67
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(43)	(31)
Accumulated Depreciation \| Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(1,403)	(1,217)
Increase	(105)	(195)
Decrease	148	14
Translation adjustments	(5)	(6)
Reclassification	0	0
Ending balance	(1,365)	(1,403)
Accumulated Depreciation \| Furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(213)	(251)
Increase	(10)	(12)
Decrease	0	50
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(223)	(213)
Accumulated Depreciation \| Construction in progress [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Increase	0	0
Decrease	0	0
Translation adjustments	0	0
Reclassification	0	0
Ending balance	0	0
Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(699)	(2,172)
Increase	0	0
Decrease	147	1,473
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(552)	(699)
Impairment \| Buildings On Non Freehold Land [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(503)	(1,182)
Increase	0	0
Decrease	48	679
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(455)	(503)
Impairment \| Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(87)	(866)
Increase	0	0
Decrease	28	779
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(59)	(87)
Impairment \| Fixtures and fittings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(93)	(93)
Increase	0	0
Decrease	69	0
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(24)	(93)
Impairment \| Vehicles [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Increase	0	0
Decrease	0	0
Translation adjustments	0	0
Reclassification	0	0
Ending balance	0	0
Impairment \| Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(12)	(27)
Increase	0	0
Decrease	2	15
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(10)	(12)
Impairment \| Furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(3)	(3)
Increase	0	0
Decrease	0	0
Translation adjustments	0	0
Reclassification	0	0
Ending balance	(3)	(3)
Impairment \| Construction in progress [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Increase	0	0
Decrease	0	0
Translation adjustments	0	0
Reclassification	0	0
Ending balance	€ 0	€ 0

Property, Plant and Equipment - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	€ 8,210	€ 9,015	€ 11,648
Impairment loss	97	196
Increase	(939)	(2,302)
Disposals, property, plant and equipment	144	(394)
Translation adjustments	(3)	(11)
Reclassification	(7)	74
Additions
Disclosure of detailed information about property, plant and equipment [line items]
Right of use asset	743
Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(552)	(699)	(2,172)
Increase	0	0
Disposals, property, plant and equipment	147	1,473
Translation adjustments	0	0
Reclassification	0	0
Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	20,794	20,017	24,911
Increase	1,014	487
Disposals, property, plant and equipment	(230)	(5,454)
Translation adjustments	0	0
Reclassification	(7)	74
Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(12,032)	(10,304)	(11,090)
Increase	(1,953)	(2,789)
Disposals, property, plant and equipment	227	3,587
Translation adjustments	(3)	(11)
Reclassification	0	0
Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right of use asset	1,502	1,369
Depreciation	(1,475)	(1,255)
Impairment loss	59	87
Scientific Equipment [Member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(59)	(87)	(866)
Increase	0	0
Disposals, property, plant and equipment	28	779
Translation adjustments	0	0
Reclassification	0	0
Scientific Equipment [Member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	6,467	6,320	9,080
Increase	228	71
Disposals, property, plant and equipment	(82)	(2,831)
Translation adjustments	0	0
Reclassification	0	0
Scientific Equipment [Member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(5,481)	(4,868)	(5,952)
Increase	(697)	(1,061)
Disposals, property, plant and equipment	79	2,145
Translation adjustments	4	0
Reclassification	0	0
Fixtures and fittings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Impairment loss	24	93
Fixtures and fittings [member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(24)	(93)	(93)
Increase	0	0
Disposals, property, plant and equipment	69	0
Translation adjustments	0	0
Reclassification	0	0
Fixtures and fittings [member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	1,537	1,474	1,703
Increase	61	(4)
Disposals, property, plant and equipment	0	(234)
Translation adjustments	0	0
Reclassification	2	9
Fixtures and fittings [member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(985)	(888)	(982)
Increase	(95)	(91)
Disposals, property, plant and equipment	0	190
Translation adjustments	(2)	(5)
Reclassification	0	0
Furniture and IT Equipment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment loss	13	15
Building on Non-Freehold Land
Disclosure of detailed information about property, plant and equipment [line items]
Right of use asset	10,665	10,056
Depreciation	(3,839)	(2,831)
Buildings On Non Freehold Land [Member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(455)	(503)	(1,182)
Increase	0	0
Disposals, property, plant and equipment	48	679
Translation adjustments	0	0
Reclassification	0	0
Buildings On Non Freehold Land [Member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	10,921	10,311	12,167
Increase	610	0
Disposals, property, plant and equipment	0	(1,912)
Translation adjustments	0	0
Reclassification	0	56
Buildings On Non Freehold Land [Member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(3,934)	(2,900)	(2,603)
Increase	(1,033)	(1,417)
Disposals, property, plant and equipment	0	1,120
Translation adjustments	0	0
Reclassification	0	0
Vehicles [member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	0	0	0
Increase	0	0
Disposals, property, plant and equipment	0	0
Translation adjustments	0	0
Reclassification	0	0
Vehicles [member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	91	91	99
Increase	0	60
Disposals, property, plant and equipment	0	(67)
Translation adjustments	0	0
Reclassification	0	0
Vehicles [member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(43)	(31)	(85)
Increase	(12)	(13)
Disposals, property, plant and equipment	0	67
Translation adjustments	0	0
Reclassification	0	0
Computer equipment [member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(10)	(12)	(27)
Increase	0	0
Disposals, property, plant and equipment	2	15
Translation adjustments	0	0
Reclassification	0	0
Computer equipment [member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	1,500	1,542	1,534
Increase	98	30
Disposals, property, plant and equipment	(149)	(18)
Translation adjustments	0	0
Reclassification	8	(4)
Computer equipment [member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(1,365)	(1,403)	(1,217)
Increase	(105)	(195)
Disposals, property, plant and equipment	148	14
Translation adjustments	(5)	(6)
Reclassification	0	0
Furniture [Member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(3)	(3)	(3)
Increase	0	0
Disposals, property, plant and equipment	0	0
Translation adjustments	0	0
Reclassification	0	0
Furniture [Member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	279	279	329
Increase	0	0
Disposals, property, plant and equipment	0	(50)
Translation adjustments	0	0
Reclassification	0	0
Furniture [Member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	(223)	(213)	(251)
Increase	(10)	(12)
Disposals, property, plant and equipment	0	50
Translation adjustments	0	0
Reclassification	0	0
Construction in progress [member] \| Impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	0	0	0
Increase	0	0
Disposals, property, plant and equipment	0	0
Translation adjustments	0	0
Reclassification	0	0
Construction in progress [member] \| Gross
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	0	0	0
Increase	16	330
Disposals, property, plant and equipment	0	(342)
Translation adjustments	0	0
Reclassification	(16)	12
Construction in progress [member] \| Accumulated Depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	0	0	€ 0
Increase	0	0
Disposals, property, plant and equipment	0	0
Translation adjustments	0	0
Reclassification	0	0
Assets under finance lease contracts \| Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	27	114
Owned equipment \| Scientific Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Impairment loss	€ 31	€ 25

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade and other receivables [abstract]
Trade receivables	€ 3,188	€ 57
Social Security Costs Receivables	1	4
Value added tax receivables	1,288	1,038
Grants Receivables	4	5
Other receivables	126	852
Total trade and other receivables	15,906	7,239
Total trade and other current receivables	15,906	7,236
Total trade and other non-current receivables	0	3
Research Tax Credit Receivable	11,299	5,282
Disclosure of trade and other receivables [Line Items]
Other receivables	126	€ 852
Increase (Decrease) of Research Tax Credit Receivable	6,017
Credit notes
Trade and other receivables [abstract]
Other receivables	752
Disclosure of trade and other receivables [Line Items]
Other receivables	€ 752

Trade and Other Receivables - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade and other receivables [abstract]
Research Tax Credit		€ 7,911
Value added tax receivables	€ 1,288	1,038
Other receivables	€ 126	€ 852

Other Financial Assets - Summary of Other Financial Assets (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure of financial assets [line items]
Investments accounted for using equity method	€ 3,133	€ 3,133
Other Investments	483	0
Financial Investments	4,550	0
Loans and receivables	428	388
Deposits And Guarantees	335	397
Liquidity Contract Net	534	513
Other financial assets	9,464	4,431
Other current financial assets	4,550	0
Other non-current financial assets	4,914	4,431
Loans And Receivables, Variations	428	388
Long Term Deposits And Guarantees, Variations	335	€ 397
Liquidity Contract, Variations	534
CAPTECH Santé
Disclosure of financial assets [line items]
Other Investments	€ 500
Other Investments - Number of units of subscription	50
Other Investments - Subscription paid	€ 175
Other Investments - Remaining subscription	€ 325
Other Investments - Percentage of Subscription paid	35.00%
Profit (loss) on disposal of investments and changes in value of investments	€ 17
Increase
Disclosure of financial assets [line items]
Investments accounted for using equity method	0
Other Investments	483
Financial Investments	4,550
Loans And Receivables, Variations	40
Long Term Deposits And Guarantees, Variations	33
Liquidity Contract, Variations	0
Financial Assets, Variations	5,107
Decrease
Disclosure of financial assets [line items]
Investments accounted for using equity method	0
Other Investments	0
Financial Investments	0
Loans And Receivables, Variations	0
Long Term Deposits And Guarantees, Variations	(95)
Liquidity Contract, Variations	21
Financial Assets, Variations	€ (74)

Other Financial Assets - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Total amount of financial assets	€ 9,464	€ 4,431
Liquidity account, cash balance	€ 534	€ 513
Number of shares recorded as deduction from equity (in shares)	138,691,000	137,012,000
Genoscience Pharma
Disclosure of financial assets [line items]
Subscription of new ordinary shares		€ 3,133

Other Assets - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Miscellaneous assets [abstract]
Other current assets	€ 1,998	€ 2,101

Loans and Borrowings - Additional Information (Details) € / shares in Units, $ in Thousands																		1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 06, 2022 EUR (€)	Mar. 02, 2022 EUR (€)	Dec. 22, 2021 shares	Nov. 26, 2021 EUR (€)	Sep. 01, 2021 EUR (€) shares	Jul. 23, 2021 EUR (€)	Jul. 20, 2021 EUR (€)	Jun. 29, 2021 EUR (€)	Jun. 24, 2021 EUR (€) bank	Jun. 20, 2021	Apr. 06, 2021 EUR (€) bond shares	Mar. 02, 2021 EUR (€) shares	Feb. 04, 2021 EUR (€) shares	Jan. 25, 2021 EUR (€) euroPerBond oCEANE	Jan. 01, 2021 bond	Nov. 23, 2020 euroPerBond oCEANE	Oct. 16, 2017 EUR (€) euroPerBond oCEANE	Feb. 28, 2021 bond	Mar. 31, 2022 bond	Dec. 31, 2022 EUR (€) euroPerBond Facility Size shares oCEANE payment installment € / shares	Dec. 31, 2021 EUR (€) euroPerBond Facility Size oCEANE shares	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 USD ($) shares	Nov. 23, 2021 EUR (€)
Disclosure of detailed information about borrowings [line items]
Volatility, first level																				30.00%
Volatility, second level																				35.00%
No-risk rate																				(0.45%)
Capital increase																				€ 0	€ 65,332,000	€ 0
New shares created (in shares) \| shares																				49,834,983	49,815,489		49,834,983
Fee and commission expense																					€ 2,303,000	745,000
Deferred tax liability (asset)																				€ 510,000	602,000	767,000
Deferred tax liabilities																				510,000	602,000
Deferred tax assets																				€ 0	0
Number of biannual installments \| installment																				2
+ Proceeds from new loans and borrowings net of issue costs																				€ 0	15,270,000	0
Number of shares issued during period (in shares) \| shares			3,985,239
Current convertible loans																				415,000	415,000
Non-current convertible loans																				49,861,000	47,682,000
Other borrowings																				24,999,000	26,138,000
Other current loans and borrowings																				4,665,000	1,773,000
Other non-current loans and borrowings																				20,334,000	€ 24,365,000
Refundable and conditional advances, Net book value																				3,229,000		3,229,000
TOTAL - Refundable and conditional advances \| $																							$ 3,229
TOTAL																				€ 75,275,000
Minimum
Disclosure of detailed information about borrowings [line items]
Credit spread																				8.74%
Maximum
Disclosure of detailed information about borrowings [line items]
Credit spread																				9.76%
Potential ordinary share transactions [member]
Disclosure of detailed information about borrowings [line items]
Percentage of new shares issued (in percent)																				21.29%	21.24%
Maximum dilution of convertible instruments, percentage																				17.50%	17.52%
Within 1 Year
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				€ 0
TOTAL																				5,080,000
Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
TOTAL																				7,350,000
Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
TOTAL																				54,485,000
Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
TOTAL																				1,901,000
Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
TOTAL																				1,817,000
Later than five years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances \| $																							$ 3,229
TOTAL																				€ 4,643,000
First Year
Disclosure of detailed information about borrowings [line items]
Borrowings, adjustment to interest rate basis																				0.25%			0.25%
Bonds after OCEANEs buyback
Disclosure of detailed information about borrowings [line items]
Notional amount																				€ 50,276,000
Bonds at origin
Disclosure of detailed information about borrowings [line items]
Reference share price \| € / shares																				€ 22.77
BPI FRANCE - IT-DIAB
Disclosure of detailed information about borrowings [line items]
Refundable and conditional advances, Total amount allocated																				€ 3,229,000	€ 3,229,000	3,229,000
Refundable and conditional advances, Receipts																				3,229,000	3,229,000	3,229,000
Refundable and conditional advances, Repayments																				0	0	0
Refundable and conditional advances, Effects of discounting																				0	0	€ 0
Refundable and conditional advances, Net book value																				€ 3,229,000	€ 3,229,000
Refundable and conditional advances, Grant date																				Dec. 23, 2008	Dec. 23, 2008
TOTAL - Refundable and conditional advances \| $																							$ 3,229
BPI FRANCE - IT-DIAB \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				€ 0
BPI FRANCE - IT-DIAB \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
BPI FRANCE - IT-DIAB \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
BPI FRANCE - IT-DIAB \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				0
BPI FRANCE - IT-DIAB \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances																				€ 0
BPI FRANCE - IT-DIAB \| Later than five years
Disclosure of detailed information about borrowings [line items]
TOTAL - Refundable and conditional advances \| $																							$ 3,229
OCEANE
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE														2,895,260		3,048,780	6,081,081
Nominal value per unit (in EUR per bond) \| euroPerBond														16.40		16.40	29.60
Aggregate nominal amount																	€ 180,000,000
Extension of maturity																3 years
Conversion Exchange Premium																550.00%
Accrued interest portion of buyback amount (in EUR per share) \| euroPerBond														0.30
Buyback amount														€ 47,480,000
Buyback (EUR per bond) \| euroPerBond														27.80
Debt component of a new amended OCEANE (in EUR per bond) \| euroPerBond														24.12
Equity instrument of new amended OCEANE (in EUR per bond) \| euroPerBond														3.68
Borrowings, recognized for amended obligation														€ 76,800,000
Payment for partial buyback														47,500,000
Recognition of financial gain before tax														35,600,000
New O C E AN E shares (in shares)					10,000						216,591	483,330	552,238		552,238			483,330	216,591	10,000
Capital increase	€ 297,812.5	€ 664,578.75			€ 13,750,000								€ 759,327.25
New shares created (in shares) \| shares					55,000						1,191,250	2,658,312
Reduction in financial debt					€ 200,000						€ 5,200,000	€ 11,660,000	€ 13,320,000
Number of shares issued during period (in shares) \| shares													3,037,309
Increase in equity before deferred taxes														11,700,000
Amount derecognized														€ 94,800,000
Notes and debentures issued																				€ 50,276,000	€ 48,097,000
OCEANE \| Bonds after OCEANEs buyback
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE																	3,185,821			1,923,662	1,923,662
Nominal value per unit (in EUR per bond) \| euroPerBond																	29.60			29.60	29.60
Effective Interest Rate																	8.80%			8.80%	8.80%
Notional amount																	€ 94,300,301.6			€ 56,940,395.2	€ 56,940,395.2
OCEANE \| Bonds at origin
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE																	6,081,081
Nominal value per unit (in EUR per bond) \| euroPerBond																	29.60
Conversion Exchange Premium																	30.00%
Interest rate (in percent)																	3.50%
Notional amount																	€ 179,999,997.6
Proportion of trading period over nominal value of OCEANEs (in percent)																	150.00%
Trading period																	20 days
Annual nominal interest rate, payable semi-annually (in percent)																	7.20%
O C E A N E 2022
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE																3,185,821
Nominal value per unit (in EUR per bond) \| euroPerBond																29.60
Conversion Exchange Premium																550.00%
Pret Garanti Par L etat (PGE) Bancaire
Disclosure of detailed information about borrowings [line items]
Number of quarterly payments, amortization and interest \| payment																				8
Number of quarterly payments, \| payment																				20
Interest rate (in percent)																				2.25%			2.25%
Notional amount									€ 11,000,000
Number of French banks \| bank									4
Repayment options, up to (in years)									6 years
+ Proceeds from new loans and borrowings net of issue costs								€ 10,919,000
Proportion of loan guaranteed by the French government (in percent)							90.00%
Increase in the debts																				€ 44,000
Pret Garanti Par L etat (PGE) Bancaire \| Third Year
Disclosure of detailed information about borrowings [line items]
Borrowings, adjustment to interest rate basis																				1.00%			1.00%
Pret Garanti Par L etat (PGE) Bancaire \| Effective Interest Rate
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				0.75%			0.75%
BPI PGE [Member]
Disclosure of detailed information about borrowings [line items]
Notional amount							€ 2,000,000
Debt instrument, initial term (in years)										1 year
Repayment options, up to (in years)										6 years
+ Proceeds from new loans and borrowings net of issue costs						€ 1,985,000
Proportion of loan guaranteed by the French government (in percent)							90.00%
BPI PGE [Member] \| Effective Interest Rate
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				1.65%	1.95%		1.65%
Subsidized Loan
Disclosure of detailed information about borrowings [line items]
Number of quarterly payments, \| payment																				20
Notional amount																								€ 2,250,000
Debt instrument, initial term (in years)				6 years
+ Proceeds from new loans and borrowings net of issue costs				€ 2,250,000
Subsidized Loan \| Revised terms
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				2.25%			2.25%
Interest Rate, including state guarantee (in percent)																				1.00%
Convertible Loans [Member]
Disclosure of detailed information about borrowings [line items]
Convertible bond, yearly interest																				€ 1,993,000
Other Loans And Borrowings																				50,276,000
Convertible Loans [Member] \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				415,000
Convertible Loans [Member] \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Convertible Loans [Member] \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				49,861,000
Convertible Loans [Member] \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Convertible Loans [Member] \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Convertible Loans [Member] \| Later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Refundable And Conditional Advances [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings																				3,229,000	€ 3,229,000
Other current loans and borrowings																				0	0
Other non-current loans and borrowings																					3,229,000
Bank Loans [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings																				15,196,000	15,824,000
Other current loans and borrowings																				3,619,000	667,000
Other non-current loans and borrowings																				11,578,000	15,156,000
Other Loans And Borrowings																				15,196,000
Bank Loans [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)
Facility size \| Facility Size																				20,465,000
Installments
Bank loan outstanding																				€ 15,221,000	15,864,000
Bank Loans [Member] \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				3,619,000
Bank Loans [Member] \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				6,339,000
Bank Loans [Member] \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				3,601,000
Bank Loans [Member] \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				867,000
Bank Loans [Member] \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				771,000
Bank Loans [Member] \| Later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Bank Loans [Member] \| C D N Three [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.72%			0.72%
Debt maturity date																				April 2016
Facility size \| Facility Size																				500,000
Installments																				60 monthly
Bank loan outstanding																				€ 0	0
Bank Loans [Member] \| C D N Four [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.36%			0.36%
Debt maturity date																				June 2017
Facility size \| Facility Size																				600,000
Installments																				48 monthly
Bank loan outstanding																				€ 0	0
Bank Loans [Member] \| C D N Five [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.46%			0.46%
Debt maturity date																				November 2018
Facility size \| Facility Size																				500,000
Installments																				48 monthly
Bank loan outstanding																				€ 0	115,000
Bank Loans [Member] \| C I C Four [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.69%			0.69%
Debt maturity date																				December 2016
Facility size \| Facility Size																				265,000
Installments																				60 monthly
Bank loan outstanding																				€ 0	4,000
Bank Loans [Member] \| C I C Five [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.69%			0.69%
Debt maturity date																				July 2017
Facility size \| Facility Size																				1,000,000
Installments																				60 monthly
Bank loan outstanding																				€ 0	152,000
Bank Loans [Member] \| B N P Two [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.80%			0.80%
Debt maturity date																				June 2016
Facility size \| Facility Size																				500,000
Installments																				20 quarterly
Bank loan outstanding																				€ 0	0
Bank Loans [Member] \| B N P Three [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.80%			0.80%
Debt maturity date																				October 2016
Facility size \| Facility Size																				1,050,000
Installments																				20 quarterly
Bank loan outstanding																				€ 0	105,000
Bank Loans [Member] \| B N P Four [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.87%			0.87%
Debt maturity date																				April 2017
Facility size \| Facility Size																				800,000
Installments																				60 monthly
Bank loan outstanding																				€ 54,000	217,000
Bank Loans [Member] \| Other [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.00%			0.00%
Debt maturity date																				-
Facility size \| Facility Size																				0
Installments																				0
Bank loan outstanding																				€ 17,000	€ 20,000
Bank Loans [Member] \| CDN PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				1.36%	1.36%		1.36%
Debt maturity date																				June 2021
Facility size \| Facility Size																				900,000	900,000
Installments																				8 quarterly
Bank loan outstanding																				€ 900,000	€ 900,000
Bank Loans [Member] \| CIC PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.75%	0.75%		0.75%
Debt maturity date																				June 2021
Facility size \| Facility Size																				2,200,000	2,200,000
Installments																				8 quarterly
Bank loan outstanding																				€ 2,200,000	€ 2,200,000
Bank Loans [Member] \| BNP PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.45%	0.45%		0.45%
Debt maturity date																				June 2021
Facility size \| Facility Size																				4,900,000	4,900,000
Installments																				8 quarterly
Bank loan outstanding																				€ 4,900,000	€ 4,900,000
Bank Loans [Member] \| Natixis PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				0.40%	0.40%		0.40%
Debt maturity date																				June 2021
Facility size \| Facility Size																				3,000,000	3,000,000
Installments																				8 quarterly
Bank loan outstanding																				€ 3,000,000	€ 3,000,000
Bank Loans [Member] \| BPI Pret Taux Bonifie [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
New debt recognized																				€ 0
Interest rate (in percent)																				2.25%			2.25%
Debt maturity date																				November 2021
Facility size \| Facility Size																				2,250,000
Installments																				20 quarterly
Bank loan outstanding																				€ 2,250,000	2,250,000
Bank Loans [Member] \| Effective Interest Rate \| CDN PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				2.08%			2.08%
Bank Loans [Member] \| Effective Interest Rate \| CIC PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				1.46%			1.46%
Bank Loans [Member] \| Effective Interest Rate \| BNP PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				1.16%			1.16%
Bank Loans [Member] \| Effective Interest Rate \| Natixis PGE [Member] \| Research and Laboratory Equipment
Disclosure of detailed information about borrowings [line items]
Interest rate (in percent)																				1.11%			1.11%
Obligations Under Leases [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings																				€ 6,559,000	7,069,000
Other current loans and borrowings																				1,032,000	1,089,000
Other non-current loans and borrowings																				5,527,000	5,980,000
Accrued Interests [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings																				14,000	16,000
Other current loans and borrowings																				14,000	16,000
Other non-current loans and borrowings																				0	0
Other Loans And Borrowings																				14,000
Accrued Interests [Member] \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				14,000
Accrued Interests [Member] \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Accrued Interests [Member] \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Accrued Interests [Member] \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Accrued Interests [Member] \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Accrued Interests [Member] \| Later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				0
Other Financial Loans And Borrowings [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings																				0	0
Other current loans and borrowings																				0	0
Other non-current loans and borrowings																				0	€ 0
Other Loans And Borrowings																				72,046,000
Other Financial Loans And Borrowings [Member] \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				5,080,000
Other Financial Loans And Borrowings [Member] \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				7,350,000
Other Financial Loans And Borrowings [Member] \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				54,485,000
Other Financial Loans And Borrowings [Member] \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,901,000
Other Financial Loans And Borrowings [Member] \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,817,000
Other Financial Loans And Borrowings [Member] \| Later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,414,000
Lease
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				6,559,000
Lease \| Within 1 Year
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,032,000
Lease \| Later than one year and not later than two years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,011,000
Lease \| Later than two years and not later than three years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,022,000
Lease \| Later than three years and not later than four years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,034,000
Lease \| Later than four years and not later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				1,046,000
Lease \| Later than five years
Disclosure of detailed information about borrowings [line items]
Other Loans And Borrowings																				€ 1,414,000

Loans and Borrowings - Summary of Bonds (Details)				12 Months Ended
Loans and Borrowings - Summary of Bonds (Details)	Jan. 25, 2021 euroPerBond oCEANE	Nov. 23, 2020 euroPerBond oCEANE	Oct. 16, 2017 EUR (€) euroPerBond oCEANE	Dec. 31, 2022 EUR (€) euroPerBond oCEANE € / shares	Dec. 31, 2021 EUR (€) euroPerBond oCEANE
OCEANE
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE	2,895,260	3,048,780	6,081,081
Nominal value per unit (in EUR per bond) \| euroPerBond	16.40	16.40	29.60
Conversion Exchange Premium		550.00%
Bonds at origin
Disclosure of detailed information about borrowings [line items]
Reference share price \| € / shares				€ 22.77
Bonds at origin \| OCEANE
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE			6,081,081
Notional amount \| €			€ 179,999,997.6
Nominal value per unit (in EUR per bond) \| euroPerBond			29.60
Conversion Exchange Premium			30.00%
Annual nominal interest rate (in percent)			3.50%
Annual nominal interest rate, payable semi-annually (in percent)			7.20%
Trading period			20 days
Proportion of trading period over nominal value of OCEANEs (in percent)			150.00%
Bonds after OCEANEs buyback
Disclosure of detailed information about borrowings [line items]
Notional amount \| €				€ 50,276,000
Bonds after OCEANEs buyback \| OCEANE
Disclosure of detailed information about borrowings [line items]
Number of debt instruments issued \| oCEANE			3,185,821	1,923,662	1,923,662
Notional amount \| €			€ 94,300,301.6	€ 56,940,395.2	€ 56,940,395.2
Nominal value per unit (in EUR per bond) \| euroPerBond			29.60	29.60	29.60
Effective Interest Rate			8.80%	8.80%	8.80%

Loans and Borrowings - Summary of Convertible Bonds (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Current convertible loans	€ 415	€ 415
Non-current convertible loans	49,861	47,682
OCEANE
Disclosure of detailed information about borrowings [line items]
Notes and debentures issued	€ 50,276	€ 48,097

Loans and Borrowings - Summary of Other Loans and Borrowings (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Other borrowings	€ 24,999	€ 26,138
Other current loans and borrowings	4,665	1,773
Other non-current loans and borrowings	20,334	24,365
Refundable And Conditional Advances [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings	3,229	3,229
Other current loans and borrowings	0	0
Other non-current loans and borrowings		3,229
Bank Loans [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings	15,196	15,824
Other current loans and borrowings	3,619	667
Other non-current loans and borrowings	11,578	15,156
Obligations Under Leases [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings	6,559	7,069
Other current loans and borrowings	1,032	1,089
Other non-current loans and borrowings	5,527	5,980
Accrued Interests [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings	14	16
Other current loans and borrowings	14	16
Other non-current loans and borrowings	0	0
Other Financial Loans And Borrowings [Member]
Disclosure of detailed information about borrowings [line items]
Other borrowings	0	0
Other current loans and borrowings	0	0
Other non-current loans and borrowings	€ 0	€ 0

Loans and Borrowings - Summary of Refundable and Conditional Advances (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about borrowings [line items]
Refundable and conditional advances, Net book value	€ 3,229		€ 3,229
BPI FRANCE - IT-DIAB
Disclosure of detailed information about borrowings [line items]
Refundable and conditional advances, Grant date	Dec. 23, 2008	Dec. 23, 2008
Refundable and conditional advances, Total amount allocated	€ 3,229	€ 3,229	3,229
Refundable and conditional advances, Receipts	3,229	3,229	3,229
Refundable and conditional advances, Repayments	0	0	0
Refundable and conditional advances, Effects of discounting	0	0	€ 0
Refundable and conditional advances, Net book value	€ 3,229	€ 3,229

Loans and Borrowings - Summary of Bank Loans (Details) - Bank Loans [Member] - Research and Laboratory Equipment € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) Facility Size	Dec. 31, 2021 EUR (€) Facility Size
Disclosure of detailed information about borrowings [line items]
Facility size \| Facility Size	20,465,000
Interest rate (in percent)
New debt recognized	€ 0
Installments
Bank loan outstanding	€ 15,221	€ 15,864
C D N Three [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	April 2016
Facility size \| Facility Size	500,000
Interest rate (in percent)	0.72%
New debt recognized	€ 0
Installments	60 monthly
Bank loan outstanding	€ 0	0
C D N Four [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2017
Facility size \| Facility Size	600,000
Interest rate (in percent)	0.36%
New debt recognized	€ 0
Installments	48 monthly
Bank loan outstanding	€ 0	0
C D N Five [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	November 2018
Facility size \| Facility Size	500,000
Interest rate (in percent)	0.46%
New debt recognized	€ 0
Installments	48 monthly
Bank loan outstanding	€ 0	115
C I C Four [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	December 2016
Facility size \| Facility Size	265,000
Interest rate (in percent)	0.69%
New debt recognized	€ 0
Installments	60 monthly
Bank loan outstanding	€ 0	4
C I C Five [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	July 2017
Facility size \| Facility Size	1,000,000
Interest rate (in percent)	0.69%
New debt recognized	€ 0
Installments	60 monthly
Bank loan outstanding	€ 0	152
B N P Two [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2016
Facility size \| Facility Size	500,000
Interest rate (in percent)	0.80%
New debt recognized	€ 0
Installments	20 quarterly
Bank loan outstanding	€ 0	0
B N P Three [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	October 2016
Facility size \| Facility Size	1,050,000
Interest rate (in percent)	0.80%
New debt recognized	€ 0
Installments	20 quarterly
Bank loan outstanding	€ 0	105
B N P Four [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	April 2017
Facility size \| Facility Size	800,000
Interest rate (in percent)	0.87%
New debt recognized	€ 0
Installments	60 monthly
Bank loan outstanding	€ 54	217
Other [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	-
Facility size \| Facility Size	0
Interest rate (in percent)	0.00%
New debt recognized	€ 0
Installments	0
Bank loan outstanding	€ 17	€ 20
CDN PGE [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2021
Facility size \| Facility Size	900,000	900,000
Interest rate (in percent)	1.36%	1.36%
New debt recognized	€ 0
Installments	8 quarterly
Bank loan outstanding	€ 900	€ 900
CIC PGE [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2021
Facility size \| Facility Size	2,200,000	2,200,000
Interest rate (in percent)	0.75%	0.75%
New debt recognized	€ 0
Installments	8 quarterly
Bank loan outstanding	€ 2,200	€ 2,200
BNP PGE [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2021
Facility size \| Facility Size	4,900,000	4,900,000
Interest rate (in percent)	0.45%	0.45%
New debt recognized	€ 0
Installments	8 quarterly
Bank loan outstanding	€ 4,900	€ 4,900
Natixis PGE [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	June 2021
Facility size \| Facility Size	3,000,000	3,000,000
Interest rate (in percent)	0.40%	0.40%
New debt recognized	€ 0
Installments	8 quarterly
Bank loan outstanding	€ 3,000	€ 3,000
BPI PGE [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	July 2021
Facility size \| Facility Size	2,000,000
Interest rate (in percent)	2.25%
New debt recognized	€ 0
Installments	16 quarterly
Bank loan outstanding	€ 1,900	2,000
BPI Pret Taux Bonifie [Member]
Disclosure of detailed information about borrowings [line items]
Debt maturity date	November 2021
Facility size \| Facility Size	2,250,000
Interest rate (in percent)	2.25%
New debt recognized	€ 0
Installments	20 quarterly
Bank loan outstanding	€ 2,250	€ 2,250

Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	€ 9,464	€ 4,431	€ 1,458
Level 1 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	140,551	258,756
Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	3,951	842
Fair value of financial liabilities	84,416	83,889
Level 3 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	3,617	3,133
Fair value of financial liabilities	3,229	3,229
Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	148,119	262,731
Carrying value of Assets at fair value through profit and loss	141,034	258,756
Financial liabilities	85,214	87,118
Aggregate nominal amount	85,214	87,118
Carrying value debt at amortized cost	3,951	842
Financial assets measured at fair value through other comprehensive income	3,133	3,133
Equity investments [member] \| Level 3 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	3,133	3,133
Equity investments [member] \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	3,133	3,133
Financial assets measured at fair value through other comprehensive income	3,133	3,133
Loans to consumers [member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	428	388
Loans to consumers [member] \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	428	388
Deposits And Guarantees [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Carrying value debt at amortized cost	335	397
Trade receivables [member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	3,188	57
Fair value of financial liabilities	8,613	12,304
Trade receivables [member] \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	3,188	57
Financial liabilities	8,613	12,304
Aggregate nominal amount	8,613	12,304
Carrying value debt at amortized cost	3,188	57
Cash And Cash Equivalents [Member] \| Level 1 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	136,001	258,756
Cash And Cash Equivalents [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	136,001	258,756
Carrying value of Assets at fair value through profit and loss	136,001	258,756
Conditional Advances [Member] \| Level 3 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	3,229	3,229
Conditional Advances [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	3,229	3,229
Aggregate nominal amount	3,229	3,229
Carrying value debt at amortized cost	428	388
Convertible Loans [Member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	52,708	48,097
Convertible Loans [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	50,276	48,097
Aggregate nominal amount	50,276	48,097
Bank Loans [Member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	15,196	15,824
Bank Loans [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	15,196	15,824
Aggregate nominal amount	15,196	15,824
Obligations Under Finance Leases [Member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	6,559	7,069
Obligations Under Finance Leases [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	6,559	7,069
Aggregate nominal amount	6,559	7,069
Accrued Interests [Member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	14	16
Accrued Interests [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	14	16
Aggregate nominal amount	14	16
Other Payables [Member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial liabilities	1,325	579
Other Payables [Member] \| Gross
Disclosure of detailed information about borrowings [line items]
Financial liabilities	1,325	579
Aggregate nominal amount	1,325	579
Other investments \| Level 3 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	483
Other investments \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets		483
Carrying value of Assets at fair value through profit and loss		483
Financial investments \| Level 1 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	4,550
Financial investments \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets		4,550
Carrying value of Assets at fair value through profit and loss		4,550
Contingent liability for guarantees [member] \| Level 2 \| Fair value
Disclosure of detailed information about borrowings [line items]
Fair value of financial assets	335	397
Contingent liability for guarantees [member] \| Gross
Disclosure of detailed information about borrowings [line items]
Current and non current financial assets	€ 335	€ 397

Trade and Other Payables - Schedule of Trade and Other Payables (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade and other payables - Total
Trade payables	€ 8,613	€ 12,304
Payables on social security and taxes other than income tax	4,838	4,087
Value added tax payables	200	23,725
Excise tax payables	316	744
Other payables	1,325	579
Total trade and other payables	15,293	41,438
Trade and other payables - Current
Current payables on social security and taxes other than income tax	4,838	4,087
Current value added tax payables	200	23,725
Current excise tax payables	316	744
Other current payables	877	128
Total trade and other current payables	14,845	40,988
Trade and other payables - Non current
Non-current trade payables	0	0
Non-current payables on social security and taxes other than income tax	0	0
Non-current value added tax payables	0	0
Non-current excise tax payables	0	0
Other non-current payables	448	450
Total trade and other non-current payables	448	450
Accrued expenses	€ 3,924	€ 6,201

Trade and Other Payables - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Trade And Other Payables [Abstract]
Trade payables	€ 8,613	€ 12,304
Accrued expenses	3,924	6,201
Value added tax payables	200	23,725
Trade payables	8,613	12,304
Payables on social security and taxes other than income tax	4,838	4,087
Excise tax payables	316	744
Other payables	1,325	579
Trade and other payables	15,293	41,438
Current payables on social security and taxes other than income tax	4,838	4,087
Current value added tax payables	200	23,725
Current excise tax payables	316	744
Other current payables	877	128
Current trade and other payables	14,845	40,988
Non-current trade payables	0	0
Non-current payables on social security and taxes other than income tax	0	0
Non-current value added tax payables	0	0
Non-current excise tax payables	0	0
Other non-current payables	448	450
Non-current trade and other payables	€ 448	€ 450

Deferred Income and Revenue (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Revenue	€ 26,566	€ 85,579	€ 7,758
Other income	6,371	5,510	6,993
Other income	6,371	5,510	6,993
Other Operating Income [Member]
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Other income	320	223	968
Licensing Agreement
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Deferred income including contract liabilities		40,000
Revenue		120,000
Partial recognition of deferred revenue	15,900
Ipsen
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Upfront payment received	120,000
Deferred income	40,000
Deferred income current	14,400
Deferred income non-current	9,700
Deferred income other than contract liabilities	24,100
Revenue	15,900
Ipsen \| Licensing Agreement
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Revenue		80,000
Ipsen \| Transition Services Agreement
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Revenue	1,000
Ipsen \| Inventory Purchase Agreement
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Revenue	€ 3,300
Labcorp \| License Agreements
Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]
Other income		€ 69	€ 765

Provisions - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
Disclosure of other provisions [line items]
Provision for litigation [Line Items]	€ 87
Provision for charges [Line Items]	225	€ 61
Current provisions	313	61
Increase in Provisions [Member]
Disclosure of other provisions [line items]
Provision for litigation [Line Items]		0
Provision for charges [Line Items]		4
Current provisions		4
Decrease (used) in Provisions [Member]
Disclosure of other provisions [line items]
Provision for litigation [Line Items]		14
Provision for charges [Line Items]		92
Current provisions		106
Decrease (unused) in Provisions [Member]
Disclosure of other provisions [line items]
Provision for litigation [Line Items]		73
Provision for charges [Line Items]		77
Current provisions		150
Return-to-Work Bonuses, Trainings, Business Start-Up Assistance and Other Benefits
Disclosure of other provisions [line items]
Current provisions	92	€ 61
Other reversals of provisions	€ 169

Employee Benefits - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) bond	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Jan. 01, 2020 EUR (€)
Disclosure of information about defined benefit plans [abstract]
Defined contribution plan expense	€ 876	€ 774	€ 923
Current provisions	61	313
Provisions for employee benefits	€ 782	€ 864
Population Description	Permanent staff
Retirement age \| bond	65
Terms of retirement	Initiated by the employee
Life expectancy	On the basis of the INSEE table (1)
Probability of continued presence in the company at retirement age	On the basis of the DARES table
Disclosure of defined benefit plans [line items]
Discount rate (as a percent)	3.25%	0.87%
Increase in net defined benefit liability (asset) resulting from current service cost	€ 169	€ 154
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	8	5
Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income	0	0
Increase (decrease) in net defined benefit liability (asset) resulting from past service cost	(258)	(216)
Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees	0	0
Net defined benefit liability (asset)	€ 782	€ 864		€ 922
Changes in assumptions/discount rate (as a percent)	0.25%
Impact/present value of the undertaking	€ (23)
Percentage of reasonably possible decrease in actuarial assumption	0.25%
Impact/present value of the undertaking	€ 24
Within 1 Year
Disclosure of defined benefit plans [line items]
Salary growth rate (as a percent)	3.00%	3.00%
Beyond
Disclosure of defined benefit plans [line items]
Salary growth rate (as a percent)	3.00%	3.00%
2023
Disclosure of defined benefit plans [line items]
Benefits paid or payable	€ 0
2024
Disclosure of defined benefit plans [line items]
Benefits paid or payable	0
2025
Disclosure of defined benefit plans [line items]
Benefits paid or payable	37
2026
Disclosure of defined benefit plans [line items]
Benefits paid or payable	21
2027
Disclosure of defined benefit plans [line items]
Benefits paid or payable	78
Years 2028 and thereafter
Disclosure of defined benefit plans [line items]
Benefits paid or payable	€ 646

Employee Benefits - Summary of Assumptions Used for Employees for the Measurement of Retirement Indemnity to Employees (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of defined benefit plans [line items]
Population Description	Permanent staff
Terms of retirement	Initiated by the employee
Life expectancy	On the basis of the INSEE table (1)
Probability of continued presence in the company at retirement age	On the basis of the DARES table
Discount rate (as a percent)	3.25%	0.87%
Within 1 Year
Disclosure of defined benefit plans [line items]
Salary growth rate (as a percent)	3.00%	3.00%
Beyond
Disclosure of defined benefit plans [line items]
Salary growth rate (as a percent)	3.00%	3.00%

Employee Benefits - Summary of Changes in Present Value of Defined Benefit Obligation (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of information about defined benefit plans [abstract]
Defined benefit obligation, beginning balance	€ 864
Increase in net defined benefit liability (asset) resulting from current service cost	169	€ 154
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	8	5
Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income	0	0
Increase (decrease) in net defined benefit liability (asset) resulting from past service cost	(258)	(216)
Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees	0	0
Defined benefit obligation, ending balance	€ 782	€ 864

Employee Benefits - Summary of Sensitivity of the Retirement and Post-Employment Benefits to a Variation of the Discount Rate (Details) € in Thousands	Dec. 31, 2022 EUR (€)
Disclosure of information about defined benefit plans [abstract]
Changes in assumptions/discount rate (as a percent)	0.25%
Impact/present value of the undertaking	€ (23)
Changes in assumptions/discount rate (as a percent)	0.25%
Impact/present value of the undertaking	€ 24

Equity - Additional Information (Details) - EUR (€)						12 Months Ended
Equity - Additional Information (Details) - EUR (€)	Apr. 06, 2022	Mar. 02, 2022	Dec. 22, 2021	Sep. 01, 2021	Feb. 04, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 06, 2021	Mar. 02, 2021
Disclosure of classes of share capital [line items]
Shareholder paid-in and registered period for double voting rights (in years)						2 years
Capital increase						€ 0	€ 65,332,000	€ 0
Issuance of new shares (in shares)						49,834,983	49,815,489
Treasury shares						0	0
Number of shares issued during period (in shares)			3,985,239
+ Proceeds from issue of share capital (net)			€ 28,000,000			€ 5,000	€ 27,972,000	7,000
Total number of shares comprising the share capital (in shares)						49,834,983	49,815,489
Additional share based instruments issued (in shares)						306,435	323,125
Increase (decrease) through other changes, equity						€ (5,000)		€ 268,000
Number of free shares acquried						19,494
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Issuance of new shares (in shares)						49,834,983	49,815,489
Preference shares [member]
Disclosure of classes of share capital [line items]
Issuance of new shares (in shares)						0	0
OCEANE
Disclosure of classes of share capital [line items]
Capital increase	€ 297,812.5	€ 664,578.75		€ 13,750,000	€ 759,327.25
Issuance of new shares (in shares)				55,000					1,191,250	2,658,312
Number of shares issued during period (in shares)					3,037,309

Operating Income - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) bond	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Disclosure Of Other Income [Line Items]
Total operating income	€ 26,566	€ 85,579	€ 7,758
Industrial income recognized	20,195	80,069	765
Revenue	26,566	85,579	7,758
Research tax credit (CIR)	6,371	5,510	6,993
Research Tax Credit		€ 7,911
Expense relating to resolution of dispute	€ 1,892
Genfit \| Ipsen
Disclosure Of Other Income [Line Items]
Proportion of ownership interest in associate (as a percent)	8.00%	8.00%
C I R Tax Credit [Member]
Disclosure Of Other Income [Line Items]
Research tax credit (CIR)	€ 6,017	€ 5,282	€ 6,020
Ipsen
Disclosure Of Other Income [Line Items]
Total operating income	15,900
Deferred income	40,000
Sale price, clinical trial phase	40,000
Revenue	€ 15,900
Ipsen \| Performance obligations satisfied over time
Disclosure Of Other Income [Line Items]
Number of Performance Obligations \| bond	4

Operating Income - Schedule of Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Other Income [Line Items]
Other income	€ 6,371	€ 5,510	€ 6,993
C I R Tax Credit [Member]
Disclosure Of Other Income [Line Items]
Other income	6,017	5,282	6,020
Other Operating Income [Member]
Disclosure Of Other Income [Line Items]
Other income	320	223	968
Government Grants And Subsidies [Member]
Disclosure Of Other Income [Line Items]
Other income	€ 34	€ 5	€ 5

Operating Expense - Summary of Operating Expenses and Other Operating Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	€ (35,818)	€ (35,166)	€ (59,097)
General and administrative expenses	(16,405)	(16,153)	(14,270)
Marketing and market access expenses	(992)	(1,539)	(11,216)
Reorganization And Restructuring Expenses	11	(142)	(5,308)
Other operating income (expense)	(652)	(763)	(764)
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	53,855	53,763	90,655
Current provisions	61	313
Raw materials & consumables used
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(1,876)	(1,305)	(1,876)
General and administrative expenses	(248)	(161)	(202)
Marketing and market access expenses	(3)	(1)	(7)
Reorganization And Restructuring Expenses	0	(5)	0
Other operating income (expense)	0	0	0
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	2,128	1,472	2,085
Contracted research & development activities conducted by third parties
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(17,407)	(18,808)	(39,216)
General and administrative expenses	(71)	(85)	(92)
Marketing and market access expenses	(1)	(1)	(2)
Reorganization And Restructuring Expenses	0	0	0
Other operating income (expense)	0	0	0
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	17,479	18,895	39,310
Employee expenses
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(10,029)	(8,192)	(11,554)
General and administrative expenses	(6,772)	(7,379)	(6,936)
Marketing and market access expenses	(565)	(783)	(1,298)
Reorganization And Restructuring Expenses	0	0	8
Other operating income (expense)	0	0	0
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	17,366	16,354	19,779
Other expenses (maintenance, fees, travel, taxes)
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(5,177)	(4,593)	(5,465)
General and administrative expenses	(9,168)	(8,003)	(6,545)
Marketing and market access expenses	(416)	(741)	(9,818)
Reorganization And Restructuring Expenses	0	(2,343)	(2,141)
Other operating income (expense)	(667)	(338)	(684)
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	15,429	16,019	24,655
Depreciation, amortization & impairment charges
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(1,328)	(2,247)	(985)
General and administrative expenses	(146)	(541)	(495)
Marketing and market access expenses	(6)	(13)	(90)
Reorganization And Restructuring Expenses	11	2,206	(3,175)
Other operating income (expense)	0	4	0
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	1,469	591	4,746
Gain / (loss) on disposal of property, plant & equipment
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	0	(19)	0
General and administrative expenses	0	15	0
Marketing and market access expenses	0	0	0
Reorganization And Restructuring Expenses	0	0	0
Other operating income (expense)	16	(429)	(80)
Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense	€ (16)	€ 433	€ 80

Operating Expense - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) employee	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee
Disclosure Of Operating Expense [Line Items]
Average number of employees \| employee	133	122	193
Share-based compensation annual expense	€ 245	€ 470	€ 1,236
Profit sharing granted to employees	0	628	0
Research and development expense	€ 35,818	€ 35,166	€ 59,097

Operating Expense - Summary of Employee Expenses and Number of Employees (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) employee	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee
Disclosure Of Operating Expense [Line Items]
Wages and salaries \| €	€ (12,188)	€ (10,328)	€ (13,570)
Social security contributions \| €	(4,765)	(4,775)	(5,047)
Adjustments for provisions \| €	(169)	(154)	74
Profit sharing granted to employees \| €	0	(628)	0
Other short-term employee benefits \| €	(245)	(470)	(1,236)
Employee benefits expense \| €	€ (17,366)	€ (16,354)	€ (19,779)
Average number of employees \| employee	133	122	193
Number of employees \| employee	148	122	130
Research And Development [Member]
Disclosure Of Operating Expense [Line Items]
Number of employees \| employee	73	55	66
Services Related To Research And Development [Member]
Disclosure Of Operating Expense [Line Items]
Number of employees \| employee	18	18	16
Administration And Management [Member]
Disclosure Of Operating Expense [Line Items]
Number of employees \| employee	55	47	43
Marketing And Commercial [Member]
Disclosure Of Operating Expense [Line Items]
Number of employees \| employee	2	2	5

Share-Based Compensation - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments exercised (in shares) \| shares	0	0
Share-based compensation annual expense \| €	€ 245	€ 470	€ 1,236

Share-Based Compensation - Summary of Share-based Compensation Under Each Plan According to Change in Estimate (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€) shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 245	€ 470	€ 1,236
Total number of BSAAR subscribed (in shares) \| shares	35,070	71,760	71,760
SOD 2020 SOC2020 SOUS2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical	50.00%
Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical	25.00%	50.00%
Percentage of exercisable instruments relating to the development of NTZ and the ACLF franchise	15.00%	15.00%
Percentage of exercisable instruments relating to development of the product pipeline of the company	10.00%
Number of other equity instruments exercisable in share-based payment arrangement relating to NSIA diagnostic \| shares		10,000
Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program \| shares		3,000
Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program \| shares		2,000
Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical \| shares		5,000
A G A S20161 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0
A G A S20162 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	0
A G A D20161 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	21
A G A D20162 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	6
S O20161 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 49
Total number of BSAAR subscribed (in shares) \| shares	34,398	34,398	34,398
S O20162 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 13
Total number of BSAAR subscribed (in shares) \| shares	15,308	15,308	15,308
S O U S20161 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0
S O U S20162 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	0
A G A S20171 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	0
A G A S20172 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	13
A G A D20171 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	0
A G A D20172 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	4
S O20171 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 335
Total number of BSAAR subscribed (in shares) \| shares	43,212	43,212	43,212
S O20172 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 110
Total number of BSAAR subscribed (in shares) \| shares	17,765	17,765	17,765
S O U S20171 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0
S O U S20172 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	0
B S A2017 A [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0
Total number of BSAAR subscribed (in shares) \| shares	0	18,345	18,345
B S A2017 B [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0
Total number of BSAAR subscribed (in shares) \| shares	0	18,345	18,345
A G A S2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 62
A G A D2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	0	0	65
S O2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 186	€ 225
Total number of BSAAR subscribed (in shares) \| shares	68,329	68,329	71,678
S O U S2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 24	€ 24
Total number of BSAAR subscribed (in shares) \| shares	9,713	9,713	9,713
A G A S2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 50	€ 39	€ 55
Total number of BSAAR subscribed (in shares) \| shares	0	10,782	12,330
A G A D2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 6	€ 16	€ 63
Total number of BSAAR subscribed (in shares) \| shares	0	13,068	15,710
S O2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ (21)	€ 105	€ 123
Total number of BSAAR subscribed (in shares) \| shares	51,343	77,015	94,530
S O2019 U S [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ (16)	€ (11)	€ 35
B S A2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 20
Total number of BSAAR subscribed (in shares) \| shares	35,070	35,070	35,070
S O U S2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ (7)	€ 14
S O D2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 14	€ 14	€ 0
Total number of BSAAR subscribed (in shares) \| shares	35,000	35,000	35,000
S O C2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 40	€ 40	€ 0
Total number of BSAAR subscribed (in shares) \| shares	81,250	81,250	103,750
S O U S2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 19	€ 19	€ 0
Total number of BSAAR subscribed (in shares) \| shares	50,000	50,000	56,250
AGA S 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 32	€ 29	€ 0
Total number of BSAAR subscribed (in shares) \| shares	26,300	29,000
AGA D 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 7	€ 5	0
Total number of BSAAR subscribed (in shares) \| shares	15,000	15,000
SO D 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 13	€ 2	0
Total number of BSAAR subscribed (in shares) \| shares	35,000	35,000
SO C2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 55	€ 9	0
Total number of BSAAR subscribed (in shares) \| shares	124,375	134,375
SO US 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 9	€ 2	0
Total number of BSAAR subscribed (in shares) \| shares	25,000	25,000
AGA S 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 11	€ 0	0
Total number of BSAAR subscribed (in shares) \| shares	38,900
AGA D 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 2	0	0
Total number of BSAAR subscribed (in shares) \| shares	20,000
SO D 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 4	0	0
Total number of BSAAR subscribed (in shares) \| shares	35,000
SO C2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 17	0	0
Total number of BSAAR subscribed (in shares) \| shares	131,000
SO US 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 4	0	0
Total number of BSAAR subscribed (in shares) \| shares	34,625
SO CH 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation annual expense	€ 0	€ 0	€ 0

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Share Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Dec. 31, 2019 € / shares	Dec. 31, 2017 € / shares	Dec. 31, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares) \| shares	35,070	71,760			71,760
Total number of BSAAR voided (in shares) \| shares	36,690	0
B S A2017 A [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares) \| shares	0	18,345			18,345
Total number of BSAAR voided (in shares) \| shares	18,345	0
Issue price (in EUR per share)				€ 2.00
Excercise price (in EUR per share)				19.97
Estimated fair value - according to IFRS 2 (in EUR per share)				€ 3.78
End of exercise period				6/30/2022
Expected dividends				0.00%
Expected volatility				36.40%
Risk-free interest rate				0.00%
Conversion ratio				1:1
B S A2017 B [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares) \| shares	0	18,345			18,345
Total number of BSAAR voided (in shares) \| shares	18,345	0
Issue price (in EUR per share)				€ 2.00
Excercise price (in EUR per share)				19.97
Estimated fair value - according to IFRS 2 (in EUR per share)				€ 3.81
End of exercise period				7/15/2022
Expected dividends				0.00%
Expected volatility				35.70%
Risk-free interest rate				0.00%
Conversion ratio				1:1
B S A2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares) \| shares	35,070	35,070			35,070
Total number of BSAAR voided (in shares) \| shares	0	0
Issue price (in EUR per share)			€ 1.23
Excercise price (in EUR per share)			12.32
Estimated fair value - according to IFRS 2 (in EUR per share)			€ 0.75
End of exercise period			5/31/2024
Expected dividends			0.00%
Expected volatility			40.00%
Risk-free interest rate			0.00%
Conversion ratio			1:1

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Free Shares (Details)	12 Months Ended
	Dec. 31, 2022 shares € / shares	Dec. 31, 2021 shares € / shares	Dec. 31, 2020 shares € / shares	Dec. 31, 2019	Dec. 31, 2018 € / shares	Dec. 31, 2017 € / shares	Dec. 31, 2016 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided (in shares)	36,690	0
Total number of AGA definitively vested (in shares)	0	0
Total number of BSAAR subscribed (in shares)	35,070	71,760	71,760
AGA D
Disclosure of terms and conditions of share-based payment arrangement [line items]
Acquisition period	From 30/03/2021 to 31/03/2024
Valuation method used	Monte Carlo
Price of the share at the time of allocation \| € / shares	€ 4.00
Expected dividends	0.00%
Expected volatility		51.00%
Risk-free interest rate	(0.59%)
Turnover rate	0.00%
AGA S
Disclosure of terms and conditions of share-based payment arrangement [line items]
Acquisition period		From 17/03/2021 to 31/03/2024
Valuation method used		Monte Carlo
Price of the share at the time of allocation \| € / shares		€ 4.15
Expected dividends		0.00%
Expected volatility		51.00%
Risk-free interest rate		(0.59%)
Turnover rate		0.00%
AGA D and S
Disclosure of terms and conditions of share-based payment arrangement [line items]
Acquisition period	From 14/10/2022 to 16/10/2025		From 18/07/2019 to 16/09/2022		From 18/07/2019 to 16/09/2022
Valuation method used	Monte Carlo			Monte Carlo	Monte Carlo
Price of the share at the time of allocation \| € / shares	€ 4.08		€ 17.06		€ 20.02
Expected dividends	0.00%		0.00%		0.00%
Expected volatility	50.00%			40.20%	38.00%
Risk-free interest rate	2.24%		0.00%		0.00%
Turnover rate	0.00%		0.00%		15.00%
AGA D and S 2017-1 and 2017-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Acquisition period						From 06/12/2017 to 31/12/2020
Valuation method used						Monte Carlo
Price of the share at the time of allocation \| € / shares						€ 21.95
Expected dividends						0.00%
Expected volatility						53.70%
Risk-free interest rate						0.00%
Turnover rate						15.00%
AGA D and S 2016-1 and 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Acquisition period							From 15/12/2016 to 15/12/2019
Valuation method used							Monte Carlo
Price of the share at the time of allocation \| € / shares							€ 20.78
Expected dividends							0.00%
Expected volatility							63.00%
Risk-free interest rate							0.00%
Turnover rate							15.00%
S O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided (in shares)	38,229	81,964
Total number of BSAAR subscribed (in shares)	805,181	634,035	514,124
Acquisition period	Du 17/10/2022 au 17/10/2025
Valuation method used	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	209,375	201,875
AGA D 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	20,000
Total number of BSAAR subscribed (in shares)	20,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	20,000
AGA S 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	32,400	32,400
Total number of BSAAR voided (in shares)	2,700	3,400
Total number of BSAAR subscribed (in shares)	26,300	29,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement		32,400
AGA S 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	39,200
Total number of BSAAR voided (in shares)	300
Total number of BSAAR subscribed (in shares)	38,900
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	39,200
AGA D 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	15,000	15,000
Total number of BSAAR subscribed (in shares)	15,000	15,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement		15,000
A G A S2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	17,556	17,556
Total number of BSAAR voided (in shares)		1,548
Total number of AGA definitively vested (in shares)	10,782
Total number of BSAAR subscribed (in shares)	0	10,782	12,330
A G A D2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of AGA subscribed (in shares)	19,070	19,070
Total number of BSAAR voided (in shares)	4,356	2,642
Total number of AGA definitively vested (in shares)	8,712
Total number of BSAAR subscribed (in shares)	0	13,068	15,710
A G A
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided (in shares)	7,356	7,590
Total number of AGA definitively vested (in shares)	19,494	0
Total number of BSAAR subscribed (in shares)	100,200	67,850	28,040
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	59,200	47,400

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Stock Options (Details)	12 Months Ended
	Dec. 31, 2022 shares € / shares	Dec. 31, 2021 shares € / shares	Dec. 31, 2020 shares € / shares	Dec. 31, 2019 € / shares	Dec. 31, 2018 € / shares	Dec. 31, 2017 € / shares	Dec. 31, 2016 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares)	35,070	71,760	71,760
Total number of BSAAR voided (in shares)	36,690	0
Number of other equity instruments exercisable in share-based payment arrangement	35,070	71,760
S O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercice period	Du 18/10/2025 au 17/10/2032
Valuation method used	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes
Acquisition period	Du 17/10/2022 au 17/10/2025
Total number of BSAAR subscribed (in shares)	805,181	634,035	514,124
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	209,375	201,875
Total number of BSAAR voided (in shares)	38,229	81,964
Number of other equity instruments exercisable in share-based payment arrangement	245,181	188,725
S O2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares				€ 13.99
Exercice period				Du 17/09/2022 au 17/09/2029
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares				€ 4.59
Price of the share at the time of allocation \| € / shares				€ 17.06
Expected dividends				0.00%
Expected volatility				40.00%
Risk-free interest rate				0.00%
Conversion ratio				1:1
Turnover rate				0.00%
Grant date				Jul. 18, 2019
Acquisition period				Du 18/07/2019 au 16/09/2022
Total number of BSAAR subscribed (in shares)	51,343	77,015	94,530
Total number of BSAAR subscribed	107,880	107,880
Total number of BSAAR voided (in shares)	25,672	17,515
Number of other equity instruments exercisable in share-based payment arrangement	51,343	0
S O2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares					€ 16.00
Exercice period					Du 01/01/2022 au 31/12/2028
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares					€ 9.32
Price of the share at the time of allocation \| € / shares					€ 22.10
Expected dividends					0.00%
Expected volatility					44.10%
Risk-free interest rate					0.00%
Conversion ratio					1:1
Turnover rate					15.00%
Grant date					Nov. 07, 2018
Acquisition period					Du 07/11/2018 au 31/12/2021
Total number of BSAAR subscribed (in shares)	68,329	68,329	71,678
Total number of BSAAR subscribed	122,000	122,000
Total number of BSAAR voided (in shares)		3,349
Number of other equity instruments exercisable in share-based payment arrangement	68,329	68,329
S O U S2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares					€ 21.65
Exercice period					Du 01/01/2022 au 31/12/2028
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares					€ 6.90
Price of the share at the time of allocation \| € / shares					€ 22.10
Expected dividends					0.00%
Expected volatility					44.10%
Risk-free interest rate					0.00%
Conversion ratio					1:1
Turnover rate					15.00%
Grant date					Nov. 07, 2018
Acquisition period					Du 07/11/2018 au 31/12/2021
Total number of BSAAR subscribed (in shares)	9,713	9,713	9,713
Total number of BSAAR subscribed	17,500	17,500
Number of other equity instruments exercisable in share-based payment arrangement	9,713	9,713
AGA D and S
Disclosure of terms and conditions of share-based payment arrangement [line items]
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	€ 4.08		€ 17.06		€ 20.02
Valuation method used	Monte Carlo			Monte Carlo	Monte Carlo
Price of the share at the time of allocation \| € / shares	€ 4.08		€ 17.06		€ 20.02
Expected dividends	0.00%		0.00%		0.00%
Expected volatility	50.00%			40.20%	38.00%
Risk-free interest rate	2.24%		0.00%		0.00%
Conversion ratio	1:1		1:1		1:1
Turnover rate	0.00%		0.00%		15.00%
Grant date	Oct. 14, 2022		Jul. 18, 2019		Nov. 22, 2018
Acquisition period	From 14/10/2022 to 16/10/2025		From 18/07/2019 to 16/09/2022		From 18/07/2019 to 16/09/2022
AGA D
Disclosure of terms and conditions of share-based payment arrangement [line items]
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	€ 4.00
Valuation method used	Monte Carlo
Price of the share at the time of allocation \| € / shares	€ 4.00
Expected dividends	0.00%
Expected volatility		51.00%
Risk-free interest rate	(0.59%)
Conversion ratio	1:1
Turnover rate	0.00%
Grant date	Mar. 30, 2021
Acquisition period	From 30/03/2021 to 31/03/2024
AGA D and S 2017-1 and 2017-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares						€ 21.95
Valuation method used						Monte Carlo
Price of the share at the time of allocation \| € / shares						€ 21.95
Expected dividends						0.00%
Expected volatility						53.70%
Risk-free interest rate						0.00%
Conversion ratio						1:1
Turnover rate						15.00%
Grant date						Dec. 06, 2017
Acquisition period						From 06/12/2017 to 31/12/2020
AGA D and S 2016-1 and 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares							€ 20.78
Valuation method used							Monte Carlo
Price of the share at the time of allocation \| € / shares							€ 20.78
Expected dividends							0.00%
Expected volatility							63.00%
Risk-free interest rate							0.00%
Conversion ratio							1:1
Turnover rate							15.00%
Grant date							Dec. 15, 2016
Acquisition period							From 15/12/2016 to 15/12/2019
A G A S [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares		€ 4.15
Valuation method used		Monte Carlo
Price of the share at the time of allocation \| € / shares		€ 4.15
Expected dividends		0.00%
Expected volatility		51.00%
Risk-free interest rate		(0.59%)
Conversion ratio		1:1
Turnover rate		0.00%
Grant date		Mar. 17, 2021
Acquisition period		From 17/03/2021 to 31/03/2024
SO C2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares		€ 2.61
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares		1.30
Price of the share at the time of allocation \| € / shares		€ 3.24
Expected dividends		0.00%
Expected volatility		50.00%
Risk-free interest rate		(0.60%)
Conversion ratio		1:1
Turnover rate		0.00%
Grant date		Oct. 20, 2021
Total number of BSAAR subscribed (in shares)	124,375	134,375
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement		134,375
Total number of BSAAR subscribed	134,375	134,375
Total number of BSAAR voided (in shares)	10,000
Number of other equity instruments exercisable in share-based payment arrangement	0	0
SO D 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares		€ 3.26
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares		1.06
Price of the share at the time of allocation \| € / shares		€ 3.24
Expected dividends		0.00%
Expected volatility		50.00%
Risk-free interest rate		(0.60%)
Conversion ratio		1:1
Turnover rate		0.00%
Grant date		Oct. 20, 2021
Total number of BSAAR subscribed (in shares)	35,000	35,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement		35,000
Total number of BSAAR subscribed	35,000	35,000
Number of other equity instruments exercisable in share-based payment arrangement	0	0
SO US 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares		€ 3.22
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares		1.07
Price of the share at the time of allocation \| € / shares		€ 3.24
Expected dividends		0.00%
Expected volatility		50.00%
Risk-free interest rate		(0.60%)
Conversion ratio		1:1
Turnover rate		0.00%
Grant date		Oct. 20, 2021
Total number of BSAAR subscribed (in shares)	25,000	25,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement		32,500
Total number of BSAAR subscribed	32,500	32,500
Total number of BSAAR voided (in shares)		7,500
Number of other equity instruments exercisable in share-based payment arrangement	0	0
SO US 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares	€ 3.94
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	1.56
Price of the share at the time of allocation \| € / shares	€ 4.16
Expected dividends	0.00%
Expected volatility	50.00%
Risk-free interest rate	2.24%
Conversion ratio	1:1
Turnover rate	0.00%
Grant date	Oct. 17, 2022
Total number of BSAAR subscribed (in shares)	34,625
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	34,625
Total number of BSAAR subscribed	34,625
Number of other equity instruments exercisable in share-based payment arrangement	0
SO C2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares	€ 3.12
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	1.90
Price of the share at the time of allocation \| € / shares	€ 4.16
Expected dividends	0.00%
Expected volatility	50.00%
Risk-free interest rate	2.24%
Conversion ratio	1:1
Turnover rate	0.00%
Grant date	Oct. 17, 2022
Total number of BSAAR subscribed (in shares)	131,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	131,000
Total number of BSAAR subscribed	131,000
Number of other equity instruments exercisable in share-based payment arrangement	0
SO D 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares	€ 3.91
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	1.57
Price of the share at the time of allocation \| € / shares	€ 4.16
Expected dividends	0.00%
Expected volatility	50.00%
Risk-free interest rate	2.24%
Conversion ratio	1:1
Turnover rate	0.00%
Grant date	Oct. 17, 2022
Total number of BSAAR subscribed (in shares)	35,000
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	35,000
Total number of BSAAR subscribed	35,000
Number of other equity instruments exercisable in share-based payment arrangement	0
SO SU 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares	€ 2.95
Exercice period	From 3/12/2022 to 3/12/2032
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares	€ 1.40
Price of the share at the time of allocation \| € / shares	€ 3.46
Expected dividends	0.00%
Expected volatility	49.00%
Risk-free interest rate	2.10%
Conversion ratio	1:1
Turnover rate	0.00%
Grant date	Dec. 02, 2022
Acquisition period	From 3/12/2022 to 3/12/2025
Total number of BSAAR subscribed (in shares)	8,750
Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement	8,750
Total number of BSAAR subscribed	8,750
Number of other equity instruments exercisable in share-based payment arrangement	0
S O US 2 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares				€ 14.31
Exercice period				Du 17/01/2023 au 17/01/2030
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares				€ 3.23
Price of the share at the time of allocation \| € / shares				€ 14.50
Expected dividends				0.00%
Expected volatility				40.00%
Risk-free interest rate				0.00%
Conversion ratio				1:1
Turnover rate				0.00%
Grant date				Nov. 27, 2019
Acquisition period				Du 27/11/2019 au 16/01/2023
Total number of BSAAR subscribed (in shares)		0	8,900
Total number of BSAAR subscribed		13,350
Total number of BSAAR voided (in shares)		8,900
Number of other equity instruments exercisable in share-based payment arrangement		0
S O US 1 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares				€ 16.90
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares				3.67
Price of the share at the time of allocation \| € / shares				€ 17.06
Expected dividends				0.00%
Expected volatility				40.00%
Risk-free interest rate				0.00%
Conversion ratio				1:1
Turnover rate				0.00%
Grant date				Jul. 18, 2019
Total number of BSAAR subscribed (in shares)	5,113	7,670	23,620
Total number of BSAAR subscribed	30,620	30,620
Total number of BSAAR voided (in shares)	2,557	15,950
Number of other equity instruments exercisable in share-based payment arrangement	5,113	0
S O U S2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares			€ 4.52
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares			1.12
Price of the share at the time of allocation \| € / shares			€ 3.99
Expected dividends			0.00%
Expected volatility			49.00%
Risk-free interest rate			(0.70%)
Conversion ratio			1:1
Turnover rate			0.00%
Grant date			Dec. 31, 2020
Total number of BSAAR subscribed (in shares)	50,000	50,000	56,250
Total number of BSAAR subscribed	56,250	56,250
Total number of BSAAR voided (in shares)		6,250
Number of other equity instruments exercisable in share-based payment arrangement	0	0
S O C2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares			€ 3.50
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares			1.46
Price of the share at the time of allocation \| € / shares			€ 3.99
Expected dividends			0.00%
Expected volatility			49.00%
Risk-free interest rate			(0.70%)
Conversion ratio			1:1
Turnover rate			0.00%
Grant date			Dec. 31, 2020
Total number of BSAAR subscribed (in shares)	81,250	81,250	103,750
Total number of BSAAR subscribed	103,750	103,750
Total number of BSAAR voided (in shares)		22,500
Number of other equity instruments exercisable in share-based payment arrangement	0	0
S O D2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares			€ 4.38
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares			1.16
Price of the share at the time of allocation \| € / shares			€ 3.99
Expected dividends			0.00%
Expected volatility			49.00%
Risk-free interest rate			(0.70%)
Conversion ratio			1:1
Turnover rate			0.00%
Grant date			Dec. 31, 2020
Total number of BSAAR subscribed (in shares)	35,000	35,000	35,000
Total number of BSAAR subscribed	35,000	35,000
Number of other equity instruments exercisable in share-based payment arrangement	0	0
S O 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercice period			Du 01/01/2024 au 31/12/2027
Acquisition period			Du 31/12/2020 au 31/12/2023
SO 2016
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares							€ 15.79
Exercice period							Du 16/12/2019 au 16/12/2026
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares							€ 10.30
Price of the share at the time of allocation \| € / shares							€ 20.79
Expected dividends							0.00%
Expected volatility							63.00%
Risk-free interest rate							0.00%
Conversion ratio							1:1
Turnover rate							15.00%
Grant date							Dec. 15, 2016
Acquisition period							Du 15/12/2016 au 15/12/2019
SO 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Excercise price (in EUR per share) \| € / shares						€ 17.91
Exercice period						Du 01/01/2021 au 31/12/2027
Estimated fair value - according to IFRS 2 (in EUR per share) \| € / shares						€ 9.32
Price of the share at the time of allocation \| € / shares						€ 21.95
Expected dividends						0.00%
Expected volatility						53.70%
Risk-free interest rate						0.00%
Conversion ratio						1:1
Turnover rate						15.00%
Grant date						Dec. 06, 2017
Acquisition period						Du 06/12/2017 au 31/12/2020
S O 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercice period		Du 21/10/2024 au 21/10/2031
Acquisition period		Du 20/10/2021 au 20/10/2024
S O20171 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares)	43,212	43,212	43,212
Total number of BSAAR subscribed	64,164	64,164
Number of other equity instruments exercisable in share-based payment arrangement	43,212	43,212
S O20161 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares)	34,398	34,398	34,398
Total number of BSAAR subscribed	41,917	41,917
Number of other equity instruments exercisable in share-based payment arrangement	34,398	34,398
S O20172 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares)	17,765	17,765	17,765
Total number of BSAAR subscribed	32,086	32,086
Number of other equity instruments exercisable in share-based payment arrangement	17,765	17,765
S O20162 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR subscribed (in shares)	15,308	15,308	15,308
Total number of BSAAR subscribed	20,958	20,958
Number of other equity instruments exercisable in share-based payment arrangement	15,308	15,308

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Details) - AGA D 2021 [Member]	Dec. 31, 2021 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE	7,500
Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company	3,750

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Parenthetical) (Details) - SOD 2020 SOC2020 SOUS2020	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024		20.00%
Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical	25.00%	50.00%
Percentage of exercisable instruments relating to the development of NTZ and the ACLF franchise	15.00%	15.00%
Percentage of exercisable instruments relating to the NIS4 diagnostic technology		15.00%
Percentage of exercisable instruments relating to development of the product pipeline of the company		25.00%
Percentage of exercisable instruments relating to NI4 diagnostics technology		25.00%

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Redeemable Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Dec. 31, 2020 shares	Dec. 31, 2019 € / shares	Dec. 31, 2018	Dec. 31, 2017 € / shares	Dec. 31, 2016
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided	36,690	0
Number of instruments exercised (in shares)	0	0
Total number of BSAAR subscribed (in shares)	35,070	71,760	71,760
Number of other equity instruments exercisable in share-based payment arrangement	35,070	71,760
A G A S [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Valuation method used		Monte Carlo
Expected dividends		0.00%
Expected volatility		51.00%
Risk-free interest rate		(0.59%)
B S A2017 B [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided	18,345	0
Number of instruments exercised (in shares)	0	0
Total number of BSAAR subscribed (in shares)	0	18,345	18,345
Issue price (in EUR per share) \| € / shares						€ 2.00
Expected dividends						0.00%
Expected volatility						35.70%
Risk-free interest rate						0.00%
Number of other equity instruments granted in share-based payment arrangement	18,345	18,345
Number of other equity instruments exercisable in share-based payment arrangement	0	18,345
S O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided	38,229	81,964
Total number of BSAAR subscribed (in shares)	805,181	634,035	514,124
Valuation method used	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Black Scholes
Number of other equity instruments exercisable in share-based payment arrangement	245,181	188,725
B S A2017 A [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided	18,345	0
Number of instruments exercised (in shares)	0	0
Total number of BSAAR subscribed (in shares)	0	18,345	18,345
Issue price (in EUR per share) \| € / shares						€ 2.00
Expected dividends						0.00%
Expected volatility						36.40%
Risk-free interest rate						0.00%
Number of other equity instruments granted in share-based payment arrangement	18,345	18,345
Number of other equity instruments exercisable in share-based payment arrangement	0	18,345
B S A2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of BSAAR voided	0	0
Number of instruments exercised (in shares)	0	0
Total number of BSAAR subscribed (in shares)	35,070	35,070	35,070
Issue price (in EUR per share) \| € / shares				€ 1.23
Expected dividends				0.00%
Expected volatility				40.00%
Risk-free interest rate				0.00%
Number of other equity instruments granted in share-based payment arrangement	35,070	35,070
Number of other equity instruments exercisable in share-based payment arrangement	35,070	35,070

Financial Income and Expenses - Summary of Financial Income and Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Income And Expenses [Abstract]
Revenue	€ 26,566	€ 85,579	€ 7,758
Interest income	137	274	1,442
Net foreign exchange gain	7,470	8,876	4,983
Finance income from renegotiation of debt	0	35,578	0
Other finance income	605	52	119
Finance income	8,212	44,780	6,544
Interest expense	(4,341)	(4,846)	(11,643)
Interest Expenses For Leases	(69)	(109)	(134)
Net foreign exchange loss	(340)	(2,163)	(13,508)
Other finance cost	(8)	(5)	(11)
Finance costs	(4,758)	(7,122)	(25,296)
Financial profit (loss)	€ 3,453	€ 37,658	€ (18,752)

Financial Income and Expenses - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Income And Expenses [Line Items]
Finance income from renegotiation of debt	€ 0	€ 35,578	€ 0
Foreign exchange gain (loss)	7,130
OCEANE
Disclosure Of Financial Income And Expenses [Line Items]
Finance income from renegotiation of debt	€ 35,600
Proportion of payment of coupons rate (as a percent)	3.50%
Proportion of discount of bond debt at effective interest rate (as a percent)	8.80%

Income Tax - Breakdown of Deferred Taxes by Nature (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in deferred tax liability (asset) [abstract]
Deferred tax liabilities	€ (2,315)	€ (2,050)
Deferred tax assets	1,712	1,282
Deferred tax liability (asset)	(602)	(767)
Impact on equity	0	2,721
Impact on the profit/loss	(93)	(2,885)
Deferred tax liabilities	(1,770)	(2,315)	€ (2,050)
Deferred tax assets	1,260	1,712	1,282
Deferred tax liability (asset)	(510)	(602)	(767)
+ Net profit (loss)	(23,719)	67,259	(101,221)
Tax expense (income)	€ (116)	€ 2,215	€ (428)
Average effective tax rate	(0.49%)	(3.19%)	(0.42%)
Profit (loss) before tax	€ (23,836)	€ 69,474	€ (101,649)
Applicable tax rate	25.00%	27.37%	28.92%
Tax expense (income) at applicable tax rate	€ (5,959)	€ 19,018	€ (29,401)
Tax Effect Of Tax Credits	(1,504)	(1,512)	(1,739)
Tax Effect Of Permanent Differences	31	(833)	404
Tax effect of foreign tax rates	67	(7,323)	(172)
Tax effect of tax losses	7,037	0	28,603
Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	0	5,590	0
Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	61	129	358
Deferred tax expense (income) relating to origination and reversal of temporary differences	(331)	24	775
Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities	453	(430)	706
Tax Effect Of Renegotiation Of Convertible Debt	0	(1,370)	0
Other tax effects for reconciliation between accounting profit and tax expense (income)	29	102	39
Impact Attributable To Deferred Tax Liabilities [Member]
Reconciliation of changes in deferred tax liability (asset) [abstract]
Impact on equity	0	2,721
Impact on the profit/loss	(545)	(2,455)
Impact Attributable To Deferred Tax Assets [Member]
Reconciliation of changes in deferred tax liability (asset) [abstract]
Impact on equity	0	0
Impact on the profit/loss	€ (453)	430
Temporary difference from postemployments
Reconciliation of changes in deferred tax liability (asset) [abstract]
Temporary differences		€ 216	€ 287

Income Tax - Schedule of Effective Tax Rate (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred tax expense (income) [abstract]
Net profit (loss)	€ (23,719)	€ 67,259	€ (101,221)
Tax expense (income)	116	(2,215)	428
Profit (loss) before tax	€ (23,836)	€ 69,474	€ (101,649)
Applicable tax rate	25.00%	27.37%	28.92%
Tax expense (income) at applicable tax rate	€ 5,959	€ (19,018)	€ 29,401
Increase (Decrease) Related To Tax Effect [Abstract]
Tax Effect Of Tax Credits	1,504	1,512	1,739
Tax Effect Of Permanent Differences	(31)	833	(404)
Tax effect of foreign tax rates	(67)	7,323	172
Tax effect of tax losses	(7,037)	0	(28,603)
Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	0	5,590	0
Tax Effect Of Adjustments Without Tax Incidence	(61)	(129)	(358)
Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences	331	(24)	(775)
Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities	(453)	430	(706)
Tax Effect Of Renegotiation Of Convertible Debt	0	1,370	0
Other tax effects for reconciliation between accounting profit and tax expense (income)	€ (29)	€ (102)	€ (39)
Average effective tax rate	(0.49%)	(3.19%)	(0.42%)

Income Tax - Narrative (Details) - EUR (€) € in Thousands	12 Months Ended
Income Tax - Narrative (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Other current tax liabilities	€ 4,906	€ 5,051
+ Income tax expense (benefit)	(116)	2,215	€ (428)
Deferred tax liabilities	510	602
Tax loss carry forwards	(477,149)	(449,679)	(483,356)
Taxable profit limit	€ 1,000
Percentage of profit exceeding limit offsetting taxable profit	50.00%
Tax loss carried forward used to offset taxable profits	€ 33,700
Deferred tax liabilities	1,770	2,315	2,050
Deferred tax assets	1,260	1,712	1,282
Tax effect of tax losses	7,037	0	28,603
Deferred tax liability (asset)	(510)	(602)	€ (767)
Impact on equity	0	(2,721)
Impact on the profit/loss	93	2,885
Impact Attributable To Deferred Tax Liabilities [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Impact on equity	0	(2,721)
Impact on the profit/loss	545	2,455
Impact Attributable To Deferred Tax Assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Impact on equity	0	0
Impact on the profit/loss	€ 453	€ (430)

Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings per share [abstract]
Profit (loss)	€ (23,719)	€ 67,259	€ (101,221)
Weighted average number of ordinary shares for the period (shares)	49,673,936,000	44,739,756,000	38,858,617,000
Basic earnings (loss) per share	€ (0.48)	€ 1.51	€ (2.60)
Weighted average number of ordinary shares used in calculating diluted earnings (loss) per share (in shares)	49,673,936,000	55,613,634,000	38,858,617,000
Diluted earnings (loss) per share	€ (0.48)	€ 1.23	€ (2.60)
Earnings per share [table]
Weighted average number of ordinary shares used in calculating diluted earnings (loss) per share (in shares)	49,673,936,000	55,613,634,000	38,858,617,000
B S A
Earnings per share [table]
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	35,070,000
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	35,070,000
A G A
Earnings per share [table]
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	53,887,000
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	53,887,000
S O
Earnings per share [table]
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	637,726,000
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	637,726,000
OCEANES
Earnings per share [table]
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	10,580,141,000
Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share	10,580,141,000

Related Parties - Additional Information (Details) - Biotech Avenir SAS	12 Months Ended
	Dec. 31, 2022 employee Co-founder
Disclosure of transactions between related parties [line items]
Number of co-founders hold share capital of related party \| Co-founder	4
Number of employees hold share capital of related party \| employee	12
Genfit
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in associate (as a percent)	3.79%

Compensation of Corporate Officers - Summary of Compensation Paid to Officers (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Of Corporate Officers [Line Items]
Key management personnel compensation, attendance fees	€ 421	€ 488	€ 456
Key management personnel compensation, contribution in kind	21	23	26
Key management personnel compensation, share-based payment	74	58	41
Key management personnel compensation,employer contributions	410	443	405
Key management personnel compensation, consulting fees	0	0	0
Key management personnel compensation	1,680	1,693	1,517
Key management personnel compensation, fixed compensation fees	585	518	518
Key management personnel compensation, variable compensation fees	€ 169	€ 163	€ 71

Commitments - Additional Information (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2022 USD ($)
Disclosure Of Commitments [Abstract]
Rental payment obligation under the lease agreement \| €	€ 600	€ 600
Asset recognised for expected reimbursement, contingent liabilities in business combination \| $			$ 193

Cash flow statement (Details) - EUR (€) € in Thousands	12 Months Ended
Cash flow statement (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Information [Abstract]
Accrued property, plant and equipment	€ 142	€ 76	€ 83
Bonus generated by the partial buyback following the renegotiation		€ 35,578

Label

Element

Value

Versantis [Member]

Other comprehensive income that will not be reclassified to profit or loss, net of tax

ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax

€ 1,400,000

Disclosure of detailed information about business combination [text block]

ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory

The net book value of assets and liabilities as of December 31, 2022 is as follows, per the application of IAS 21:


Net assets, in thousands of euros			31/12/2022
Cash and cash equivalents			2,168
Current trade and others receivables			17
Other current assets			197
Intangible assets			43,850
Property, plant and equipment			295
Other non-current financial assets			13
Total assets			46,540

Current trade and other payables			1,614
Current provisions			672
Other current tax liabilities			33
Lease liabilities			282
Total liabilities			2,601

Net assets			43,939

Loans and Borrowings - Summary of Maturities of Financial Liabilities (Details) - Dec. 31, 2022 € in Thousands, $ in Thousands	EUR (€)	USD ($)
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances \| $		$ 3,229
TOTAL	€ 75,275
Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	50,276
Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	15,196
Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	6,559
Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	14
Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	72,046
BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances \| $		3,229
Within 1 Year
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
TOTAL	5,080
Within 1 Year \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	415
Within 1 Year \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	3,619
Within 1 Year \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,032
Within 1 Year \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	14
Within 1 Year \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	5,080
Within 1 Year \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
Later than one year and not later than two years
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
TOTAL	7,350
Later than one year and not later than two years \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than one year and not later than two years \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	6,339
Later than one year and not later than two years \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,011
Later than one year and not later than two years \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than one year and not later than two years \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	7,350
Later than one year and not later than two years \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
Later than two years and not later than three years
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
TOTAL	54,485
Later than two years and not later than three years \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	49,861
Later than two years and not later than three years \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	3,601
Later than two years and not later than three years \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,022
Later than two years and not later than three years \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than two years and not later than three years \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	54,485
Later than two years and not later than three years \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
Later than three years and not later than four years
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
TOTAL	1,901
Later than three years and not later than four years \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than three years and not later than four years \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	867
Later than three years and not later than four years \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,034
Later than three years and not later than four years \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than three years and not later than four years \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,901
Later than three years and not later than four years \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
Later than four years and not later than five years
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
TOTAL	1,817
Later than four years and not later than five years \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than four years and not later than five years \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	771
Later than four years and not later than five years \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,046
Later than four years and not later than five years \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than four years and not later than five years \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,817
Later than four years and not later than five years \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances	0
Later than five years
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances \| $		3,229
TOTAL	4,643
Later than five years \| Convertible Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than five years \| Bank Loans [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than five years \| Lease
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	1,414
Later than five years \| Accrued Interests [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	0
Later than five years \| Other Financial Loans And Borrowings [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Other loans and borrowings	€ 1,414
Later than five years \| BPI FRANCE - IT-DIAB
Disclosure of maturity analysis for derivative financial liabilities [line items]
TOTAL - Refundable and conditional advances \| $		$ 3,229